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1.
BIFIDOBACTERIA ARE WELL CAPABLE TO COLONISE 
AND TO BE METABOLICALLY ACTIVE IN THE PRE-
TERM INFANT INTESTINAL TRACT. (THIS THESIS)
2. 
AS LONG AS ANTIBIOTICS ARE A NECESSITY IN  
PRETERM INFANT CARE, DEVELOPMENT OF THEIR 
GUT MICROBIOTA REMAINS IMPEDED. (THIS THESIS)
3. 
THE FULL POTENTIAL OF EXISTING -OMICS DATA 
SHOULD BE EXPLOITED BEFORE GENERATING  
NEW DATA.
4. 
THE PERCEPTION THAT UNPAID OVERTIME, HIGH 
WORK-LOAD, LACK OF SUPPORT AND TEMPORAL 
CONTRACTS ARE NORMAL WORKING CONDITIONS, 
CONTRIBUTES TO THE HIGH RATES OF ANXIETY  
AND DEPRESSION IN ACADEMIA.  
(LEVECQUE ET AL., RESEARCH POLICY, 2017).
5. 
EXTENSIVE KNOWLEDGE ABOUT HUMAN NUTRITION 
AND GUT MICROBIOLOGY DOES NOT GUARANTEE 
HEALTHY DIETARY HABITS. 
6. 
WHILE BEING TYPICALLY PERCEIVED AS PETS  
FOR CHILDREN, RABBITS ARE BETTER SUITED  
FOR ADULT-ONLY HOUSEHOLDS. 
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Summary
SUMMARY
Functioning of the gastrointestinal tract, and of the microbiota residing 
therein, is of significance for nutrient digestion and absorption, pathogen 
resistance and optimal immune performance. During early life, development 
of the gut microbiota coincides, and affects, development of the metabolic, 
cognitive and immune system. Proper establishment of the gut microbiota 
is therefore considered essential for healthy development. In early life, the 
intestinal microbiota is relatively unstable and responsive to perturbations. 
Factors that are recognised to influence neonatal microbiota development 
include gestational age, delivery mode, nutrition and antibiotic use. As such, 
gut microbiota establishment is likely to be impacted in preterm infants, since 
they have an immature gut and are commonly exposed to caesarean section 
delivery, specific feeding regimens and antibiotic treatment. Although gut 
microbiota development can be negatively impacted during early life, the 
developing microbiota also provides an opportunity to be targeted as means 
of therapeutic strategy to support healthy growth and development. In light 
of this, it is important to understand how the preterm infant gastrointestinal 
tract is functioning, which microbes colonise, what the microbes are doing 
and how microbiota establishment is affected. In this thesis, gastrointestinal 
function and microbiota development during the early life of preterm infants, 
and the impact of various host and environmental factors on this development, 
were studied. 
The research described in this thesis was performed using material obtained 
during a single-centre, observational study including infants admitted to the 
neonatal unit born between 24-42 weeks gestation. A total of 238 infants (119 
<32 weeks gestation, 119 >32 weeks gestation) were followed during the first 
six postnatal weeks, during which clinical factors were documented, and 
faeces and gastric aspirates were longitudinally collected for microbiota 
analysis. Microbiota development was not only approached compositionally 
via the application of qPCR and 16S rRNA gene amplicon sequencing, but also 
functionally via metaproteomics through LC-MS/MS, giving new insights into 
gut function and microbiota development in preterm infants. 
Via a metaproteomics approach, gestational age-specific developmental 
patterns of the preterm infant gastrointestinal proteome were identified. 
Gestational and postnatal age were associated with quantity of specific markers 
for gut function and maturation, as well as with composition of the gut microbiota. 
The faecal proteome of very preterm infants indicated a gut environment 
dominated by Bifidobacterium, and with better digestive capacity, compared 
to extremely preterm infants. We showed that a Bifidobacterium-dominated 
community is associated with increased proteins involved in carbohydrate and 
energy metabolism, including those involved in the degradation of complex 
carbohydrates like human milk oligosaccharides. Regarding preterm infants, 
who commonly experience protein deficits and growth retardation, further 
exploration of the gut microbiota’s metabolic traits is particularly relevant. The 
observed gestational age-specific developmental patterns were associated 
with the degree of exposure to perinatal antibiotics and respiratory support. 
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Studying the sole effect of gestational age on gut microbiota development 
remains challenging due to the cohesion between gestational age and the 
degree of special care.
Antibiotics are the most used therapeutics in neonatal intensive care units, 
prescribed for the prevention and treatment of infections and sepsis. It is 
important to understand the consequences of antibiotic treatment in neonates, 
as disturbances in microbiota development during this key developmental 
time window might affect early and later life health outcomes. We showed 
that two vancomycin dosages around time of removal of a central venous 
catheter presumably has no profound lasting effect on microbiota composition. 
However, postpartum amoxicillin/ceftazidime treatment impacts microbiota 
development, particularly by increasing the relative abundance of Enterococcus 
species, while decreasing Bifidobacterium abundance, during the first two 
postnatal weeks. In addition, more than five days of treatment seems to have 
a longer lasting effect on microbiota composition than less than three days of 
treatment as indicated by delayed (re)colonisation by Bifidobacterium species. 
In addition to gestational age and perinatal antibiotics, we included various 
factors during data analysis to elucidate their impact on gut microbiota 
development in preterm infants. As well as factors acknowledged for their 
influence on microbiota development, such as delivery mode and feeding 
strategy, we identified a potential influence of gender, respiratory support 
and maternal preeclampsia. These findings could serve as incentive for the 
initiation of future studies to unravel the true influence of such factors on 
microbiota development.
The research described in this thesis contributes to current knowledge 
regarding gastrointestinal function and microbiota development during the 
early life of preterm infants and the factors associated with this development. 
This contribution could aid clinical practice and development of therapeutic 
strategies. In light of this, future work should consider 1) to implement functional 
analysis of the microbiota, 2) to study alternatives to antibiotics for the treatment 
and prevention of infections and 3) to elucidate the effect of microbiota targeting 
therapeutic strategies during preterm infant care. 
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CHAPTER 1
GENERAL INTRODUCTION AND 
THESIS OUTLINE
PRETERM BIRTH
It is estimated that approximately fifteen million babies are born preterm every 
year and that complications associated with preterm birth are responsible for 
one million deaths worldwide1. In addition to mortality, preterm birth contributes 
to the development of early and later life health complications associated with 
organ immaturity2. Health complications are therefore related to gestational 
age, with babies born with lower gestational age generally needing more 
extensive care. Caring for the preterm neonate includes providing warmth, 
feeding support, breathing support, pain reduction and infection prevention3. 
Despite special care, preterm infants commonly suffer from complications 
during their early life which include respiratory distress syndrome, jaundice, 
infection, sepsis and necrotising enterocolitis (NEC). In addition, preterm birth 
is related to negative health outcomes in later life such as learning impairment, 
visual disorders, asthma and allergies, exerting a heavy burden on families, 
society and the health care system2. 
Preterm birth is defined as live birth before 37 complete weeks of pregnancy 
and is further categorised, based on gestational age, in extremely preterm 
(<28 weeks), very preterm (28 - <32 weeks) and moderate to late preterm (32 - 
<37 weeks) birth4. The incidence of preterm birth ranges from five percent in 
northern European countries to 18 percent in some African countries. Although 
preterm birth is generally higher in low-income countries, rates are high in 
some high-income counties, including the United States of America where 
one in eight babies are born preterm1. 
The pathway of labour consists of increased uterine contractility, cervical 
dilatation, and rupture of the chorioamniotic membranes. In the case of 
spontaneous preterm labour, one or more of these components is initiated too 
early5. Early initiation has been associated with vascular disorders, decidual 
senescence, uterine over-distension, cervical disease, stress, breakdown of 
maternal-foetal tolerance and infection5. Risk factors for preterm birth, related 
to abovementioned pathologies, are low or high maternal age, short pregnancy 
intervals, multiple pregnancies, infections like urinary tract infection, HIV, 
bacterial vaginosis and chorioamnionitis, low or high BMI, smoking, alcohol 
consumption, excessive physical work and bad psychological health1.
FEEDING THE IMMATURE GASTROINTESTINAL TRACT
Development of the gastrointestinal tract (GIT) during gestation is generally 
subdivided in processes involved in cytodifferentiation, digestion, absorption 
and motility (Fig 1.1)6,7. Many structural and functional properties of the GIT 
develop within 24 weeks gestation. Anatomically, all parts of the GIT are 
developed within the first 12 weeks of gestation, while it takes up to 20 weeks 
for the villi and crypts to develop. In case of preterm birth, the infant particularly 
suffers from immaturity related to digestion and motility, since these are mainly 
developing during later stages of gestation (Fig 1.1). Digestive enzymes (e.g. 
lactase, sucrase, maltase, peptidase) can be detected from eight weeks 
gestation, but some enzymes are at that stage far below their full potential 012
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concentration and activity. Lactase activity, important for the degradation 
of lactose from milk, starts maturing from 24 weeks onwards and reaches 
maximum activity at 40 weeks gestation. Maximum activity of lactase during 
gestation is estimated to be just 30% of the adult capacity, and its activity is 
particularly triggered by the first feeding after birth6. Sucking, swallowing, 
gastric emptying and intestinal motility develop during the third trimester and 
effective coordination of these processes is reached at term (Fig 1.1). 
Figure 1.1 | Timeline of 
structural and functional 
development of the 
gastrointestinal tract. EP: 
extremely preterm, VP: very 
preterm, MLP: moderate to 
late preterm, MMC: migrating 
motor complex. Adjusted from 
Commare and Tappenden6 and 
supplemented with information 
from Patole et al 7. 
0       3       6       9       12       15       18       21       24       27       30       33       36       39       42
 Trimester 1         Trimester 2          Trimester 3
EP   VP   MLP         Term
Cytodifferentiation
Development of intestinal segments
Villi and crypt development
Digestion
Peptidase, sucrase, lactase, insulin, glucagon detected Sucrase 70%    Lactase
Pancreatic secretions
Gastric lipase
Pepsin activity increasing
Absorption
Glucose transporters
Motility
Swallowing  Effective suckling/swallowing
Intestinal motility             Mature
Poor oesophageal reflux
MMC
Gastric emptying
Motilin receptors
Elongation of intestine   50 cm              100 cm  200 cm
The decreased activity of digestive enzymes, in combination with immature 
motility functions and increased protein demands in preterm infants, raises a 
major challenge in meeting their nutritional needs8. Preterm infants, particularly 
those born before 32 weeks gestation, are prone to be intolerant to enteral feeding 
and most nutrients are provided intravenously via parenteral feeding for several 
weeks. However, the lack of enteral nutrients is not favourable and has been 
associated with a decrease in hormone activity, intestinal mucosa maturation, 
digestive enzyme activity, nutrient absorption and motility maturation and 
with an increase in gut permeability and bacterial translocation8. To stimulate 
functional maturation of the gastrointestinal tract of preterm infants, minimal 
enteral nutrition has been practiced widely in neonatal intensive care units9. 
During minimal enteral nutrition, small volumes (12 - 24 mL/kg/d) of breast milk 013
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or formula are provided to the infant, without nutritive intend but aiming to reach 
full enteral feeding as quick as possible. Major determinants of withholding 
enteral feeding are NEC and feeding intolerance. Both, however, are not 
negatively affected by minimal enteral nutrition10,11. In addition to its function 
in nutrient digestion and absorption, the gastrointestinal tract is in close 
interaction with the endocrine, neural and immune system. Gastrointestinal 
immaturity may therefore impact processes distant from the gut. As mentioned 
before, preterm birth is associated with sepsis, NEC, learning impairment, 
asthma and allergies, all of which can be related to underdeveloped gut 
functioning and nutrient deficits during a critical developmental time window. 
Important to mention in this context is that the gastrointestinal tract is host to 
a complex community of microorganisms. Development of the gut microbiota 
coincides with maturation of the gastrointestinal tract and immune system and 
its establishment is stimulated by the dietary components in the gut lumen. 
Taking this all together, optimal feeding of the immature gastrointestinal tract 
is crucial for healthy growth and development of the infant. 
HOST-MICROBE INTERACTIONS FOR HEALTH
The realisation that microorganisms are critical for human physiology has led 
to a new era in biology and medicine, expanding the number of studies aiming 
to find a relation between the human microbiota and health and disease. The 
human microbiota comprises bacteria, archaea, fungi and viruses that can be 
found on various body sites. Since bacteria achieve the highest cell density, 
most studies only consider the bacterial fraction of the microbiota, which also 
accounts throughout this thesis. It is estimated that the ratio of bacterial to 
human cells is around 1:1, depending on colon volume, blood volume, bacterial 
density of the colon and haematocrit12. The gastrointestinal tract is the most 
densely populated site of the human body13, varying from 104-108 cells per ml 
luminal content in the small intestine to 1010-1011 cells per gram faeces in the 
colon of adults14-16. 
The gut microbiota contributes to human physiology by its participation in several 
metabolic processes, its resistance to pathogen colonisation, its interaction 
with the immune system and its influence on organ development17. Germ-free 
mice, compared to specific-pathogen-free and wild-type mice, have different 
anatomical and physiological features including vitamin K and B deficiency, 
reduced liver size, reduced cardiac output and blood flow, smaller intestinal 
surface area, underdeveloped villi, high levels of mucin and longer transit 
time18. Although findings in mice cannot be directly extrapolated to humans, 
it demonstrates that host development and physiology are modulated by the 
microbiota. Regarding host metabolism, the gut microbiota has an important 
contribution via the breakdown of polysaccharides and polyphenols and via the 
synthesis of vitamins using enzymes that are not encoded in the human genome. 
In addition, the gut microbiota is involved in degradation of all sorts of dietary 
components and of some host-generated compounds, including bile acids and 
mucus19. Several studies have linked the gut microbiota to energy harvest capacity 
and adiposity of the host20,21. These metabolic features of the gut microbiota 014
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deserve additional attention in relation to preterm infants, since these infants 
commonly suffer from nutrient deficits resulting in suboptimal growth outcomes. 
In addition to its metabolic function, the gastrointestinal tract, including its 
microbiota, plays a crucial role in host immune functioning. The mucosal immune 
system within the intestines provides tolerance to mutualistic microorganisms, 
is responsive to pathogens and acts a barrier against microbial translocation17. 
The role of the gut microbiota in providing colonisation resistance has been 
well demonstrated by the success rate of faecal microbiota transplantation as 
treatment for recurrent Clostridium difficile infection22. The contribution of the 
gastrointestinal tract and its microbiota to maturation and functioning of the 
immune system should be regarded in the case of preterm infants, who’s immune 
compromised condition may have lifelong consequences. Thus far, an aberrant 
microbiota composition has been associated with the progression of numerous 
diseases and health conditions within and distant from the gastrointestinal tract, 
such as obesity, metabolic syndrome, several auto-immune diseases, irritable 
bowel syndrome and inflammatory bowel disease23-26. In most cases, however, 
it remains unclear whether an altered microbiota is a cause, a contribution or a 
consequence. Experiments in which specific microbes, a consortium of microbes 
or a complete microbiota is transplanted into healthy or diseased hosts are, so 
far, best in providing evidence for a causal relation between the gut microbiota 
and health outcomes 21,27-30.
Regarding early life, Bifidobacterium species are particularly abundant and 
regarded as beneficial for their positive influence on development and function 
of the metabolic and immune system and for their role in pathogen exclusion31,32. 
Bifidobacteria are gram-positive, anaerobic, non-motile, non-spore forming 
bacteria that can be branched shaped (bifid). Bifidobacteria produce lactic 
acid, which exhibits antimicrobial activity, as one of their main fermentation end 
products31. In addition, the ability of bifidobacteria to degrade glycan structures 
contained in human milk and mucus provides a competitive advantage during 
colonisation of the infant gut. Divergence in the diversity or abundance of 
Bifidobacterium species has been observed in several early and later life 
diseases and their beneficial properties are currently exploited as probiotics33. 
STUDYING THE GASTROINTESTINAL MICROBIOTA
For characterising the gut microbiota, most studies rely on the use of faecal 
samples as representative. Collection of faecal samples is relatively simple and 
non-invasive compared to alternatives such as biopsies and lavage collected 
via colonoscopy. It must be noted, however, that microbiota composition exhibits 
marked variation along different sites of the gastrointestinal tract and that 
findings vary with the use of different sample types34-36. 
For a long time, studying the gut microbiota consisted of cultivation, isolation 
and morphological and biochemical characterisation of microbial isolates. A 
major limitation of these conventional techniques is its selectivity towards 
readily cultivatable microbes, while the vast majority of microorganisms cannot 
be cultured37. Recent advances in technology and associated computational 015
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methods allows for the assessment of the composition, function and activity 
of microorganisms in an ecosystem by studying their DNA (metagenomics), 
RNA (metatranscriptomics), proteins (metaproteomics) and metabolites 
(metabolomics). By combining these techniques, scientists attempt to answer 
the questions ‘who are there?’, ‘what can they do?’ and ‘what are they doing?’. 
All technologies have their specific advantages and disadvantages related to 
information obtained, accuracy, costs and complexity. 
In addition to metagenomics, in which the whole genomic content is sequenced, 
microbiota composition can be assessed by sequencing of specific genes such 
as the 16S rRNA gene and the 18S rRNA gene for prokaryotic and eukaryotic 
microorganisms respectively. Most studies, so far, applied sequencing of the 
16S rRNA gene to determine the composition of the bacterial fraction of the gut 
microbiota, with the advantage that costs and complexity are relatively low, and 
the disadvantage that classification is up to genus level and no information about 
functionality is obtained. To understand the role of the gut microbiota in health 
and disease, it is of great importance to characterise its functional traits. In light 
of this, metaproteomics, in which the whole protein content of a sample is studied, 
is emerging38. This technique allows for the identification of expressed proteins 
and therefore provides insight in activity of the gut microbiota, thereby filling the 
functional gap created by sequencing of the 16S rRNA gene or the metagenome. 
However, identification of low abundant proteins remains challenging and the 
overall methodology is labour intensive compared to sequencing-based methods. 
Nevertheless, metaproteomics can provide a great amount of qualitative and 
quantitative data, giving insights in the host-microbiota relationship and its 
consequences to health and the development of complex diseases39-42. In 2009, 
Verberkmoes et al. reported the faecal metagenome and metaproteome of an 
adult twin pair43. They identified a common core proteome that was stable, but 
distinctive, for each individual. In addition, observed dissimilarities between 
the metagenome-based prediction of the proteome and the actual proteome 
highlight the added value of a metaproteomics approach.
INTESTINAL MICROBIOTA DEVELOPMENT
Foetal development is believed to occur in a sterile environment and colonisation 
of foetal membranes and amniotic fluid is particularly presented in the context 
of infections and preterm delivery. The concept of a sterile in utero environment 
has recently been challenged by studies showing bacterial signatures in the 
placenta, amniotic fluid, meconium and umbilical cord blood44-46. However, 
critical evaluation revealed that such studies generally lack good biological 
and technical controls and that they, when attempted, often failed to show 
viable bacteria47. Nevertheless, this field of research is emerging, and it may 
only be a matter of time before the answer to ‘when do bacteria first colonise 
the human body?’ is revealed. 
It has been generally accepted that initial acquisition of the neonatal microbiota 
occurs during and after birth, a dynamic process during which microbial density 
and diversity are increasing and the community changes from being dominated 016
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by aerotolerant to anaerobic bacteria48. The colonisation process is influenced 
by several host and environmental factors like gestational age, delivery mode, 
diet and antibiotic treatment. Delivery mode is a major determinant of which 
microbes are provided as first inoculum to the infant. The microbiota of vaginally 
delivered infants resembles that of the vagina and maternal faeces, while the 
microbiota of infants born through caesarean section resembles the skin and 
environmental microbiota49,50. In addition, delivery through caesarean section 
has been associated with delayed colonisation by specific taxa during the first 
six postnatal months51. During this time, the infant is solely exposed to milk 
feedings, either breastmilk or infant formula. The World Health Organisation 
recommends exclusive breastmilk feeding up till six months of age for the infant 
to benefit from the nutrients, immunoglobulin A and antimicrobial components 
contained in human breastmilk52. Exclusive breastmilk feeding selects for 
bacteria specialised in degradation of complex human milk oligosaccharides, 
particularly specific members of the Bifidobacterium genus53. This is shown by 
the observation that the microbiota of breastfed infants is typically dominated 
by Bifidobacterium species, while formula-fed infants harbour a more diverse 
microbiota. However, infant formulas have become more bifidogenic since the 
addition of prebiotics such as a mixture or short chain galactooligosaccharides 
(GOS) and long chain fructooligosaccharides (FOS)54. Solid food is generally 
introduced to an infant at around four to six months of age. This introduction 
exposes the gut microbiota to a larger array of non-digestible carbohydrates 
and other dietary components, thereby promoting bacterial species with the 
ability to utilise these substrates55. As such, transition towards a more diverse, 
adult-like microbiota is started and is achieved around three years of age50,56. The 
composition of the adult gut microbiota is generally stable and mainly comprises 
members of the Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria and 
Verrucomicrobia phyla57. Each individual harbours up to 1000 different bacterial 
species, with a host-specific composition and diversity that are influenced by 
lifestyle and dietary factors56,58. As humans age, the microbiota ages with them. 
Changes occur gradually over time, its rate and pattern being affected by age-
associated alterations in lifestyle, diet, frailty and inflammation59.
As mentioned before, the gut microbiota plays an essential role in human 
physiology and some consider the intestinal microbiota, containing its own 
specific functional traits, as an organ within an organ60. The human host and its 
microbiota must establish and maintain mutualistic symbiosis. Although the 
composition of the gut microbiota is individual-specific, it contains common 
compositional and functional signatures that, in healthy adults, are resilient 
and resistant to change61. Factors contributing to a resilient microbiota include 
its composition and diversity, as well as specific host-microbe and microbe-
microbe interactions61. In early life, the intestinal microbiota can be considered 
simple, with low bacterial load, diversity and resilience and is therefore more 
responsive to perturbations. When circumstances are not allowing healthy 
microbiota development, like in the case of preterm birth, this may have serious 
consequences for health throughout life. However, the developing microbiota 
also provides a window of opportunity to manipulate the microbiota to our 
benefit. 017
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INTESTINAL MICROBIOTA OF THE PRETERM INFANT
Preterm infants have an immature gut and are exposed to factors like extended 
hospitalisation, caesarean section, delayed enteral feeding and antibiotics. 
Therefore, establishment of their gut microbiota is likely to be impacted. 
Compared to term infants, preterm infants gut microbiota is less diverse and 
characterised by high levels of facultative anaerobic bacteria and delayed 
colonisation with obligate anaerobic bacteria like Bifidobacterium62-64. 
Immaturity of the gastrointestinal tract could affect the colonisation process 
and be an explanation for the observation that Bifidobacterium species colonise 
the preterm infant gut between 33-36 weeks postconceptional age, independent 
of postnatal age65. However, because of the strong association between 
gestational age and the extent and duration of care, it is practically impossible 
to examine the sole effect of gestational age on microbiota development. 
Antibiotics are the most used therapeutics in neonatal intensive care 
units (NICUs), prescribed for the prevention and treatment of infections 
and sepsis66. Antibiotics, especially broad-spectrum antibiotics, such as 
vancomycin, penicillin’s and cephalosporins, are commonly provided in a 
prophylactic and empirical manner. Early antibiotic treatment in preterm 
infants has been associated with perturbation of microbiota development by 
decreasing community diversity, delaying colonisation with Bifidobacterium 
and increasing the abundance of multi-drug resistant members of the Klebsiella, 
Escherichia, Enterobacter and Enterococcus genera64,67,68. Prolonged antibiotic 
treatment decreased microbiota diversity more profoundly than short antibiotic 
treatment69,70. In addition, maternal antibiotic use during the perinatal period 
has been related to aberrant gut microbiota establishment of the preterm 
infant and potentially affects the overall function of the developing bacterial 
community67. The early use of antibiotics and its associated disturbances of the 
gut microbiota have been associated with negative health outcomes including 
asthma, atopy and adiposity71,72. Adverse health outcomes, together with the risk 
of emerging multi-drug resistant strains, highlight the importance of limiting 
the unnecessary use of empiric antibiotics in the NICU73,74.
Diet is acknowledged as major determinant for microbiota composition. During 
early life, nutritional needs are solely covered by milk feeding, preferably by 
breastfeeding. However, meeting the nutritional needs of preterm infants 
is challenging and requires the application of specific feeding strategies at 
individual level, including parenteral feeding, enteral feeding via a nasogastric 
tube, minimal enteral nutrition and supplementation of milk with fortifiers75. 
The influence of such feeding strategies on microbiota development are not 
well studied and outcomes are so far mainly presented in the context of growth 
rates, feeding intolerance, infections and NEC10,76,77. Up till date, studies 
have particularly focussed on the effect of various milk types, probiotics and 
prebiotics on the preterm infant gut microbiota. Mother’s own milk seems most 
favourable compared to human donor milk and infant formula, promoting a more 
stable microbiota and colonisation with anaerobic bacteria like clostridia and 
bifidobacteria78. Like in term infants, a mixture of prebiotics GOS and FOS has 
bifidogenic capacities in preterm infants. However, whether probiotics affect 018
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microbiota development remains to be elucidated since current findings are 
inconsistent78. In addition to the effect of diet on microbiota development, 
one should consider the role of the microbiota in processing these dietary 
inputs. Early differences in microbiota composition may affect the infants’ 
food digestion capacity and subsequent energy harvest21,79.
In addition to understanding how the gut microbiota of preterm infants develops 
and which factors influence this, it is of importance to comprehend the relation 
between the microbiota and health outcomes. NEC and infections are major 
contributors to mortality and morbidity among preterm infants. Several studies 
have shown abnormalities in gut microbiota composition and diversity before the 
onset of NEC and late onset sepsis80. However, a specific microbiota signature 
or causative bacterium has not been identified so far81. Associations have 
been made between NEC and the presence of members of the Proteobacteria 
phylum, specific Clostridium species and Staphylococcus aureus77,80. Targeting 
the gut microbiota is considered as strategy to prevent the onset of infections 
and NEC in preterm infants. In light of this, several nutritional intervention 
strategies are being studied, of which human milk, probiotics and lactoferrin 
seem most promising82. 
To truly understand the relation between the gut microbiota and the developing 
preterm infant, one should not solely focus on microbiota composition but 
take microbiota activity and function into account. Multi-omics techniques 
are giving the first insights in functioning of the bacterial community in the 
preterm infant gut. Metagenomics has so far particularly shown activity of the 
preterm infant microbiota in view of antibiotic resistance and pathogenicity. 
Pressured by broad-spectrum antibiotics, the gut microbiota of preterm infants 
is likely to become dominated by potential pathogenic and antibiotic resistant 
species62,83-85. Analysing the metaproteome of preterm infant faeces revealed 
temporal changes in bacterial community structure alongside increasing 
activity towards the metabolism of complex carbohydrates86,87. In addition, 
this methodology has been applied to focus on the functionality of specific 
bacterial taxa contained in the preterm infant gut88. The temporal increase in 
functional complexity of the preterm infant gut microbiota has also been shown 
by metabolomics, with metabolic complexity being related to weaning89. In 
addition, metabolomics has been applied to link specific metabolites to the 
onset of NEC and late-onset sepsis90. 
THE EIBER STUDY
‘To investigate early life colonisation and establishment of the gut microbiota in 
extremely and very preterm infants’ and ‘to understand the effect of antibiotic 
treatment duration on gut microbiota development in preterm and term infants’. 
These two aims were the incentive for initiation of the EIBER study. The EIBER 
study is an observational, single-centre, non-intervention study conducted 
between 2011-2014 at Isala, Zwolle, The Netherlands. All preterm and term 
infants born between 24-42 weeks gestation that were admitted to the neonatal 
intensive care unit and the paediatric high care unit fulfilling the inclusion 019
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criteria, but not the exclusion criteria, were eligible. In total, 119 preterm infants 
born between 24-32 weeks gestation and 119 preterm and term infants born 
between 32-42 weeks gestation were included. These infants were followed 
during the first six postnatal weeks, during which faeces and gastric aspirates 
were longitudinally collected for microbiota analysis. At all time, mothers were 
encouraged to provide human milk for tube feeding or to breastfeed when 
possible. The EIBER study provides the opportunity to get more insight in 
gastrointestinal function and microbiota development during the early life of 
preterm infants, and to link this development to various parameters including 
gestational age, nutritional factors and antibiotic treatment (Fig 1.2). Improved 
understanding of gastrointestinal functioning, which microbes colonise, 
what the microbes are doing and how microbiota establishment is affected in 
preterm infants may facilitate clinical practice and the development of effective 
strategies to prevent or treat diseases by targeting the gut microbiota. 
Figure 1.2 | A schematic 
representation of the EIBER 
study.Delivery mode
Gestational age
Feeding regimen
Hospitalisation
Antibiotics
Genetics
Maternal 
conditions
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THESIS OUTLINE
The perinatal period is regarded as window of opportunity for priming of lifelong 
metabolic, neurologic and immune functioning, with a profound role of the gut 
microbiota. Increasing the knowledge of gut microbiota development in preterm 
infants during this critical developmental period might aid clinical practice and 
improvement of early and later life health outcomes. The research described in 
this thesis aims to provide a better understanding of gastrointestinal function 
and microbiota development during the early life of preterm infants and to 
provide insight in which host and environmental factors play a key role in this 
development.
The first part of this thesis reports gastrointestinal function and microbiota 
development of extremely and very preterm infants. Current nutrition support 
strategies regularly fail to achieve in utero growth rates among preterm infants. 
In order to improve this, it is important to increase the understanding of how 
dietary inputs are processed by the immature and developing gastrointestinal 
system of preterm infants. Chapter 2 describes the gastric and faecal 
metaproteome of ten infants as determined by LC-MS/MS. Here, were focussed 
on human- and bovine-derived proteins as an indication for gastrointestinal 
functioning and related this to bacterial protein-based microbiota composition. 
Regarding gut microbiota development in preterm infants, most studies so far 
focussed on microbiota composition, while knowledge about the functional 
signatures remains limited. In chapter 3, we concentrated on the bacterial 
fraction of the faecal proteome from the same ten infants and applied 16S rRNA 
gene amplicon sequencing as complementary approach to study functional and 
compositional development of the gut microbiota. We identified gestational 
age-specific developmental patterns of the preterm infant gastrointestinal tract 
and its microbiota and thereby increased the understanding of gastrointestinal 
function and maturation in relation to microbiota development. In addition, 
the observed gestational age-specific developmental patterns of the gut 
microbiota were associated with the degree of exposure to perinatal antibiotics 
and respiratory support.
The second part of this thesis aims to understand the effect of antibiotic 
treatment on early life gut microbiota development. The prophylactic and 
empirical use of antibiotics in the neonatal unit has led to decreased morbidity 
and mortality rates. However, it may also result in antibiotic overuse, antibiotic 
resistance and disturbed gut microbiota development. Chapter 4 describes 
the effect of the prophylactic use of vancomycin during removal of a central 
venous catheter on gut microbiota development in a pilot of nineteen preterm 
infants born before 32 weeks gestation. Another pilot study, including fifteen 
infants born between 32 and 41 weeks gestation, is reported in chapter 5. Here 
we studied microbiota development during the early life of infants who varied in 
the duration of intravenous amoxicillin/ceftazidime treatment during the first 
postnatal week. As a continuation of this pilot study, chapter 6 describes the 
effect of intravenous antibiotic treatment duration on intestinal microbiota 
development in 63 infants. We showed that elongation of postpartum antibiotic 
treatment with a few days potentially delays recovery of the microbiota with 021
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weeks. Understanding the consequences of antibiotic treatment on microbiota 
development may support clinicians during the cost-benefit determination for 
antibiotic prescription (e.g. does the prophylactic use of antibiotics do more 
harm or good to the neonate?). In addition, we observed that bifidobacteria, 
despite being dominant, support a more rich and diverse community than 
other dominant bacterial taxa. In this way, bifidobacteria may contribute to 
development of a healthy and diverse ecosystem.
Chapter 7 provides a summary of the research described in this thesis and 
discusses its contribution to current knowledge in this field. In addition, it 
proposes future research directions to further increase and implement our 
knowledge about the preterm infant gut microbiota.
022
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CHARACTERISATION OF 
THE GASTRIC AND FAECAL 
PROTEOME TO UNRAVEL 
GASTROINTESTINAL 
FUNCTIONING AND MATURATION 
IN PRETERM INFANTS
ROMY D. ZWITTINK, INGRID B. RENES, RICHARD A. VAN LINGEN,  
DINY VAN ZOEREN-GROBBEN, ROCIO MARTIN, LIESBETH J. GROOT JEBBINK, 
SJEF BOEREN, RUURD M. VAN ELBURG, JAN KNOL AND CLARA BELZER
ABSTRACT
Despite the existence of various nutrition support strategies, preterm infants 
rarely meet in utero growth rates, and feeding the preterm infant remains 
challenging. In order to improve this, it is important to increase the understanding 
of how dietary inputs are processed by the immature and developing 
gastrointestinal system of preterm infants. We aimed to characterise the gastric 
and faecal proteome in order to obtain more insight in gastrointestinal function 
and maturation during the early life of preterm infants and to relate this to 
gut microbiota development. Therefore, gastric aspirates and faecal samples 
were collected from ten preterm infants during respectively the first two and 
first six postnatal weeks for metaproteomics through LC-MS/MS. In addition, 
gastric aspirates were collected daily during the first two postnatal weeks 
from 40 preterm infants for pH measurements and protease activity analysis. 
Gastric pH, pepsin and total protease activity showed high inter- and intra-
individual variation. Median pH and pepsin activity were relatively stable over 
time, while median total protease activity increased during the second postnatal 
week. The gastric proteome was mainly affected by the ratio of human milk 
and formula feeding, with multiple bioactive components being significantly 
increased at times of human milk-predominated feeding. Composition of the 
faecal proteome was associated with gestational and postnatal age. Various 
enzymes, including lactase, sucrase-isomaltase and maltase-glucoamylase, 
were more abundant in very preterm infants than in extremely preterm infants, 
and were generally higher at higher postnatal age. Such proteins could therefore 
potentially serve as markers for gut maturation status. Quantity of various 
gut maturation markers could be associated with the abundance of specific 
bacterial taxa in faeces. It is important to combine gestational age-related 
digestive capacity, microbiota composition, and feeding type accordingly to 
further improve strategies for feeding the preterm infant. In light of this, specific 
host and microbial markers regarding gut function and maturation need to be 
identified. Insights in the gastric and faecal proteome, as described herein, 
might contribute to this.
INTRODUCTION
During early life, nutritional needs are completely covered by milk feeding, 
preferably by breastmilk feeding. The World Health Organisation recommends 
exclusive breastmilk feeding up till six months of age for the infant to benefit 
from the nutritional, immunomodulatory and antimicrobial components 
contained in human breastmilk52. Whether an infant is capable of meeting 
its nutritional needs by exclusive milk feeding is largely determined by the 
level of gastrointestinal (GI) maturity. Since some digestive enzymes and GI 
motility functions develop during later stages of gestation, preterm infants 
can experience feeding constraints involving abdominal distension, vomiting 
and gastric retention8. This raises a major challenge in meeting the nutritional 
needs of preterm infants and it therefore requires application of specific feeding 
strategies at individual level, including parenteral feeding, enteral feeding via 
a nasogastric tube, minimal enteral nutrition and supplementation of milk with 
fortifiers. Nevertheless, preterm infants rarely meet in utero growth rates and 026
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feeding the preterm infant remains challenging91. Preterm infants generally 
have higher gastric pH than term infants, which may reduce activity of specific 
proteases92. However, proteolysis of the major milk proteins has been reported 
for preterm infants, in order from least to most resistant to degradation; β-casein, 
lactoferrin, serum albumin and α-lactalbumin93. A recent study showed that 
gastric protein digestion capacity is lower in preterm infants compared to term 
infants and that milk-derived proteases cannot compensate for this limitation94. 
The incomplete breakdown of proteins can be beneficial or harmful to the 
infant, depending on which specific protein remains intact (e.g. antimicrobials 
or allergens)95. In addition to the importance of gastrointestinal maturity for 
meeting nutritional needs, bacteria residing the human gastrointestinal tract 
play an essential role in metabolism of dietary components. The metabolic 
capacity of the gut microbiota is distinct, but complementary, to the activity of 
human gastrointestinal enzymes96. Variation in microbiota composition might 
differentially affect energy harvest and storage, and therefore weight gain, of 
the preterm infant21,97,98. In order to improve current feeding strategies, it is 
important to increase the understanding of how dietary inputs are processed 
by the immature and developing GI system of preterm infants. In addition, 
the relation between gut maturation and microbiota development needs 
to be further elucidated. In the study described herein, we characterised 
the gastric and faecal metaproteome of preterm infants by LC-MS/MS. In 
addition, the influence of multiple environmental factors on composition of 
the gastrointestinal proteome, and the relation between the proteome and gut 
microbiota development, were determined.
MATERIALS AND METHODS
Subjects and sample collection
This study was part of an observational, single-centre, non-intervention study 
involving (pre)term infants admitted to the hospital level III NICU or the level 
II neonatal ward of Isala in Zwolle, The Netherlands. The ethics board from 
METC Isala Zwolle concluded that this study does not fall under the scope 
of the Medical Research Involving Human Subjects Act (WMO). Informed 
consent was obtained from both parents of all individual participants included 
in the study. To get insight in digestive functioning of preterm infants, gastric 
aspirates and faecal samples were collected for metaproteomics (LC-MS/
MS) and enzyme activity analysis. Aspirates of residual gastric content were 
collected daily during the first two postnatal weeks from 40 preterm infants. 
Faecal samples were collected right after birth and at postnatal weeks one, 
two, three, four and six from ten preterm infants. A sampling scheme can be 
found in table 2.1. All samples were stored temporally at -20°C until transfer 
to -80°C. Infant clinical characteristic can be found in table 2.2.
LC-MS/MS - protein extraction, in gel digestion procedures and data analysis
Gastric aspirates and faecal samples that were collected weekly from ten 
preterm infants during respectively the first two and six postnatal weeks were 
used (table 2.1). Proteins were mechanically extracted from faeces by repeated 
bead beating as described previously99. Gastric aspirates were defrosted on ice, 
centrifuged (3000rpm; 4°C) and the pellet was removed. pH of the supernatant 027
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was determined, and the sample was centrifuged again to remove all debris 
(max rpm; 4°C). Faecal and gastric proteins were quantified using the Qubit® 
Protein Assay Kit a on a Qubit®2.0 fluorometer (Life Technologies, Carlsbad, 
CA, USA) and diluted in PBS to obtain a 3 μg/μl and 5 μg/μl concentration 
respectively. In gel digestion procedures and database construction were 
performed as previously described99. Obtained MS/MS spectra were analysed 
with MaxQuant 1.3.0.5100 as previously described99. False discovery rates were 
set to 0.01 on peptide and protein level. Minimally two peptides were necessary 
for protein identification of which at least one is unique and at least one is 
unmodified. This led to the identification of 2315 protein groups, of which 867 
were human and/or bovine derived. Each protein group was assigned to its 
corresponding KEGG Orthology (KO) identifier and annotated using the KEGG 
Brite Orthology and KEGG Brite Exosome databases101. 770 human- and bovine-
derived protein groups were identified in gastric samples of which up to 40% 
and 70% could be functionally classified using respectively the KEGG Brite 
Orthology and Exosome databases. Classified proteins identified in gastric 
aspirates during the first two postnatal weeks were mainly assigned to CHO 
metabolism, transport and catabolism, signal transduction and lipid metabolism 
and were part of immune, digestive and endocrine functioning (Fig S2.1a, S2.1b). 
Exosomal proteins mainly derived from breast milk and hepatic cells (Fig S2.1c). 
792 human- and bovine-derived protein groups were identified in meconium 
and faeces of which up to 70% and 30% could be functionally classified using 
respectively the KEGG Brite Orthology and Exosome databases. Classified 
proteins identified in meconium and faeces during the first six postnatal weeks 
contributed to signal transduction and transport and catabolism and were part 
of immune, digestive and endocrine functioning (Fig S2.1a, S2.1b). Exosomal 
proteins derived from breast milk, hepatic cells and other body fluids (saliva 
and urine) (Fig S2.1c). Intensity based absolute quantification (iBAQ) and 
label free quantification (LFQ) intensities were used for within and between 
sample comparisons respectively. When one protein could be classified 
into multiple functional categories, iBAQ intensity values were balanced 
between these categories for profile generation. Protein profiles based on 
iBAQ intensities were used for redundancy analysis using Canoco multivariate 
statistics software v5102. Here, a p-value of less than 0.05 was used as threshold 
for statistical significance. Further statistical analyses were performed in 
Perseus103. Here, LFQ intensities were 10Log transformed, samples were 
assigned to its designated study group, protein groups were filtered based 
on at least two valid values in at least one group, invalid values were replaced 
with 4, and a two-sample t-test was performed (Benjamini-Hochberg correction, 
S0=1). Bacterial-derived proteins contained in the faecal proteome were 
taxonomically classified and quantified as described previously99. To relate 
microbiota composition to human- and bovine-derived proteins, LFQ intensities 
of proteins identified in ≥50% of the samples (n=101 proteins) were correlated 
(Spearman correlation) with the abundance of the three most abundant bacterial 
genera: Bifidobacterium, Klebsiella and Enterococcus. A p-value of less than 
0.05 was used as threshold for statistical significance. 
028
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Enzyme activity analysis
Gastric aspirates were collected daily during the first two postnatal weeks 
from 40 preterm infants and stored at -20°C until transfer to -80°C (Table 2.1). 
Samples were defrosted on ice, centrifuged (3000rpm; 4°C) and the cream layer 
was removed. The pH of the supernatant was determined, and the sample was 
centrifuged again to remove any remaining cream fraction (14000rpm; 4°C). Total 
protease and pepsin activity were determined using the green fluorescence 
EnzChek® Protease Assay Kit (Molecular Probes, Eugene, OR, USA) in 
duplicate and according to manufacturer’s instructions. For determining total 
protease activity, 10mM TRIS buffer with pH 7.8 was used and the standard 
curve was generated using pancreatin from porcine pancreas (Sigma-Aldrich) 
to reach activities of 0, 0.78, 1.55, 3.10, 6.20, 12.40, 24.80 and 49.60 U/ml. For 
determining pepsin activity, 10mM HCl buffer with pH 2.2 was used and the 
standard curve was generated using pepsin from porcine gastric mucosa 
(Sigma-Aldrich) to reach activities of 0, 1.56, 3.13, 6.25, 12.50, 25, 50 and 100 U/ml.
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Table 2.2 | Infant 
characteristics.  
A-J: individual infants, GA: 
gestational age, EP: extremely 
preterm, VP: very preterm, MLP: 
moderate- to late preterm, 
BW: birth weight, FI: food 
intolerance, FEF: full enteral 
feeding, AB1: first antibiotics 
course, AB2: second antibiotic 
course, Amx: amoxicillin, Ctz: 
ceftazidime, Va: vancomycin, 
Erm: erythromycin, mem: 
meropenem, Mtz: metronidazole. 
* Data was available for 24 
infants; 9 EP and 15 VP infants. 
** Percentage of human milk 
as enteral feeding at postnatal 
weeks 1, 2, 3, 4 and 6.
Table 2.1 | Sampling scheme. 
Red: gastric aspirate, Black: 
faeces. Number next to 
circle indicates the number 
of available samples for that 
specific time point.
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RESULTS
Gastric pH and protease activity are highly variable during the first two postnatal weeks 
Gastric pH, total protease and pepsin activity were determined in 40 preterm 
infants during the first two postnatal weeks and tested for associations with 
gestational age, postnatal age, delivery mode, gender, food intolerance, % 
enteral feeding and % human milk feeding. In general, gastric pH varied greatly 
between and within infants, with a mean difference of 4.2 ± 1.3 between the 
lowest and highest pH measured within infants over time. Median gastric 
pH fluctuated between 4.5 and 5.5 over time (Fig 2.1a) and was not related to 
gestational age or any other variable. Gastric pH was exceptionally high (>8.0) 
in six infants at day of birth, but their gastric pH did not vary from the other 
infants during the following six postnatal weeks. Total protease and pepsin 
activity showed high inter- and intra-individual variation. Nevertheless, median 
activity indicated that total protease activity was higher during the second 
than first postnatal week, while pepsin activity remained more stable with 
a minor increasing trend during the first five postnatal days and a gradual 
decrease thereafter (Fig 2.1b, 2,1c). Variation in pepsin activity significantly 
correlated with gastric pH (ρ=-0.404, p=5.9E-18), but pepsin- and total protease 
activity were not associated with gestational age, delivery mode, gender, food 
intolerance, % enteral feeding and % human milk feeding (data not shown). 
Pepsin could not be identified in the generated gastric proteome data. However, 
other proteases, like chymotrypsin-like elastase family members 2A, 3A and 
3B, endo- and ceruloplasmin and trypsin, could be identified. Of these, trypsin 
(ρ=0.432, p=0.010) and chymotrypsin-like elastase family member 3A (ρ=0.475, 
p=0.004) correlated with total protease activity. 
Figure 2.1 | Dynamics of 
gastric pH (A), total protease 
activity (B) and pepsin 
activity (C) during the 
first two postnatal weeks. 
Boxplots show the median, 
25th and 75th percentiles, 
and minimal and maximal 
values with the exception of 
outliers (circles) and extremes 
(asterisks). 
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Human milk feeding is associated with an increase in digestive- and immune-related proteins
Throughout the first two postnatal weeks, milk-derived proteins, including 
lactotransferrin, alpha-lactalbumin and caseins, were particularly abundant 
in gastric samples (Table 2.3). Serum albumin, bile-salt activated lipase and 
several immunoglobulin structures were among the 25 most abundant proteins 
in gastric aspirates and are very likely to be milk-derived as well. The percentage 
of human milk in enteral feeding (22.7%, p=0.002) and sample pH (11.8%, p=0.002) 
were the main drivers for differences in the gastric proteome of preterm infants 
during the first two postnatal weeks (Fig 2.2a). Forty-five (out of 350) proteins 
were significantly different between gastric samples at time that enteral 
feedings contained more or less than 80% human milk (Fig 2.3a, Table S2.1). At 
the time when infants received less than 80% human milk, bovine-derived milk 
proteins were significantly increased. On the other hand, when enteral feeding 
consisted of more than 80% human milk, not the major human milk proteins, but 
proteins involved in digestive functioning (e.g. bile salt-activated lipase, mucin-
4, α-amylase) and immune functioning (e.g. immunoglobulins, antigens) were 
significantly increased. The contribution of gestational age to composition of the 
gastric proteome was on the edge of significance (3.7%, p=0.056). Comparing the 
gastric proteome between extremely preterm (EP) and very preterm (VP) infants, 
however, mainly reflected their difference in the ratio of human milk to formula 
intake. Since the percentage of human milk as enteral feeding during the first 
two postnatal weeks was lower in VP infants, their gastric proteome contained 
significantly increased cow milk-derived whey proteins and caseins (Table S2.2). 
Passage of milk-derived proteins through the GI-tract
The gastric proteome was very distinct from the faecal proteome, with sample 
type explaining 41.7% of the variation in proteome composition (p=0.002) (Fig 
2.2d). Between gastric and faecal samples, 271 (out of 569) proteins were 
significantly different (Fig 2.3c, Table S2.3). In gastric aspirates, 137 proteins 
were more abundant of which milk-derived whey proteins and caseins, as well 
as bile-salt activated lipase and lysozyme C were among the most differentially 
abundant proteins. Although being significantly decreased, human milk-derived 
whey proteins serum albumin and lactotransferrin were still detected in high 
quantity in faecal samples of all preterm infants, while this was not observed for 
cow milk-derived proteins (Table 2.5). In addition, bile-salt activated lipase was 
still highly abundant in faeces of extremely preterm (EP) infants, but not in very 
preterm (VP) infants (Table 2.5). During the first postnatal week, bovine-derived 
whey proteins and caseins were abundant in gastric aspirates of very preterm 
infants receiving a lower proportion of human milk as enteral feeding (Table 2.5; 
infant F, G and J; 32%, 4%, 30% human milk). In faeces, various proteases and 
peptidases, including trypsin, chymotrypsin and several brush border enzymes 
were more abundant compared to gastric samples. A big variety of proteins 
were consistently identified in the gastric and faecal proteome, but did not 
differ in quantity, including prostasin, annexin A2, antithrombin-III, Ig alpha-1 
chain C region, triosephosphate isomerase, ceruloplasmin, leucine-rich alpha-
2-glycoprotein, galectin-3-binding protein, Ig lambda-2 chain C region, protein 
S100-A8, histone H4, alpha-1-antichymotrypsin, Ig kappa variable 3-11 and Ig 
kappa chain V-I region (data not shown). 
Figure 2.2 | Ordination 
analysis of the gastric and 
faecal proteome.  
A. Redundancy analysis of the 
gastric proteome during the first 
two postnatal weeks.  
B. Principal component analysis 
of the meconium and faecal 
proteome during the first six 
postnatal weeks.  
C. Redundancy analysis of 
the faecal proteome during 
postnatal weeks 1-6.  
D. Redundancy analysis of the 
gastric and faecal proteome at 
postnatal weeks 1 and 2.  
Arrows and stars indicate 
explanatory variables that are 
respectively continuous or a 
factor. AB: antibiotics, AB2: 
second antibiotic course, EP: 
extremely preterm, VP: very 
preterm, HM: human milk.
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Figure 2.3 | Volcano plots 
showing the difference within 
and between the gastric and 
faecal proteomes. Label free 
quantification (LFQ) intensities 
were 10log transformed, 
samples were assigned to its 
designated study group, protein 
groups were filtered based on 
at least two valid values in at 
least one group, invalid values 
were replaced with 4, and a two-
sample t-test with Benjamini-
Hochberg correction and S0=1 
was performed. p-values as 
indicated on the y-axis are -10log 
transformed. Text in red, orange 
and black indicate human-, 
humanbovine- and bovine-
derived proteins respectively.  
A. Differentially abundant 
proteins in gastric aspirates 
at time that enteral feedings 
contained more or less than 80% 
human milk. HM: human milk.  
B. Differentially abundant 
proteins in faeces from 
preterm infants born at varying 
gestational age. EP25-26: 
extremely preterm born at 25 
or 26 weeks gestation, EP27: 
extremely preterm born at 
27 weeks gestation, VP: very 
preterm.  
C. Differentially abundant 
proteins between gastric and 
faecal samples at postnatal 
weeks 1 and 2.
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The faecal proteome reflects gestational- and postnatal age
The proteome of meconium was distinct from that of faecal samples (Fig 2.2b). 
Differentiation was mainly associated with increased ras-related protein Rab-
11A, claudin-3 and mucin-13 in meconium. Majority of the 25 most abundant 
proteins were shared between meconium and faecal samples of which alpha-
1-antitrypsin, and immunoglobulin kappa variable 3-11 were particularly 
abundant (Table 2.4). Lactotransferrin and immunoglobulin alpha-1 chain 
C region were abundant in faeces, but not in meconium, and intestinal-type 
alkaline phosphatase was especially abundant during postnatal weeks 3-6 
(Table 2.4). Gestational age (10.4%, p=0.002) and postnatal age (6.3%, p=0.002) 
were the main drivers for differences in the faecal proteome of preterm infants 
during the first six postnatal weeks (Fig 2.2c). Twenty-six (out of 447) proteins 
were significantly different between faecal samples from infants at 25-26 
weeks gestation (EP25-26) compared to those born at 27 weeks (EP27) and 
30 weeks (VP) gestation (Fig 2.3b, Table S2.4). Twenty-two proteins were 
increased in EP25-26 infants, of which serotransferrin, liver-type fatty acid 
binding protein and several haemoglobin subunits were most differentially 
abundant. Intestinal maltase-glucoamylase, n-acetylated-alpha-linked acidic 
dipeptidase, lysosomal alpha-glucosidase and aspartylglucosaminidase 
were more abundant in EP27 and VP infants. In addition to age, percentage 
parenteral feeding (4.6%, p=0.006) and antibiotic treatment-related factors 
(7.3%, p<0.05) contributed to the composition of the faecal proteome. Here, 
percentage parenteral feeding was positively associated with abundance 
of annexin A4 and A13, glutathione S-transferase A2 and dihydrolipoyl 
dehydrogenase (data not shown). The number of samples at time of high 
parenteral feeding was limited, which prohibited statistical analysis to 
determine differentially abundant proteins between samples collected at 
time of high or low parenteral feeding.
Assisting the quest towards markers for gut maturation and function
Several proteins have been suggested as potential marker for gut 
maturation, including digestive enzyme markers lactase, trehalase (TREH), 
fucosyltransferase (FUT), sucrase-isomaltase (SI), maltase-glucoamylase 
(MGAM), gut wall integrity and inflammation markers fatty acid binding 
protein (FABP), calprotectin, claudin-3, trefoil factors, S100A12 and intestinal 
stem cell marker olfactomedin-4. TREH, FUT, trefoil factors and S100A12 
were not or only scarcely detected in the preterm infant faecal proteome. 
Human-derived lactase, sucrase-isomaltase, MGAM, FABP, calprotectin, 
claudin-3 and olfactomedin-4 were detected in the faecal proteome and their 
temporal patterns can be found in figure 2.4. Lactase showed an increasing 
pattern over time in very preterm infants, which was not observed in extremely 
preterm infants, resulting in higher lactase levels from the second postnatal 
week onwards in VP compared to EP infants. Sucrase-isomaltase levels were 
highest in meconium samples of preterm infants and while being stable from 
the first postnatal week onwards in VP infants, SI levels further decreased 
over time in EP infants. From the first postnatal week onwards, MGAM levels 
were higher in the faecal proteome of VP infants than of EP infants. In contrast, 
liver- and intestinal-type FABP were only observed during the first postnatal 035
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week in VP infants, while also being observed at later postnatal age in EP 
infants, particularly liver-type FABP. Calprotectin, a heterodimer of S100A8/
A9, was not detected as an entity, but S100A8 and S100A9 were separately 
identified. Both showed to be more consistently detected in VP infants than 
in EP infants. Claudin-3 and olfactomedin-4 were only abundant during early 
time points in both EP and VP infants. 
Figure 2.4 | Temporal dynamics 
of gastrointestinal integrity 
and maturation markers in the 
faecal proteome of extremely 
and very preterm infants. The 
y-axis shows 10Log transformed 
label free quantification (LFQ) 
intensity. The x-axis shows the 
postnatal age in weeks for each 
gestational age group. Boxplots 
show the median, 25th and 
75th percentiles, and minimal 
and maximal values with the 
exception of outliers (circles) 
and extremes (asterisks). 
Mec: meconium, EP: extremely 
preterm, VP: very preterm
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Microbiota development coincides with GI maturation
To relate gastrointestinal function and maturation to the developing gut 
microbiota, relative abundances of the three most abundant bacterial genera 
contained in meconium and faeces were correlated to the amount of human- 
and bovine-derived proteins therein (Table 6). Various proteins, including 
I-FABP, serum albumin, and immunoglobulins negatively correlated with 
Bifidobacterium, of which the correlation with I-FABP was most profound. 
The quantity of antioxidant superoxide dismutase positively correlated with 
Bifidobacterium abundance, and negatively correlated with Enterococcus. While 
Bifidobacterium abundance also positively correlated with digestive enzymes 
maltase-glucoamylase and lactase, the abundance of respectively Enterococcus 
and Klebsiella correlated negatively with these enzymes. Aminopeptidase N, an 
enzyme involved in the degradation of peptides resulting from protein cleavage 
by gastric and pancreatic proteases, negatively correlated with Enterococcus, 
while being positively associated with Klebsiella. Regarding immune regulation, 
abundance of Klebsiella positively correlated with acid sphingomyelinase-like 
phosphodiesterase 3b, a protein acting as negative regulator of toll-like receptor 
signalling. Carcinoembryonic antigen-related cell adhesion molecules, a human 
glycoprotein belonging to the immunoglobulin superfamily, was also positively 
associated with abundance of Klebsiella, while negatively correlating with 
Bifidobacterium and Enterococcus.
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Table 2.3 | Top 25 most 
abundant gastric proteins 
during the first two postnatal 
weeks. Relative abundances 
are based on intensity based 
absolute quantification (iBAQ) 
intensities.
  	 	 Ta
bl
e	
2.
3	
|	T
op
	2
5	
m
os
t	a
bu
nd
an
t	g
as
tri
c	p
ro
te
in
s	d
ur
in
g	t
he
	fi
rs
t	t
w
o	
po
st
na
ta
l	w
ee
ks
.	R
el
at
ive
	ab
un
da
nc
es
	ar
e	
ba
se
d	
on
	in
te
ns
ity
	b
as
ed
	ab
so
lu
te
	q
ua
nt
ifi
ca
tio
n	
(iB
AQ
)	i
nt
en
sit
ie
s.	
Fir
st
	
	
	
W
ee
k	1
	
	
	
W
ee
k	2
	
	
	
Pr
ot
ei
n	
Fr
ac
tio
n	
Ho
st
	
Pr
ot
ei
n	
Fr
ac
tio
n	
Ho
st
	
Pr
ot
ei
n	
Fr
ac
tio
n	
Ho
st
	
Se
ru
m
	al
bu
m
in
	
0.
22
63
	
Hu
m
an
	
Un
ch
ar
ac
te
riz
ed
	p
ro
te
in
	
0.
14
68
	
Bo
vin
	
La
ct
ot
ra
ns
fe
rri
n	
0.
15
33
	
Hu
m
an
	
Un
ch
ar
ac
te
riz
ed
	p
ro
te
in
	
0.
17
91
	
Bo
vin
	
La
ct
ot
ra
ns
fe
rri
n	
0.
13
21
	
Hu
m
an
	
Be
ta
-c
as
ei
n	
0.
14
61
	
Hu
m
an
	
Ha
em
og
lo
bi
n	
su
bu
ni
t	b
et
a	
0.
05
68
	
Hu
m
an
	
Se
ru
m
	al
bu
m
in
	
0.
11
67
	
Hu
m
an
	
Se
ru
m
	al
bu
m
in
	
0.
12
13
	
Hu
m
an
	
Pr
ot
ei
n	
IG
KV
3-
11
	
0.
04
46
	
Hu
m
an
	
Be
ta
-c
as
ei
n	
0.
08
69
	
Hu
m
an
	
Al
ph
a-
lac
ta
lb
um
in
	
0.
10
36
	
Hu
m
an
	
La
ct
ot
ra
ns
fe
rri
n	
0.
04
10
	
Hu
m
an
	
Al
ph
a-
lac
ta
lb
um
in
	
0.
07
56
	
Hu
m
an
	
Ka
pp
a-
ca
se
in
	
0.
06
84
	
Hu
m
an
	
Ha
em
og
lo
bi
n	
su
bu
ni
t	a
lp
ha
	
0.
03
53
	
Hu
m
an
	
Ka
pp
a-
ca
se
in
	
0.
03
80
	
Hu
m
an
	
Po
lym
er
ic	
im
m
un
og
lo
bu
lin
	re
ce
pt
or
	
0.
04
31
	
Hu
m
an
	
Al
ph
a-
lac
ta
lb
um
in
	
0.
03
02
	
Hu
m
an
	
Pr
ot
ei
n	
IG
KV
3-
11
	
0.
03
75
	
Hu
m
an
	
Bi
le
	sa
lt-
ac
tiv
at
ed
	lip
as
e	
0.
04
01
	
Hu
m
an
	
Al
ph
a-
1-
an
tit
ry
ps
in
	
0.
02
89
	
Hu
m
an
	
Po
lym
er
ic	
im
m
un
og
lo
bu
lin
	re
ce
pt
or
	
0.
03
66
	
Hu
m
an
	
Pr
ot
ei
n	
IG
KV
3-
11
	
0.
03
90
	
Hu
m
an
	
Be
ta
-c
as
ei
n	
0.
02
64
	
Hu
m
an
	
Bi
le
	sa
lt-
ac
tiv
at
ed
	lip
as
e	
0.
02
69
	
Hu
m
an
	
Ig	
alp
ha
-1
	ch
ain
	C
	re
gio
n	
0.
02
96
	
Hu
m
an
	
Po
lym
er
ic	
im
m
un
og
lo
bu
lin
	re
ce
pt
or
	
0.
02
18
	
Hu
m
an
	
Ig	
alp
ha
-1
	ch
ain
	C
	re
gio
n	
0.
02
49
	
Hu
m
an
	
Al
ph
a-
S1
-c
as
ei
n	
0.
02
15
	
Hu
m
an
	
Ig	
alp
ha
-1
	ch
ain
	C
	re
gio
n	
0.
02
02
	
Hu
m
an
	
Al
ph
a-
lac
ta
lb
um
in
	
0.
01
93
	
Bo
vin
	
Ig	
lam
bd
a-
3	
ch
ain
	C
	re
gio
ns
	(F
ra
gm
en
t)	
0.
01
68
	
Hu
m
an
	
Se
ro
tra
ns
fe
rri
n	
0.
01
98
	
Hu
m
an
	
Al
ph
a-
S1
-c
as
ei
n	
0.
01
58
	
Bo
vin
	
Cl
us
te
rin
	
0.
01
18
	
Hu
m
an
	
Ig	
lam
bd
a-
3	
ch
ain
	C
	re
gio
ns
	(F
ra
gm
en
t)	
0.
01
61
	
Hu
m
an
	
Ig	
lam
bd
a-
3	
ch
ain
	C
	re
gio
ns
	(F
ra
gm
en
t)	
0.
01
24
	
Hu
m
an
	
Un
ch
ar
ac
te
riz
ed
	p
ro
te
in
	
0.
01
16
	
Bo
vin
	
Al
ph
a-
lac
ta
lb
um
in
	
0.
01
36
	
Bo
vin
	
Cl
us
te
rin
	
0.
01
20
	
Hu
m
an
	
Ly
so
zy
m
e	C
	
0.
01
13
	
Hu
m
an
	
Ha
em
og
lo
bi
n	
su
bu
ni
t	g
am
m
a-
2	
0.
01
26
	
Hu
m
an
	
Al
ph
a-
S1
-c
as
ei
n	
0.
01
20
	
Hu
m
an
	
Al
ph
a-
1-
an
tic
hy
m
ot
ry
ps
in
	
0.
00
87
	
Hu
m
an
	
Ne
ut
ro
ph
il	d
ef
en
sin
	3
	
0.
01
14
	
Hu
m
an
	
Al
ph
a-
1-
an
tic
hy
m
ot
ry
ps
in
	
0.
01
18
	
Hu
m
an
	
Ne
ut
ro
ph
il	d
ef
en
sin
	3
	
0.
00
83
	
Hu
m
an
	
Ka
pp
a-
ca
se
in
	
0.
01
02
	
Hu
m
an
	
Ly
so
zy
m
e	C
	
0.
01
04
	
Hu
m
an
	
Al
ph
a-
1-
an
tit
ry
ps
in
	
0.
00
82
	
Hu
m
an
	
Hi
st
on
e	H
4	
(F
ra
gm
en
t)	
0.
00
91
	
Bo
vin
	
Al
ph
a-
1-
an
tit
ry
ps
in
	
0.
00
99
	
Hu
m
an
	
Hi
st
on
e	H
4	
(F
ra
gm
en
t)	
0.
00
80
	
Bo
vin
	
Cl
us
te
rin
	
0.
00
89
	
Hu
m
an
	
Al
ph
a-
S2
-c
as
ei
n	
0.
00
78
	
Bo
vin
	
Im
m
un
og
lo
bu
lin
	J	
ch
ain
	(F
ra
gm
en
t)	
0.
00
77
	
Hu
m
an
	
Ha
em
og
lo
bi
n	
su
bu
ni
t	a
lp
ha
	
0.
00
83
	
Bo
vin
	
Im
m
un
og
lo
bu
lin
	J	
ch
ain
	(F
ra
gm
en
t)	
0.
00
71
	
Hu
m
an
	
M
on
oc
yt
e	d
iff
er
en
tia
tio
n	
an
tig
en
	C
D1
4	
0.
00
65
	
Hu
m
an
	
Al
ph
a-
1-
an
tic
hy
m
ot
ry
ps
in
	
0.
00
78
	
Hu
m
an
	
Ha
em
og
lo
bi
n	
su
bu
ni
t	g
am
m
a-
2	
0.
00
67
	
Hu
m
an
	
Hi
st
on
e	H
2A
.J	
0.
00
54
	
Bo
vin
	
Ly
so
zy
m
e	C
	
0.
00
75
	
Hu
m
an
	
Hi
st
on
e	H
4	
(F
ra
gm
en
t)	
0.
00
55
	
Bo
vin
	
Ha
em
og
lo
bi
n	
su
bu
ni
t	g
am
m
a-
2	
0.
00
49
	
Hu
m
an
	
Im
m
un
og
lo
bu
lin
	J	
ch
ain
	(F
ra
gm
en
t)	
0.
00
72
	
Hu
m
an
	
Ka
pp
a-
ca
se
in
	
0.
00
54
	
Bo
vin
	
La
ct
ad
he
rin
	
0.
00
45
	
Hu
m
an
	
Al
ph
a-
S1
-c
as
ei
n	
0.
00
69
	
Hu
m
an
	
Pr
ot
ea
se
	se
rin
e	2
	p
re
pr
op
ro
te
in
	
0.
00
51
	
Hu
m
an
	
Ha
em
og
lo
bi
n	
su
bu
ni
t	a
lp
ha
	
0.
00
40
	
Hu
m
an
	
Hi
st
on
e	H
2A
.J	
0.
00
52
	
Bo
vin
	
Be
ta
-c
as
ei
n	
0.
00
50
	
Bo
vin
	
Bu
ty
ro
ph
ilin
	su
bf
am
ily
	1
	m
em
be
r	A
1	
0.
00
36
	
Hu
m
an
	
	
038
Chapter 2
Table 2.4 | Top 25 most 
abundant proteins in 
meconium and faeces during 
the first six postnatal weeks. 
Relative abundances are based 
on iBAQ intensities.
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Table 2.5 | Abundance of 
major milk-derived proteins 
in gastric aspirates and 
faeces during the first two 
postnatal weeks. Log10 
transformed LFQ values are 
shown. Colouring is based on 
abundance from most abundant 
(red) to medium abundant 
(orange) to least abundant 
(green). A-J: individual infants.
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DISCUSSION
To get more insight in gastrointestinal function and maturation during the 
early life of preterm infants, the gastric and faecal proteome of ten preterm 
infants were determined by LC-MS/MS during respectively the first two and 
first six postnatal weeks. In addition, gastric pH, pepsin activity and total 
protease activity were determined in 40 preterm infants during the first two 
postnatal weeks.
Gastric pH, pepsin activity and total protease activity varied greatly between 
infants and within infants over time. Average gastric pH fluctuated between 4.5-
5.5 during the first two postnatal weeks. A previous study among late preterm 
infants reported that gastric pH varied between 2-5 at two hours after feeding, 
with lowest pH being detected in the mid- and lower-stomach104. Extremely 
high gastric pH at day of birth, as observed in some infants, might be due to 
swallowing of alkaline amniotic fluid105, and did not seem to affect pH during 
the following six weeks. Median pepsin activity was relatively stable during 
the first two postnatal weeks, and the observed variation between samples 
correlated with sample pH. While its activity could be measured, pepsin was 
not identified in the gastric proteome, which might be a result of the LC-MS/
MS detection limit. Average gastric total protease activity increased during 
the second postnatal week. Since total protease activity was determined at 
pH 7.8, and major gastric protease pepsin is active between pH 1.5-4.5, active 
proteases measured in gastric aspirates were most likely milk-derived. Human 
milk contained proteases include trypsin, plasmin, pepsin and elastase106. 
Chymotrypsin-like elastase family member 3A and trypsin were identified in 
the gastric proteome as described herein, and correlated with total protease 
activity. This indicates that human milk derived proteases may aid protein 
digestion. A previous study, however, showed that human milk-derived 
proteases cannot compensate for the low gastric protein digestion capacity 
observed in preterm infants94. High pH, combined with low pepsin activity 
could therefore still affect gastric digestive capacity of preterm infants and 
thereby decrease their nutrient utilisation potential. 
Composition of the gastric proteome was mainly driven by the percentage of 
human milk in enteral feedings. As expected, major cow milk-derived proteins 
were increased at times of more formula feeding. Human milk caseins and whey 
proteins, however, were not increased at times of more human milk feeding. 
Instead, various proteins with digestive and immune function were increased 
when feeding predominantly consisted of human milk. Among those proteins 
were various immunoglobulins, multiple antigens, bile salt-activated lipase, 
alpha-amylase and mucin-4. These proteins are present in human milk, but may 
not or to a lesser extent be available from infant formula107,108. More human milk 
feeding might therefore support digestive and immune function in preterm 
infants and positively influence health outcomes, like has been shown in term 
infants109. Compared to formula feeding, human milk feeding reduces the risk 
of NEC in preterm infants110. 
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To obtain insights in digestive capacity and protein passage through the 
GI-tract, the gastric and faecal proteome were compared. The gastric and 
faecal proteome differed greatly from each other, driven by the high amount 
of milk-derived proteins in gastric aspirates and by the presence of various 
digestive enzymes in faecal samples. Lower levels of milk-derived caseins and 
whey proteins in faeces indicates that the preterm infant gastrointestinal tract 
is capable of degrading these proteins. However, the high amount of human 
milk-derived serum albumin and lactotransferrin remaining in faeces indicates 
that these proteins are to a certain extent resistant to proteolytic degradation, 
which has been previously reported111. The passage of lactotransferrin through 
the GI system might be beneficial to the infant, since it has been shown to 
possess antimicrobial and immune modulating properties and it has been 
suggested to protect against neonatal sepsis and NEC112. Alpha-1-antitrypsin 
and alpha-1-antichymotrypsin, which were among the most abundant proteins 
identified in the gastric and faecal proteome, limit the activity of proteolytic 
enzymes and have been shown to decrease degradation of lactotransferrin 
in vitro113. Various immunoglobulin structures, including Ig alpha-1 chain C 
region, which is part of immunoglobulin A (IgA), were also among the most 
abundant proteins identified in gastric aspirates and faeces. Secretory IgA 
levels are low or non-existent in newborn infants, and are acquired via human 
milk feeding. Since IgA represents the first line of defence for the neonate by 
preventing bacterial translocation, the passage of IgA through the GI system 
is considered beneficial114. 
Composition of the faecal proteome was mainly driven by gestational age 
and postnatal age. Although majority of the 25 most abundant proteins were 
shared between meconium and faeces, divergence was observed between 
them when taking into account all identified human- and bovine-derived 
proteins. Meconium particularly consists of material ingested in utero, 
including intestinal epithelial cells, mucus and amniotic fluid. Herein, this 
was reflected by increased ras-related protein Rab-11A, claudin-3 (both 
constituents of epithelial cells) and mucin-13, and by absence of milk-derived 
proteins lactotransferrin and IgA. Intestinal-type alkaline phosphatase (IAP), 
became part of the most abundant faecal proteins from the third postnatal 
week onwards. IAP is expressed by enterocytes and secreted into the mucosa 
and lumen, where it plays an important role in maintaining gut homeostasis115. 
Its deficiency has been linked to bacterial translocation in neonates116. The 
increase of this protein with age might indicate gut maturation. Considering 
gestational age, the faecal proteome of preterm infants born at 25-26 weeks 
differed from infants born at 27 or 30 weeks. Faeces of infants born at later 
gestation showed more glycolytic and proteolytic enzymes and less red blood 
cell-related proteins (serotransferrin, haemoglobin subunits) and liver-type 
fatty acid binding protein (FABP). Liver-type and intestinal-type FABP are 
respectively considered markers for hepatic and enterocyte damage, and the 
latter has been suggested as measure for the early diagnosis of NEC117. Both 
showed high levels in meconium of all infants, but only remained abundant at 
later time points in extremely preterm infants, particularly L-FABP. None of the 
infants included in our study developed NEC, hindering the validation of faecal 043
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I-FABP as marker for its onset. Lactase, sucrase-isomaltase and maltase-
glucoamylase are suggested enzyme markers for gut maturation118, and were 
generally more abundant in very preterm compared to extremely preterm 
infants, particularly from the third postnatal week onwards. The identification of 
specific gestational age- and age-related proteins, including those mentioned 
above, might facilitate the quest towards markers for gastrointestinal function 
and maturation.
An important contributor to digestive capacity are the bacteria residing in the 
gut. Our previous work showed that a Bifidobacterium-dominated community, as 
observed in very preterm but not in extremely preterm infants, is associated with 
increased proteins involved in carbohydrate and energy metabolism, including 
those involved in the degradation of complex carbohydrates like human milk 
oligosaccharides99. Elucidating the sole effect of the gut microbiota on digestive 
functioning is challenging since the composition of the faecal proteome and 
microbiota were both related to gestational and postnatal age. The most 
abundant bacterial genera, Bifidobacterium, Klebsiella and Enterococcus, 
correlated significantly with various proteins, including some that are suggested 
as markers for GI maturation like lactase and maltase-glucoamylase. This 
demonstrates that gut maturation and microbiota development are coinciding. 
Whether these processes also affect each other could not be elucidated with 
the data described herein. Nevertheless, customising feeding regimen to 
microbiota composition is suggested as strategy to improve growth outcomes 
in preterm infants98.
Our data provides insight in the gastric and faecal proteome of preterm infants 
and presents a link to its association with gut microbiota development. In 
addition, dynamics of gastric pH, pepsin and total protease activity are 
presented. Gastric pH and protease activity are highly variable during the 
immediate weeks after birth and are not associated with any of the clinical 
variables, including food intolerance. The gastric proteome is mainly affected 
by percentage human milk feeding. Human milk can be considered a source of 
proteins involved in digestive and immune functioning. Human milk-derived 
lactotransferrin and IgA are abundant in preterm infant faeces. Human milk 
and cow milk vary in composition, and their protein counterparts might possess 
different bioactivity. The faecal proteome reflects gestational and postnatal 
age. Various enzymes, including lactase, were more abundant in very preterm 
infants than in extremely preterm infants, an indication for gut maturation 
status. Gut maturation coincided with development of the gut microbiota. 
Deeper understanding of gastrointestinal maturation and functioning in 
preterm infants in relation to microbiota development, and including the 
processing of their feedings, might contribute to the improvement of current 
nutrition support strategies. In light of this, various strategies could be 
considered to improve growth and development of preterm infants, including 
pre-treatment of milk feeding by specific digestive enzymes and the addition 
of antimicrobials (e.g. immunoglobulins) and probiotics to formula feedings.
Table S2.1 | Differentially 
abundant proteins between 
gastric samples at time 
of more versus less than 
80% human milk feeding. 
A difference below zero 
indicates the protein is higher 
in abundance at times of >80% 
human milk. 
 
Table S2.2 | Differentially 
abundant proteins between 
gastric samples from 
extremely preterm versus 
very preterm infants. A 
difference below zero indicates 
the protein is higher in 
abundance in EP infants. 
Table S2.3 | Differentially 
abundant proteins between 
gastric and faecal samples 
during postnatal weeks one 
and two. A difference below 
zero indicates the protein is 
higher in abundance in faeces.  
 
Table S2.4 | Differentially 
abundant proteins between 
faecal samples from EP25-26 
versus EP27 and VP infants 
during postnatal weeks one 
to six. A difference below zero 
indicates the protein is higher in 
abundance in EP25-26 infants. 
 
Figure S2.1 | Gastric and faecal 
profiles as annotated to KEGG 
Brite Orthology level B (A), 
Organismal systems (B) and 
Exosome (C) databases. 
Relative abundances are 
based on intensity based 
absolute quantification (iBAQ) 
intensities. 
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Table	S2.1	|	Differentially	abundant	proteins	between	gastric	samples	at	time	of	more	versus	less	than	80%	
human	milk	 feeding.	A	difference	below	zero	 indicates	 the	protein	 is	higher	 in	abundance	at	 times	of	>80%	
human	milk.	
	
-Log	p-value	 Difference	 Protein	IDs	 Protein	names	 KO	 Host	
5.50706	 -3.23666	 P01877	 Ig	alpha-2	chain	C	region	 K06856	 Human	
6.091825	 -2.96557	 P22897	 Macrophage	mannose	receptor	1	 K06560	 Human	
4.470568	 -2.70813	 E7EU05	 Platelet	glycoprotein	4	 K06259	 Human	
4.509782	 -2.55503	 O00391	 Sulfhydryl	oxidase	1	 K10758	 Human	
5.208046	 -2.4883	 P36871	 Phosphoglucomutase-1	 K01835	 HumanBovin	
4.099251	 -2.29561	 D6RD17	 Immunoglobulin	J	chain	 K06856	 Human	
3.336462	 -2.25081	 P24821	 Tenascin	 K06252	 Human	
4.248159	 -2.23497	 P49327	 Fatty	acid	synthase	 K00665	 Human	
3.197202	 -2.14536	 Q2HJ20	 Sclerostin	domain-containing	protein	1	 -	 HumanBovin	
2.705126	 -2.13861	 P08571	 Monocyte	differentiation	antigen	CD14	 K04391	 Human	
3.267333	 -2.08735	 E9PJK1	 CD81	antigen	 K06508	 Human	
2.714694	 -2.0817	 P02794	 Ferritin	heavy	chain	 K00522	 Human	
2.73336	 -2.03373	 E7ENC5	 Mucin-4	 K13908	 Human	
4.436551	 -1.98034	 P27105	 Erythrocyte	band	7	integral	membrane	protein	 K17286	 HumanBovin	
2.465505	 -1.83469	 P19440	 Gamma-glutamyltranspeptidase	1	 K18592	 Human	
3.422953	 -1.74731	 X6R868	 Bile	salt-activated	lipase	 K12298	 Human	
3.265716	 -1.65942	 Q08431	 Lactadherin	 K17253	 Human	
2.141533	 -1.65176	 Q99541	 Perilipin-2	 K17284	 Human	
2.175327	 -1.62367	 P04745	 Alpha-amylase	1	 K01176	 Human	
2.295631	 -1.60987	 P63103	 14-3-3	protein	zeta/delta	 K16197	 HumanBovin	
2.437494	 -1.58276	 Q16651	 Prostasin	 K08664	 Human	
2.101745	 -1.57743	 P07737	 Profilin-1	 K05759	 Human	
3.176606	 -1.56065	 P07996	 Thrombospondin-1	 K16857	 HumanBovin	
3.556275	 -1.55312	 A2VE41	 EGF-containing	fibulin-like	extracellular	matrix	protein	1	 K18262	 HumanBovin	
1.920706	 -1.54922	 P11021	 78	kDa	glucose-regulated	protein	 K09490	 HumanBovin	
2.397253	 -1.5448	 Q9P2E9	 Ribosome-binding	protein	1	 K14000	 Human	
3.01088	 1.336409	 Q0P569	 Nucleobindin-1	 K20371	 HumanBovin	
3.155507	 1.48516	 F1N514	 Uncharacterized	protein	 -	 Bovin	
2.222805	 1.574554	 G5E5H7	 Uncharacterized	protein	 -	 Bovin	
3.154709	 1.614098	 Q0IIA2	 Odorant-binding	protein-like	 -	 Bovin	
1.9113	 1.627408	 P81265	 Polymeric	immunoglobulin	receptor	 K13073	 Bovin	
3.174371	 1.778531	 V9GYE3	 Apolipoprotein	A-II	 K08758	 Human	
2.425921	 1.874571	 P02662	 Alpha-S1-casein	 K17281	 Bovin	
2.167456	 1.888943	 P00711	 Alpha-lactalbumin	 K00704	 Bovin	
2.2379	 1.894912	 F1N726	 Uncharacterized	protein	 K19899	 Bovin	
2.226647	 1.998172	 P02668	 Kappa-casein	 K17282	 Bovin	
3.372123	 2.043895	 F1MLW7	 Uncharacterized	protein	 K06554	 Bovin	
3.753987	 2.101781	 Q3ZCH5	 Zinc-alpha-2-glycoprotein	 -	 Bovin	
4.187334	 2.128034	 F1MI46	 Osteopontin	 K06250	 Bovin	
4.098723	 2.162103	 P24627	 Lactotransferrin	 K17283	 Bovin	
4.291268	 2.313393	 Q32PJ2	 Apolipoprotein	A-IV	 K08760	 Bovin	
4.293207	 2.325902	 Q5GN72	 Alpha-1-acid	glycoprotein	 K17308	 Bovin	
3.032697	 2.531097	 P02663	 Alpha-S2-casein	 K17281	 Bovin	
4.043882	 2.671918	 P02666	 Beta-casein	 K17107	 Bovin	
7.439817	 2.793574	 P01888	 Beta-2-microglobulin	 K08055	 Bovin	
	
	
 	Table S2.1 | Differentially 
abundant proteins between 
gastric samples at time 
of more versus less than 
80% human milk feeding. 
A difference below zero 
indicates the protein is higher 
in abundance at times of >80% 
human milk. 
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Table	S2.2	|	Differentially	abundant	proteins	between	gastric	samples	from	extremely	preterm	versus	very	
preterm	infants.	A	difference	below	zero	indicates	the	protein	is	higher	in	abundance	in	EP	infants.		
	
-Log	p-value	 Difference	 Protein	names	 KO	 Host	
2.814517	 -1.9169	 Carboxypeptidase	A1	 K08779	 Human	
2.097275	 -1.85968	 Ig	kappa	chain	V-II	region	TEW	 K06856	 Human	
1.946705	 -1.85762	 Ig	alpha-2	chain	C	region	 K06856	 Human	
3.063118	 -1.8449	 L-lactate	dehydrogenase	A	chain	 K00016	 Human	
2.384905	 -1.75755	 Mucin-4	 K13908	 Human	
2.521457	 -1.71811	 Gamma-glutamyltranspeptidase	1	 K18592	 Human	
3.106728	 -1.68606	 Colipase	 K14460	 Human	
2.216421	 -1.59295	 Chymotrypsin-like	elastase	family	member	3A	 K01345	 Human	
2.175924	 1.616146	 Polymeric	immunoglobulin	receptor	 K13073	 Bovin	
2.603476	 1.703413	 Apolipoprotein	A-IV	 K08760	 Bovin	
4.016775	 1.934035	 Uncharacterized	protein	 -	 Bovin	
2.75029	 2.060393	 Kappa-casein	 K17282	 Bovin	
3.317378	 2.08754	 Zymogen	granule	protein	16	homolog	B	 -	 Human	
2.40223	 2.087646	 Alpha-S2-casein	 K17281	 Bovin	
3.801568	 2.14862	 Alpha-S1-casein	 K17281	 Bovin	
3.428185	 2.193123	 Alpha-lactalbumin	 K00704	 Bovin	
 	
 
Table S2.3 | Differentially abundant 
proteins between gastric and faecal 
samples during postnatal weeks 
one and two. A difference below 
zero indicates the protein is higher in 
abundance in faeces. 
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Table	S2.3	|	Differentially	abundant	proteins	between	gastric	and	faecal	samples	during	postnatal	weeks	one	
and	two.	A	difference	below	zero	indicates	the	protein	is	higher	in	abundance	in	faeces.			
	
-Log	p-value	 Difference	 Protein	names	 KO	 Host	
25.09376	 -4.46708	 Intestinal-type	alkaline	phosphatase	 K01077	 Human	
13.44494	 -3.89651	 Calcium-activated	chloride	channel	regulator	1	 K05027	 Human	
22.6324	 -3.74009	 Neprilysin	 K01389	 Human	
22.82569	 -3.69612	 Xaa-Pro	aminopeptidase	2	 K14208	 Human	
13.62569	 -3.62145	 Chymotrypsin-C	 K01311	 Human	
31.57058	 -3.46235	 Intelectin-1	 K17527	 Human	
19.55465	 -3.31728	 Metalloendopeptidase	 K01395	 Human	
13.90661	 -3.30292	 Mucin-2	 K10955	 Human	
12.28733	 -3.29774	 Galectin-4	 K10091	 Human	
10.81467	 -3.20438	 Dipeptidyl	peptidase	4	 K01278	 Human	
11.73002	 -3.08569	 IGLV1-47	 K06856	 Human	
13.04377	 -2.99248	 Serpin	B6	 K13963	 Human	
10.38673	 -2.95383	 Zymogen	granule	membrane	protein	16	 -	 Human	
16.40163	 -2.8924	 Superoxide	dismutase	[Cu-Zn]	 K04565	 Human	
12.11245	 -2.85163	 N-acetylglucosamine-6-sulfatase	 K01137	 Human	
11.86395	 -2.8343	 Ig	kappa	chain	V-IV	region	Len	 K06856	 Human	
11.59421	 -2.69903	 IgGFc-binding	protein	 -	 Human	
9.660729	 -2.65032	 Serum	amyloid	P-component	 -	 Human	
11.03776	 -2.55858	 Carboxypeptidase	Q	 K01302	 Human	
10.21915	 -2.55196	 Carcinoembryonic	antigen-related	cell	adhesion	molecule	5	 K06499	 Human	
7.589604	 -2.52503	 Ig	lambda	chain	V-IV	region	Hil	 K06856	 Human	
5.363149	 -2.49785	 Trypsin-1	 K01312	 Human	
5.824536	 -2.49444	 Chymotrypsin-like	elastase	family	member	3A	 K01345	 Human	
9.701286	 -2.45268	 Glutamate	carboxypeptidase	2	 K14592	 Human	
11.00804	 -2.44731	 Sucrase-isomaltase,	intestinal	 K01203	 Human	
5.769871	 -2.43448	 Ferritin	light	chain	 K13625	 Human	
9.103516	 -2.39713	 Acid	ceramidase	 K12348	 Human	
7.389843	 -2.3833	 Acid	sphingomyelinase-like	phosphodiesterase	3b	 K01128	 Human	
9.494332	 -2.33281	 Retinol-binding	protein	2	 K18271	 Human	
6.702665	 -2.31486	 Angiotensin-converting	enzyme	 K01283	 Human	
11.0202	 -2.30367	 N-sulphoglucosamine	sulphohydrolase	 K01565	 Human	
7.642232	 -2.29781	 Ectonucleotide	pyrophosphatase/phosphodiesterase	family	member	7	 K12354	 Human	
6.050263	 -2.2701	 Transthyretin	 K20731	 Human	
5.879048	 -2.26329	 Annexin	A4	 K17093	 Human	
12.0344	 -2.25556	 Aminopeptidase	N	 K11140	 Human	
9.128276	 -2.24332	 N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase	 K01444	 Human	
6.501842	 -2.2401	 Dipeptidase	1	 K01273	 Human	
7.658119	 -2.17146	 Carcinoembryonic	antigen-related	cell	adhesion	molecule	1	 K06499	 Human	
5.005836	 -2.16617	 Ig	kappa	chain	V-III	region	WOL	 K06856	 Human	
7.824743	 -2.13384	 Lactase-phlorizin	hydrolase	 K01229	 Human	
3.527874	 -2.04826	 Trypsin-2	 K01312	 Human	
4.958143	 -1.9949	 Annexin	A13	 K17099	 Human	
5.739732	 -1.93758	 Aminoacylase-1	 K14677	 Human	
4.210144	 -1.9249	 Fatty	acid-binding	protein,	liver	 K08750	 Human	
4.228546	 -1.88101	 Pancreatic	secretory	granule	membrane	major	glycoprotein	GP2	 K19899	 Human	
3.734944	 -1.87825	 Ig	heavy	chain	V-III	region	TRO	 K06856	 Human	
5.63512	 -1.79163	 Neutral	ceramidase	 K12349	 Human	
4.128731	 -1.73317	 Protein	IGHV3-72	 K06856	 Human	
3.213611	 -1.70679	 Carboxypeptidase	A1	 K08779	 Human	
3.200024	 -1.68626	 Mucin-13	 K17298	 Human	
5.693431	 -1.68623	 Nicastrin	 K06171	 Human	
3.472017	 -1.61476	 Plasma	protease	C1	inhibitor	 K04001	 Human	
4.150643	 -1.61162	 Apical	endosomal	glycoprotein	 -	 Human	
4.752537	 -1.6054	 Sulfate	transporter	 K14701	 Human	
4.712509	 -1.56313	 Deoxyribonuclease-1	 K11994	 Human	
3.895984	 -1.53406	 Glutathione	reductase,	mitochondrial	 K00383	 Human	
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3.7698	 -1.53261	 Cathepsin	D	 K01379	 Human	
4.227371	 -1.52655	 Dehydrogenase/reductase	SDR	family	member	11	 -	 HumanBovin	
3.639286	 -1.44226	 Cadherin-related	family	member	2	 K16502	 Human	
4.259099	 -1.4243	 Long-chain-fatty-acid--CoA	ligase	5	 K01897	 Human	
2.049678	 -1.40894	 Ig	kappa	chain	V-I	region	EU	 K06856	 Human	
4.068925	 -1.39418	 Epidermal	growth	factor	receptor	kinase	substrate	8-like	protein	3	 K17277	 Human	
2.898492	 -1.36752	 Villin-1	 K05761	 Human	
3.43769	 -1.36217	 ADP/ATP	translocase	2	 K05863	 HumanBovin	
2.644483	 -1.3307	 Complement	component	C9	 K04000	 Human	
3.158821	 -1.31545	 Carcinoembryonic	antigen-related	cell	adhesion	molecule	7	 K06499	 Human	
3.295297	 -1.31044	 Microsomal	triglyceride	transfer	protein	large	subunit	 K14463	 Human	
2.742225	 -1.29324	 Ferritin	heavy	chain	 K00522	 Human	
3.600475	 -1.29293	 Metalloendopeptidase	 K08606	 Human	
1.393154	 -1.2848	 Ig	lambda	chain	V-III	region	LOI	 K06856	 Human	
3.646625	 -1.2839	 NHL	repeat-containing	protein	3	 -	 Human	
1.738629	 -1.28371	 Ig	kappa	chain	V-II	region	TEW	 K06856	 Human	
3.64693	 -1.27627	 N-acetylated-alpha-linked	acidic	dipeptidase-like	protein	 K01301	 Human	
3.153011	 -1.26608	 Guanine	nucleotide-binding	protein	G(I)/G(S)/G(O)	subunit	gamma-12	 K04347	 Human	
2.607099	 -1.24097	 Protein	S100	 -	 Human	
3.09992	 -1.22618	 Voltage-dependent	anion-selective	channel	protein	1	 K05862	 HumanBovin	
3.188948	 -1.20627	 Desmoplakin	 K10381	 HumanBovin	
3.14394	 -1.20619	 Kallikrein-1	 K01325	 Human	
1.71956	 -1.19981	 Pancreatic	triacylglycerol	lipase	 K14073	 Human	
1.788684	 -1.16694	 Carbonic	anhydrase	1	 K01672	 Human	
2.48068	 -1.16546	 Selenium-binding	protein	1	 K17285	 Human	
2.138065	 -1.15095	 Transthyretin	 K20731	 Bovin	
2.304758	 -1.14674	 Olfactomedin-4	 -	 Human	
2.022767	 -1.14102	 Eosinophil	peroxidase	 K10788	 Human	
2.969206	 -1.11053	 Guanine	deaminase	 K01487	 Human	
2.688112	 -1.107	 Nicotinate-nucleotide	pyrophosphorylase	[carboxylating]	 K00767	 Human	
1.979262	 -1.10597	 Plasma	serine	protease	inhibitor	 K03913	 Human	
1.579184	 -1.08231	 Myeloperoxidase	 K10789	 Human	
2.350154	 -1.08009	 Maltase-glucoamylase,	intestinal	 K12047	 Human	
2.612725	 -1.06609	 Small	integral	membrane	protein	24	 -	 Human	
2.723637	 -1.06045	 Ubiquitin-60S	ribosomal	protein	L40	 K04551	 Human	
1.896486	 -1.05053	 Azurocidin	 -	 Human	
3.122508	 -1.04098	 Complement	component	C7	 K03996	 Human	
2.622129	 -1.02555	 Hornerin	 -	 Human	
2.035052	 -1.01388	 Alpha-2-macroglobulin	 K03910	 Human	
2.690146	 -1.01309	 Sodium/glucose	cotransporter	1	 K14158	 Human	
1.449919	 -1.01265	 Lumican	 K08122	 Human	
1.982676	 -0.99947	 Lysosomal	alpha-glucosidase	 K12316	 Human	
2.011267	 -0.97261	 Alpha-1-acid	glycoprotein	1	 K17308	 Human	
2.30346	 -0.96567	 Gamma-glutamyl	hydrolase	 K01307	 Human	
2.215805	 -0.95261	 Chloride	anion	exchanger	 K14078	 Human	
2.217492	 -0.93783	 Fatty	acid-binding	protein,	intestinal	 K08751	 Human	
13.73433	 -0.92269	 Alpha-1-antitrypsin	 K03984	 Human	
2.235524	 -0.9176	 Melanotransferrin	 K06569	 Human	
2.197076	 -0.91453	 Cystatin-A	 K13907	 Human	
1.529349	 -0.90729	 Cytosol	aminopeptidase	 K11142	 Human	
1.865	 -0.90727	 Ig	kappa	chain	V-II	region	RPMI	6410	 K06856	 Human	
1.617794	 -0.89993	 Apolipoprotein	D	 K03098	 Human	
2.551525	 -0.89845	 Filamin-C	 K04437	 HumanBovin	
2.212369	 -0.87568	 Voltage-dependent	anion-selective	channel	protein	2	 K15040	 HumanBovin	
2.243479	 -0.87185	 Very	long-chain	specific	acyl-CoA	dehydrogenase,	mitochondrial	 K09479	 Human	
1.849431	 -0.86586	 Glutathione	S-transferase	A2	 K00799	 Human	
1.657315	 -0.84414	 Malate	dehydrogenase,	mitochondrial	 K00026	 HumanBovin	
2.671186	 -0.84303	 Arylsulfatase	A	 K01134	 Human	
1.871733	 -0.82325	 Angiotensin-converting	enzyme	2	 K09708	 Human	
1.50818	 -0.80705	 Ig	heavy	chain	V-I	region	EU	 K06856	 Human	
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2.268936	 -0.80659	 Tissue	alpha-L-fucosidase	 K01206	 Human	
2.254875	 -0.80034	 Complement	C5	 K03994	 Human	
2.250713	 -0.79157	 Unconventional	myosin-Ia	 K10356	 Human	
1.180558	 -0.79005	 Histone	H2B	 K11252	 Bovin	
1.50786	 -0.78853	 Chymotrypsin-like	elastase	family	member	2A	 K01346	 Human	
1.857129	 -0.78816	 Glia-derived	nexin	 K16643	 Human	
1.169543	 -0.78798	 Keratin,	type	I	cytoskeletal	19	 K07604	 Human	
1.838409	 -0.78741	 Dihydrolipoyl	dehydrogenase,	mitochondrial	 K00382	 Human	
2.137576	 -0.78591	 Deleted	in	malignant	brain	tumors	1	protein	 K13912	 Human	
1.69649	 -0.78396	 Sodium/potassium-transporting	ATPase	subunit	alpha-1	 K01539	 HumanBovin	
1.869727	 -0.78048	 Superoxide	dismutase	[Mn],	mitochondrial	 K04564	 Human	
1.8593	 -0.77643	 Cytochrome	c	 K08738	 Human	
1.301134	 -0.77376	 Peroxiredoxin-4	 K03386	 HumanBovin	
1.863452	 -0.76944	 Thioredoxin-dependent	peroxide	reductase,	mitochondrial	 K20011	 HumanBovin	
1.857048	 -0.75098	 Ras-related	protein	Rab-11A	 K07904	 HumanBovin	
1.822892	 -0.74077	 Aspartate	aminotransferase,	mitochondrial	 K14455	 Human	
1.829629	 -0.7145	 Thyroxine-binding	globulin	 K20734	 Human	
2.218828	 -0.6912	 Xaa-Pro	dipeptidase	 K14213	 HumanBovin	
2.401273	 0.669959	 Phospholipase	A2	 K01047	 Human	
1.709281	 0.712965	 Calreticulin	 K08057	 HumanBovin	
1.760937	 0.74456	 Actin,	cytoplasmic	2	 K05692	 HumanBovin	
1.717486	 0.747565	 Lactoperoxidase	 K12550	 Human	
2.014561	 0.774792	 Tropomyosin	alpha-4	chain	 K10373	 Human	
1.698113	 0.785788	 Lipoprotein	lipase	 K01059	 HumanBovin	
2.411904	 0.796159	 Insulin-like	growth	factor-binding	protein	1	 K10138	 Human	
2.015633	 0.820865	 Ig	alpha-2	chain	C	region	(Fragment)	 K06856	 Human	
0.964422	 0.823346	 Mucin-1	 K06568	 Human	
1.060383	 0.832489	 Ig	mu	chain	C	region	 K06856	 Human	
1.296064	 0.836877	 Beta-casein	 K17107	 Bovin	
1.114008	 0.843219	 Erythrocyte	band	7	integral	membrane	protein	 K17286	 HumanBovin	
2.066449	 0.848449	 Kininogen-1	 K03898	 Human	
2.664517	 0.850805	 Brain	acid	soluble	protein	1	 K17272	 Human	
1.304475	 0.854267	 Syntenin-1	 K17254	 Human	
2.016271	 0.854905	 Pancreatic	secretory	granule	membrane	major	glycoprotein	GP2	 K19899	 Human	
2.06375	 0.861298	 BPI	fold-containing	family	B	member	2	 -	 Human	
1.192646	 0.875628	 Glyceraldehyde-3-phosphate	dehydrogenase	 K00134	 Human	
1.25496	 0.886047	 Vitronectin	 K06251	 Human	
0.984169	 0.888012	 L-lactate	dehydrogenase	A	chain	 K00016	 Human	
1.071766	 0.920803	 Fibrinogen	beta	chain	 K03904	 Human	
2.817484	 0.922651	 Plasminogen	activator	inhibitor	1	RNA-binding	protein	 K13199	 HumanBovin	
1.717927	 0.935489	 Programmed	cell	death	6-interacting	protein	 K12200	 HumanBovin	
1.14773	 0.943545	 Fibrinogen	gamma	chain	 K03905	 Human	
2.398294	 0.954307	 Periplakin	 K10386	 Human	
3.458847	 0.981291	 Lactotransferrin	 K17283	 Human	
2.11518	 0.991164	 High	mobility	group	nucleosome-binding	domain-containing	protein	4	 K11302	 Human	
1.252575	 1.032889	 Hemoglobin	subunit	beta	 K13823	 Human	
1.843898	 1.033984	 	Uncharacterized	protein	 -	 Bovin	
1.412589	 1.039781	 Histone	H1.5	 K11275	 Human	
3.176515	 1.050741	 Histone	H1x	 K11275	 Human	
2.068581	 1.054669	 Cystatin-C	 K13899	 Human	
2.053556	 1.059834	 Phosphatidylethanolamine-binding	protein	1	 -	 HumanBovin	
2.304287	 1.060208	 Pigment	epithelium-derived	factor	 K19614	 Human	
0.956189	 1.0802	 Ig	alpha-2	chain	C	region	 K06856	 Human	
2.280811	 1.116889	 Uncharacterized	protein	 K19899	 Bovin	
1.453618	 1.124051	 Alpha-fetoprotein	 K16144	 Human	
2.808067	 1.126183	 Beta-1,4-galactosyltransferase	1	 K07966	 Human	
1.158861	 1.133613	 Immunoglobulin	J	chain	 K06856	 Human	
2.419912	 1.147362	 40S	ribosomal	protein	S14	 K02955	 Human	
1.854921	 1.148736	 Alpha-amylase	1	 K01176	 Human	
3.102516	 1.148952	 Coronin-1A	 K13882	 HumanBovin	
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2.208675	 1.185629	 Alpha-2-macroglobulin-like	protein	1	 K03910	 Human	
1.648172	 1.196673	 Hemoglobin	subunit	gamma-2	 K13824	 Human	
4.401353	 1.20076	 Complement	component	C8	alpha	chain	 K03997	 Human	
2.045817	 1.208372	 Lithostathine-1-alpha	 -	 Human	
2.874076	 1.214295	 Xanthine	dehydrogenase/oxidase	 K00106	 Human	
1.683957	 1.223903	 UTP--glucose-1-phosphate	uridylyltransferase	 K00963	 HumanBovin	
2.396141	 1.273185	 Keratin,	type	I	cytoskeletal	13	 K07604	 Human	
1.970598	 1.279662	 Alpha-S1-casein	 K17281	 Bovin	
2.250845	 1.281654	 Cornulin	 -	 Human	
3.048952	 1.292423	 Colipase	 K14460	 Human	
2.169122	 1.349201	 14-3-3	protein	zeta/delta	 K16197	 HumanBovin	
2.222032	 1.35753	 Gamma-glutamyltranspeptidase	1	 K18592	 Human	
2.845047	 1.382222	 Malate	dehydrogenase,	cytoplasmic	 K00025	 Human	
3.731391	 1.382299	 40S	ribosomal	protein	S18	 K02964	 HumanBovin	
2.784779	 1.418743	 Angiotensinogen	 K09821	 Human	
3.705013	 1.423345	 Polymeric	immunoglobulin	receptor	 K13073	 Bovin	
3.254038	 1.428878	 Mucin-5AC	 K13908	 Human	
2.006171	 1.428903	 Hemoglobin	subunit	alpha	 K13822	 Human	
2.397428	 1.440498	 L-lactate	dehydrogenase	B	chain	 K00016	 Human	
5.031481	 1.502334	 Serum	albumin	 K16141	 Human	
3.541757	 1.523183	 Cornifin-A	 -	 Human	
2.033081	 1.526697	 Carbonic	anhydrase	6	 K01672	 Human	
3.311638	 1.527865	 Sciellin	 -	 Human	
6.18575	 1.549819	 Plastin-2	 K17276	 HumanBovin	
3.975788	 1.554291	 Alpha-1B-glycoprotein	 -	 Human	
2.919112	 1.612798	 78	kDa	glucose-regulated	protein	 K09490	 HumanBovin	
3.555538	 1.632684	 Zinc-alpha-2-glycoprotein	 -	 Human	
6.388124	 1.656447	 Myristoylated	alanine-rich	C-kinase	substrate	 K12561	 HumanBovin	
3.271841	 1.667513	 Histone	H1.2	 K11275	 HumanBovin	
3.77534	 1.694085	 Annexin	A1	 K17091	 Human	
3.46091	 1.714334	 Fatty	acid	synthase	 K00665	 Human	
6.13638	 1.733894	 Non-histone	chromosomal	protein	HMG-17	 K11300	 Human	
4.412529	 1.771607	 CD81	antigen	 K06508	 Human	
6.695169	 1.781214	 Intercellular	adhesion	molecule	1	 K06490	 Human	
6.897817	 1.800893	 Protein	AMBP	 Human	
3.922411	 1.820034	 Kappa-casein	 K17282	 Bovin	
3.906188	 1.946164	 Serotransferrin	 K14736	 Human	
5.127475	 2.03566	 Gelsolin	 K05768	 Human	
8.605782	 2.067162	 Trefoil	factor	2	 -	 Human	
5.871166	 2.107727	 Mucin-5B	 K13908	 Human	
9.247864	 2.122904	 Afamin	 -	 Human	
5.094615	 2.128814	 CD59	glycoprotein	 K04008	 Human	
5.420452	 2.14729	 Neutrophil	defensin	3	 K05230	 Human	
5.618481	 2.147578	 Gastric	triacylglycerol	lipase	 K14452	 Human	
4.846356	 2.190524	 Fatty	acid-binding	protein,	heart	 K08752	 Human	
5.295207	 2.204296	 Fibrinogen	alpha	chain	 K03903	 Human	
5.854271	 2.215418	 Mucin-4	 K13908	 Human	
5.702605	 2.242363	 Alpha-lactalbumin	 K00704	 Bovin	
6.369677	 2.244624	 Apolipoprotein	A-I	 K08757	 Human	
5.794502	 2.247385	 Alpha-enolase	 K01689	 Human	
5.846826	 2.256198	 Beta-2-microglobulin	 K08055	 Human	
8.63126	 2.262198	 Ribosome-binding	protein	1	 K14000	 Human	
6.642832	 2.274194	 Prosaposin	 K12382	 Human	
8.133053	 2.325265	 Polymeric	immunoglobulin	receptor	 K13073	 Human	
7.187705	 2.334863	 Complement	factor	H	 K04004	 Human	
7.746131	 2.345229	 Phosphoglucomutase-1	 K01835	 HumanBovin	
7.047976	 2.422425	 Perilipin-2	 K17284	 Human	
6.230864	 2.423571	 Chitinase-3-like	protein	1	 K17523	 Human	
5.66476	 2.454629	 Complement	C4-A	 K03989	 Human	
6.606495	 2.49818	 Apolipoprotein	E	 K04524	 Human	
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6.20343	 2.505115	 Thrombospondin-1	 K16857	 HumanBovin	
6.797285	 2.51676	 Beta-2-glycoprotein	1	 K17305	 Human	
10.74021	 2.521944	 Salivary	acidic	proline-rich	phosphoprotein	1/2	 K13910	 Human	
14.02157	 2.53439	 EGF-containing	fibulin-like	extracellular	matrix	protein	1	 K18262	 HumanBovin	
10.58327	 2.609303	 Small	proline-rich	protein	3	 -	 Human	
6.451511	 2.621134	 Platelet	glycoprotein	4	 K06259	 Human	
8.043074	 2.626363	 Haptoglobin	 K16142	 Human	
6.888783	 2.66327	 BPI	fold-containing	family	B	member	1	 -	 Human	
9.953033	 2.692564	 Neutrophil	gelatinase-associated	lipocalin	 -	 Human	
9.65398	 2.703362	 Complement	factor	B	 K01335	 Human	
6.699166	 2.731617	 Osteopontin	 K06250	 Human	
7.142818	 2.773215	 Fructose-bisphosphate	aldolase	A	 K01623	 Human	
6.417421	 2.794992	 Sulfhydryl	oxidase	1	 K10758	 Human	
13.95951	 2.81531	 Apolipoprotein	A-IV	 K08760	 Human	
13.71184	 2.822483	 Nucleobindin-1	 K20371	 HumanBovin	
13.30885	 2.958828	 Alpha-2-HS-glycoprotein	 -	 Human	
9.183569	 2.985416	 Macrophage	mannose	receptor	1	 K06560	 Human	
9.143253	 2.991422	 Sclerostin	domain-containing	protein	1	 -	 HumanBovin	
7.457353	 3.023797	 Lactadherin	 K17253	 Human	
7.327101	 3.048476	 Tenascin	 K06252	 Human	
8.299934	 3.095148	 Lysozyme	C	 K13915	 Human	
10.43425	 3.151538	 Vitamin	D-binding	protein	 K12258	 Human	
18.25288	 3.171959	 Insulin-like	growth	factor-binding	protein	2	 K10138	 Human	
8.534266	 3.382471	 Bile	salt-activated	lipase	 K12298	 Human	
27.49858	 3.476053	 Antileukoproteinase	 -	 Human	
11.84738	 3.539449	 Prolactin-inducible	protein	 -	 Human	
10.75772	 3.560811	 Butyrophilin	subfamily	1	member	A1	 K06712	 Human	
34.62338	 3.588661	 Epididymal	secretory	protein	E1	 K13443	 Human	
12.40428	 3.721429	 Monocyte	differentiation	antigen	CD14	 K04391	 Human	
17.56549	 3.884707	 Chordin-like	protein	2	 K17280	 Human	
8.589263	 4.119535	 Beta-casein	 K17107	 Human	
14.95258	 4.128901	 Clusterin	 K17252	 Human	
15.01235	 4.145622	 Alpha-S1-casein	 K17281	 Human	
16.46909	 4.822657	 Alpha-lactalbumin	 K00704	 Human	
21.8837	 4.856932	 Kappa-casein	 K17282	 Human	
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Table	S2.4	|	Differentially	abundant	proteins	between	faecal	samples	from	EP25-26	versus	EP27	and	VP	infants	
during	postnatal	weeks	one	to	six.	A	difference	below	zero	indicates	the	protein	is	higher	in	abundance	in	EP25-
26	infants.	
	
-Log	p-value	 Difference	 Protein	names	 KO	 Host	
5.71821	 -2.68333	 Serotransferrin	 K14736	 Human	
7.578675	 -2.57419	 Fatty	acid-binding	protein,	liver	 K08750	 Human	
8.810937	 -2.43149	 Haemoglobin	subunit	beta	 K13823	 Human	
6.147903	 -1.90143	 Keratin,	type	II	cytoskeletal	8	 K07605	 Human	
5.490808	 -1.86804	 Hemoglobin	subunit	alpha	 K13822	 Human	
4.767281	 -1.80972	 Hemoglobin	subunit	gamma-2	 K13824	 Human	
3.128532	 -1.76624	 Triosephosphate	isomerase	 K01803	 HumanBovin	
3.862375	 -1.6755	 Complement	C4-A	 K03989	 Human	
1.847451	 -1.6564	 Immunoglobulin	J	chain	 K06856	 Human	
3.094607	 -1.55873	 Alpha-2-macroglobulin	 K03910	 Human	
2.435085	 -1.54018	 Glyceraldehyde-3-phosphate	dehydrogenase	 K00134	 Human	
4.839152	 -1.48895	 Alpha-fetoprotein	 K16144	 Human	
3.706777	 -1.43323	 Alpha-enolase	 K01689	 Human	
3.320974	 -1.4272	 Microsomal	triglyceride	transfer	protein	large	subunit	 K14463	 Human	
3.779303	 -1.41779	 Serum	albumin	 K16141	 Human	
2.84338	 -1.41114	 Actin	 K05692	 HumanBovin	
3.969636	 -1.4111	 Guanine	deaminase	 K01487	 Human	
2.191973	 -1.38689	 Annexin	A4	 K17093	 Human	
5.646106	 -1.34649	 Complement	C5	 K03994	 Human	
2.655013	 -1.31808	 Fibrinogen	gamma	chain	 K03905	 Human	
2.857688	 -1.26023	 Fibrinogen	alpha	chain	 K03903	 Human	
3.048467	 -1.25909	 Malate	dehydrogenase,	mitochondrial	 K00026	 HumanBovin	
4.03927	 1.589653	 N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase	 K01444	 Human	
3.955492	 1.81078	 Lysosomal	alpha-glucosidase	 K12316	 Human	
5.169723	 1.882697	 N-acetylated-alpha-linked	acidic	dipeptidase-like	protein	 K01301	 Human	
4.953836	 2.29195	 Maltase-glucoamylase,	intestinal	 K12047	 Human	
	
 	 Table S2.4 | Differentially 
abundant proteins between 
faecal samples from EP25-26 
versus EP27 and VP infants 
during postnatal weeks one 
to six. A difference below zero 
indicates the protein is higher in 
abundance in EP25-26 infants. 
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Figure S2.1 | Gastric and faecal 
profiles as annotated to 
KEGG Brite Orthology level B 
(A), Organismal systems (B) 
and Exosome (C) databases. 
Relative abundances are 
based on intensity based 
absolute quantification (iBAQ) 
intensities.
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ABSTRACT
Development of the gastrointestinal tract and immune system can be modulated 
by the gut microbiota. Establishment of the intestinal microbiota, in its turn, is 
affected by host and environmental factors. As such, development of the gut 
microbiota is greatly impacted in preterm infants, who have an immature gut 
and are exposed to factors like hospitalisation, caesarean section, antibiotics, 
and respiratory support. We analysed faecal microbiota composition and 
activity of ten preterm infants (gestational age 25-30 weeks; birthweight 
630-1750 gram) during the first six postnatal weeks through metaproteomics 
(LC-MS/MS) and 16S rRNA gene sequencing. A gestational age-dependent 
microbial signature is observed, enabling microbiota-based differentiation 
between extremely preterm (25-27 weeks gestation) and very preterm (30 weeks 
gestation) infants. In very preterm infants, the intestinal microbiota developed 
towards a Bifidobacterium-dominated community, and was associated with 
high abundance of proteins involved in carbohydrate and energy metabolism. 
Extremely preterm infants remained predominantly colonised by facultative 
anaerobes and were associated with proteins involved in membrane transport 
and translation. Delayed colonisation by obligate anaerobes could be associated 
with antibiotic treatment and respiratory support. We speculate that gestational 
age and its associated intensity of care (e.g. antibiotics and respiratory support) 
affects intestinal microbiota composition and activity in preterm infants. As 
the gut microbiota plays a major role in development of the neonate, gestational 
age and its associated factors could set the state for early and later life health 
complications via interference with microbiota development. 
INTRODUCTION
During birth and rapidly thereafter, microbes colonise the human gastrointestinal 
(GI) tract and eventually forms a stable, adult-like microbial population55,56,119. It 
is generally believed that the first colonisers are facultative anaerobes, primarily 
Staphylococcus, Streptococcus, Enterococcus and Enterobacter, who create 
an anaerobic environment to allow for colonisation by obligate anaerobes 
like Bifidobacterium, Bacteroides and Clostridium48. In early life, the intestinal 
microbiota is dynamic and its development is highly susceptible to host and 
environmental factors120. An abnormal pattern of microbial colonisation is 
characterised in preterm infants, with high levels of facultative anaerobes 
and delayed colonisation with obligate anaerobes like Bifidobacterium121-123. 
Furthermore, it has been shown that dominance of anaerobes occurs around 
postconceptional age 33-36 weeks, underlining the substantial influence of 
gestational age (GA) on microbiota development65. More frequent than term 
infants, preterm infants are exposed to caesarean section, hospitalisation, 
antibiotic treatment, delayed introduction of enteral feeding and formula 
feeding, contributing to a bacterial community rich in facultative anaerobes124. 
Respiratory support is a potential influencer of microbiota development, but 
is only occasionally mentioned in current studies. Administration of air or an 
air-oxygen mixture might interfere with microbiota development, particularly 
with colonisation of anaerobic bacteria. Altogether, the preterm infant is very 
likely to develop an altered intestinal microbiota, which can be associated 056
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with adverse early and later life health outcomes. Host-microbe interactions 
influence GI-tract and immune system development125, and disturbances 
in microbiota development have been related to development of disorders 
like NEC, infant colic, atopy, inflammatory bowel disease and obesity126-129. 
Despite increasing knowledge about microbiota composition in preterm 
infants, knowledge about the functional signatures of the intestinal microbiota 
remains limited. A metaproteomics case study of one preterm infant revealed 
that bacterial activity transits towards more complex metabolic functions in 
time87. The temporal increase in functional complexity has been confirmed by 
metabolomics in a bigger set of preterm infants, in which metabolic complexity 
was related to weaning89. The same group also showed increase in specific 
metabolites prior NEC diagnosis in preterm infants130. In the present study, 16S 
rRNA gene sequencing and metaproteomics are combined to study microbiota 
development during the first six postnatal weeks in preterm infants and to 
identify the factors associated with this development.
MATERIALS AND METHODS
Subjects and sample collection
This study was part of an observational, non-intervention study involving (pre)
term infants admitted to the neonatal intensive care unit or the paediatric ward 
of Isala in Zwolle, The Netherlands. The ethics board from METC Isala Zwolle 
concluded that this study does not fall under the scope of the Medical Research 
Involving Human Subjects Act (WMO). Informed consent was obtained from 
both parents of all individual participants included in the study. Ten preterm 
infants were included for faecal microbiota characterisation. Five infants 
(infants A-E) were born extremely preterm (EP, 25-27 weeks gestation) and five 
(infants F-J) were born very preterm (VP, 30 weeks gestation). Infant clinical 
characteristics are shown in table 3.1. Meconium and faecal samples were 
collected during the first six postnatal weeks. For metaproteomics analysis, 
meconium and faecal samples collected at week one, two, three, four and six 
were used. For infant H, samples collected daily during the first two postnatal 
weeks were also included for metaproteomics analysis, resulting in a total of 64 
samples for LC-MS/MS (Table S3.1). For 16S rRNA gene sequencing, meconium 
and faecal samples collected daily during the first two postnatal weeks, and 
collected at week three, four and six were used, resulting in 116 samples (Table 
S3.1). Samples were stored temporally at -20°C until transfer to -80°C.
Protein extraction
Proteins were extracted mechanically by repeated bead beating as described 
previously131. In short, approximately 0.125 g of meconium or faeces was 
resuspended in 375 μl PBS, mixed by vortexing and covered with gaseous 
nitrogen. Cells were lysed mechanically by five times bead beating with 0.1 
mm zirconia/silica beads using the Precellys®24 instrument at 6.5 ms-1 for 
45 s (Bertin Technologies, Montigny le Bretonneux, France). The mixture was 
centrifuged to remove beads (10.000 g; 4°C; 5min) and cell debris (14.000 g; 
4°C; 8min). Proteins were quantified using the Qubit® Protein Assay Kit a on 
a Qubit®2.0 fluorometer (Life Technologies, Carlsbad, CA, USA).057
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In gel-digestion procedures
Protein extracts were diluted in PBS to obtain a 3 μg/μl concentration. 40 
μl of each sample was mixed with 20 μl loading buffer and subsequently 50 
μl was loaded on precast 10% acrylamide gels (PreciseTM Protein Gels, 
Thermo Scientific, Rockford, IL, USA) using the Mini-PROTEAN® Tetra 
Electrophoresis System (Bio-Rad Laboratories, Hercules, CA, USA) according 
to manufacturer instructions. After short electrophoresis (20 mA; 10min) to 
allow for the complete sample to enter, the gels were stained with Coomassie 
Brilliant Blue. Proteins were reduced by incubating the SDS gels in 50mM 
dithiothreitol (60min; 60°C) while gently shaking. The gels were washed with 
water followed by protein alkylation by incubation in 100 mM iodoacetamide 
(60min; RT). The protein containing fraction of the gel was cut out with a clean 
scalpel, placed on parafilm, and further processed into 1mm2 pieces. In addition, 
a non-protein containing fraction was taken along as negative control. The gel 
pieces obtained were transferred to a 1.5 ml Eppendorf Protein LoBind tube 
and placed in 5 ng/μl trypsin solution to allow for in-gel digestion (overnight; 
RT). Protein digests were sonicated and centrifuged (14.000rpm; 5min). The pH 
of the obtained supernatant was adjusted to 2-4 with 10% trifluoroacetic acid. 
The peptide solutions were desalted and concentrated using in-house made 
C18 stage tip micro columns as described previously132. Sample volumes were 
reduced to 10 μl using a SpeedVac vacuum centrifuge at 35°C, and increased 
to 50 μl with 1 ml/l formic acid in water. Samples were analysed by nano-LC-
LTQ-Orbitrap-MS as previously described133.
Database construction
The obtained MS/MS spectra were searched against the public available Human 
Microbiome Project (HMP) reference genomes from the gastrointestinal tract, 
containing 457 bacterial genomes (2014, http://www.hmpdacc.org/HMRGD/). 
A smaller in-house database was constructed to be more representative 
to the study group and to decrease the chance of false matches. For this 
database, representative bacterial genera were selected based on the 
genera identified by using the HMP database or by 454 pyrosequencing. The 
proteomes of species within these genera were obtained from Uniprot (http://
www.uniprot.org/proteomes/) and merged into one database together with 
the proteomes of human, cow, candida spp. and common contaminants (e.g. 
trypsin and keratin). This led to an in-house database containing 87 bacterial 
species, and a total size of 438537 sequences (Table S3.2).
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Table 3.1 | Infant 
characteristics.
*  Days to reach full enteral 
feeding (>140 ml/kg/day)
**  Percentage of total feeding 
(enteral + parenteral)
***  Days until discharge
****  Respiratory support as 
mechanical ventilation 
and/or CPAP in days
Abbreviations: BW: birth 
weight, FI: food intolerance, 
#AB: number of antibiotic 
treatments, AB1: first course 
antibiotics, AB2: second 
course antibiotics, EF: enteral 
feeding, Amx: amoxicillin, Ctz: 
ceftazidime, Erm: erythromycin, 
Mem: meropenem, Mtz: 
metronidazole, Va: vancomycin
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LC-MS/MS data analysis
The mass spectrometry data have been deposited to the ProteomeXchange 
Consortium134 via the PRIDE partner repository with dataset identifier 
PXD005574. Obtained MS/MS spectra were analysed with MaxQuant 1.3.0.5100 
using the “Specific Trypsin/P” Digestion mode with maximally two missed 
cleavages, match between runs on in default settings, LFQ on in default 
settings, and default settings for the Andromeda search engine (first search 
20 ppm peptide tolerance, main search 6 ppm tolerance, ITMSMS fragment 
match tolerance of 0.5 Da, Carbamidomethyl set as a fixed modification, while 
variable modifications were set for Protein N-terminal Acetylation and M 
oxidation which were completed by non-default settings for de-amidation of 
N and Q, the maximum number of modifications per peptide was 5)135. False 
discovery rates were set to 0.01 on peptide and protein level. Minimally two 
peptides were necessary for protein identification of which at least one is 
unique and at least one is unmodified. After filtering, 1641 protein groups 
could be identified of which 953 were bacterial derived. MaxQuant creates 
protein groups containing one or more proteins. 1021 protein groups with 
more than two proteins were created, meaning that those proteins cannot 
be discriminated based on the measured peptides. In case of ambiguous 
protein assembly, the protein with highest peptide count and highest number 
of unique peptides in its group was selected for further analysis. For each 
sample, intensity based absolute quantification (iBAQ) intensities were 
used for the generation of taxonomic and functional profiles136. For taxonomic 
classification, no further ranking than genus level was applied because of high 
protein sequence homology among species from the same genus. For functional 
classification, protein IDs were assigned to KEGG Orthology (KO) identifiers 
and functionally annotated using the KEGG Brite database on hierarchy level 
B. When one protein could be classified into multiple functional categories, 
iBAQ intensity values were balanced between these categories. Sample 
proteome, KO identifier, taxonomic and functional profiles and corresponding 
clinical data were imported in Canoco multivariate statistics software v5 
for principal component analysis (PCA), redundancy analysis (RDA) and 
principal response curve analysis (PRC). Here, a p-value of less than 0.05 
was used as threshold for statistical significance. Analysis were generally 
performed using Canoco’s default settings. Specific settings are described 
in the figure captions.
DNA extraction 
DNA was extracted from faeces by the repeated bead beating plus phenol/
chloroform method as described previously137. DNA was quantified using a 
NanoDrop ND-2000 spectrophotometer (Thermo Scientific, Wilmington, DE, 
USA) and by using a Qubit®2.0 fluorometer (Life Technologies, Carlsbad, 
CA, USA).
454 Pyrosequencing
Amplification of the V3-V5 regions of the 16S rRNA gene was performed 
using the Bifidobacterium-optimised 357F and 926Rb primers as described 
previously138. For each sample, the reverse primer included a unique barcode 060
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sequence to allow for demultiplexing. PCR and 454 pyrosequencing (GS Junior, 
Roche) were performed by LifeSequencing S.L. (Valencia, Spain) as described 
previously138. Sequencing data is available in the European Nucleotide Archive 
(http://www.ebi.ac.uk/ena) under study accession PRJEB18915.
Sequencing data analysis
Pyrosequencing data was analysed using the QIIME software package 
(v1.8)139. Fasta data was demultiplexed and filtered using default settings. 
Sequences were denoised using Acacia140, followed by chimera removal 
using the Usearch algorithm141. UCLUST software142 was used to pick de 
novo operational taxonomic units (OTUs) with 97% sequence similarity. A 
representative sequence from each OTU was picked and taxonomy assigned 
using the SILVA 111 reference database143 clustered at 97% similarity and 
complying with the six taxonomic levels of Ribosomal Database Project 
(RDP) classifier. The obtained OTU table was filtered for OTUs with a total 
observation count of less than two and for OTUs that were present in less 
than two samples. This resulted in the identification of 2789 OTUs and the 
remaining of 975,238 sequences, representing 7332 ± 3022 reads per sample 
(mean+ SD). To compare the faecal microbial communities between and within 
infants, weighted unifrac distances were determined. The core microbiota was 
identified using the QIIME compute_core_microbiome.py script. OTUs present 
in at least 70% of the samples were considered to be part of the core microbiota. 
To study (dis)similarities in microbiota composition and relate changes in 
microbiota composition to clinical data, principal component analysis and 
redundancy analysis were performed using the Canoco multivariate statistics 
software v5. Specific settings are described in the figure captions.
16S rRNA gene sequence similarity
All 16S rRNA gene sequences from members of the Enterobacter (2515) and 
Klebsiella (1783) genus were downloaded from the SILVA SSU r126 RefNR 
database (www.arb-silva.de). Enterobacter sequences were blasted against 
Klebsiella sequences and vice versa and the average similarity of the hits 
was determined.
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RESULTS
Microbiota development is highly variable during the first two postnatal weeks
Analyses of the faecal metaproteome revealed that the proportion of 
bacterial proteins was low (0.7-12.1%) till the second postnatal week in all 
preterm infants (Fig 3.1). Microbiota composition, as determined by 16S rRNA 
sequencing, showed high inter- and intra-individual variation during these 
first two postnatal weeks (Fig S3.1a, S3.1b). In all infants, the core microbiota 
consisted of Enterococcus and Staphylococcus, present in 73% and 97% of the 
samples respectively (Table 3.2). Other genera, including Propionibacterium and 
Enterobacter, were identified as highly abundant during the first two postnatal 
weeks, but their abundances were more sample specific (Fig S3.2).
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Figure 3.1 | Distribution of 
bacterial-, human-, and 
bovine-derived faecal 
proteins. Relative abundances 
were calculated using iBAQ 
intensities. Human and bovin-
derived homologous proteins 
are indicated as Human/Bovin. 
Mec: meconium, A-J: individual 
infants
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Table	3.2	|	Core	fraction	and	relative	abundance	of	the	bacterial	genera	identified	in	faecal	samples	during	the	
first	 two	 postnatal	weeks.	 Core	microbiota	 and	 relative	 abundances	 of	 genera	were	 identified	 using	 faecal	
samples	from	all	preterm	infants	collected	during	the	first	two	postnatal	weeks.	
	
Phylum	 Genus	 Core*	 Rel.	abundance**	
Actinobacteria	 Bifidobacterium	 -	 0.040	±	0.137	
		 Propionibacterium	 -	 0.059	±	0.128	
Firmicutes	 Staphylococcus	 0.97	 0.338	±	0.330	
		 Enterococcus	 0.73	 0.146	±	0.253	
		 Streptococcus	 -	 0.011	±	0.036	
		 Veillonella	 -	 0.015	±	0.046	
		 Clostridium	 -	 0.021	±	0.084	
		 Lactobacillales;	Other	 -	 0.005	±	0.013	
Proteobacteria	 Enterobacter	 -	 0.058	±	0.203	
		 Escherichia-Shigella	 -	 0.001	±	0.003	
		 Enterobacteriaceae;	Other	 -	 0.001	±	0.002	
*		 Fraction	of	 samples	 in	which	 the	genus	 is	 identified.	Genera	were	 considered	 to	belong	 to	 the	 core	
microbiota	when	identified	in	at	least	70%	of	the	samples.		
**		 Mean	±	SD	
	
Gestational	age	is	predictive	for	microbial	signatures	during	early	microbiota	development	
From	the	third	postnatal	week	onwards,	the	proportion	of	bacterial-derived	proteins	rapidly	increased	
(Fig	3.1).	However,	this	process	was	delayed	in	EP	infants	(infants	A-E).	Strikingly,	the	delay	was	most	
obvious	in	EP	infants	born	at	25-26	weeks	gestation	(infants	A-C).	In	addition,	ordination	analysis	of	
the	faecal	bacterial	proteome	revealed	a	clear	separation	between	samples	from	EP	and	VP	infants,	
but	also	between	samples	from	EP	infants	born	at	25-26	or	27	weeks	gestation	(Fig	3.2a).	For	further	
analysis,	 the	 EP	 infants	were	 therefore	 stratified	 as	 born	 extremely	 preterm	at	 25-26	or	 27	weeks	
gestation	(EP25-26;	EP27).	The	GA-related	separation	of	the	faecal	bacterial	proteomes	by	ordination	
analysis	 could	 be	 explained	 by	 taxonomic	 differences	 (Fig	 3.2b).	 VP	 infants	 were	 associated	 with	
increased	 abundance	 of	 Bifidobacterium-derived	 proteins	 while	 EP25-26	 and	 EP27	 infants	 were	
associated	with	 increased	abundance	of	Enterococcus-	 and	Klebsiella-derived	proteins	 respectively.	
These	differences	remained	throughout	postnatal	weeks	3-6	(Fig	S3.3a).	Such	separation	of	samples	
could	also	be	observed	based	on	16S	rRNA	gene	sequencing	data,	associated	with	the	abundance	of	
Streptococcus,	Enterobacter	and	Bifidobacterium	(Fig	3.2c).	However,	microbiota	composition	became	
more	similar	over	time	between	EP25-26,	EP27	and	VP	infants	(Fig	S3.3b).	In	general,	EP	infants	were	
colonised	 with	 a	 higher	 proportion	 of	 aerobic	 and	 facultative	 anaerobic	 bacteria	 compared	 to	 VP	
infants	(Fig	S3.4).	Bacterial	protein	based	taxonomic	classification	revealed	that	the	biggest	proportion	
(66-90%)	of	identified	proteins	derived	from	Klebsiella,	Bifidobacterium	and	Enterococcus,	(Fig	3.3a).	
Based	on	16S	rRNA	gene	sequencing	data,	Bifidobacterium,	Enterobacter	and	Enterococcus,	comprised	
the	most	abundant	genera	(42-87%)	(Fig	3.3b).	Blasting	revealed	,	that	all	SILVA	derived	16S	rRNA	gene		
Table 3.2 | Core fraction and 
relative abundance of the 
bacterial genera identified 
in faecal samples during the 
first two postnatal weeks. 
Core microbiota and relative 
abundances of genera were 
identified using faecal samples 
from all preterm infants 
collected during the first two 
postnatal weeks.
*  Fraction of samples 
in which the genus is 
identified. Genera were 
considered to belong to 
the core microbiota when 
identified in at least 70% of 
the samples. 
** Mean ± SD
Gestational age is predictive for microbial signatures during early microbiota development
From the third postnatal week onwards, the proportion of bacterial-derived 
proteins rapidly increased (Fig 3.1). However, this process was delayed in EP 
infants (infants A-E). Strikingly, the delay was most obvious in EP infants born 
at 25-26 weeks gestation (infants A-C). In addition, ordination analysis of the 
faecal bacterial proteome revealed a clear separation between sample  from 
EP and VP infants, but also between samples from EP infants born at 25-26 or 27 
weeks gestation (Fig 3.2a). For further analysis, the EP infants were therefore 
stratified as born extremely preterm t 25-26 or 27 weeks gestation (EP25-
26; EP27). The GA-related separation of the faecal bacterial proteomes by 
ordination analysis could be explained by taxonomic differences (Fig 3.2b). 
VP infants were associated with increased abundance of Bifidobacterium-
derived proteins while EP25-26 and EP27 infants were associated with increased 
abundance of Enterococcus- and Klebsiella-d rived proteins respe tively. 
These differences remained throughout postnatal weeks 3-6 (Fig S3.3a). 
Such separation of samples could also be observed based on 16S rRNA gene 
sequencing data, associated with the abundance of Streptococcus, Enterobacter 
and Bifidobacterium (Fig 3.2c). However, microbiota composition became more 
similar over time between EP25-26, EP27 and VP infants (Fig S3.3b). In general, 
EP infants were colonised with a higher proportion of aerobic and facultative 
anaerobic bacteria compared to VP infants (Fig S3.4). Bacterial protein based 
taxonomic classification rev aled that the biggest proportio  (66-90%) of 
identified proteins derived from Klebsiella, Bifidobacterium and Enterococcus, 
(Fig 3.3a). Based on 16S rRNA gene sequencing data, Bifidobacterium, 
Enterobacter and Enterococcus, comprised the most abundant genera (42-
87%) (Fig 3.3b). Blasting revealed , that all SILVA derived 16S rRNA gene 
sequences from Enterobacte  hit Klebsiella and vice versa, with an average 16S 
rRNA gene similarity of 97.7 ± 1.7% and 98.1 ± 1.5% (mean ± SD) respectively. 
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This means that these genera cannot be distinguished based on their 16S 
rRNA gene sequence, which could lead to misclassification and contributes 
to dissimilar findings when comparing sequencing data with metaproteomics 
data. Abundance of Bifidobacterium, Enterobacter/Klebsiella, Enterococcus, 
Streptococcus and Clostridium correlated significantly (Spearman correlation 
p<0.01) between the protein- and 16S-based approach (Table S3.3).
Divergence between bacterial activity in preterm infants of varying gestational age
Faecal bacterial proteins were matched to their corresponding KO ID and could 
be classified into 21 KEGG Brite functional categories. Proteins involved in 
translation, carbohydrate (CHO) metabolism, energy metabolism, membrane 
transport and unspecified processes were most abundant (64-93%) (Fig 3.3c). 
Ordination analysis using the KEGG Brite functional profiles revealed no 
clear functional differences related to gestational age (Fig 3.2d). Similar 
functional processes were covered by different bacterial genera (Fig S3.5). 
In VP infants, Bifidobacterium was the main genus involved in each functional 
process. In EP infants, metabolic processes CHO and energy metabolism were 
predominantly covered by Enterococcus. In EP27 infants, membrane transport 
proteins were mostly derived from Klebsiella, while in EP25-26 infants these 
derived from both Klebsiella and Enterococcus. Thus, different bacteria cover 
similar functional processes leading to comparable KEGG Brite functional 
profiles. Functional (dis)similarities between infants born at varying GA were 
further explored at protein level using KO ID-based profiles. Ordination analysis 
revealed a clear separation between EP and VP infants (Fig 3.2e). EP infants 
were associated with higher abundance of KO identifiers within functional 
categories translation and membrane transport. VP infants were associated 
with increased abundance of KO identifiers within CHO and energy metabolism. 
This could also be observed from the ten most abundant KO identifiers per GA 
group (Table 3.3). The ten most abundant proteins accounted for 63.5%, 77.6% 
and 58.8% of total proteins in EP25-26, EP27 and VP infants respectively. In VP 
infants, the top 10 KO identifiers mainly represented proteins involved in CHO 
and energy metabolism, while in EP infants they represented proteins involved 
in translation and membrane transport. Murein lipoprotein was particularly 
abundant in EP27 infants, but decreased over time resulting in profiles more 
similar to EP25-26 and VP infants (Fig S3.3c). 
Figure 3.2 | Principal 
component analysis of the 
faecal bacterial community 
using (A) proteome profiles, 
(B) protein-based taxonomic 
profiles, (C) 16S rRNA gene-
based microbiota profiles, 
(D) protein-based KEGG 
Brite functional profiles and 
(E) protein-based KEGG 
Orthology identifier profiles. 
A-D: Taxa and KEGG Brite level 
B categories fitting into the 
ordination space from 75-100% 
are shown. E: KEGG Orthology 
identifiers fitting into the 
ordination space from 50-100% 
are shown.
Figure 3.3 | Protein-based (A) 
and 16S-based (B) taxonomic 
profiles and protein-based 
functional profiles (C) in 
EP25-26, EP27 and VP infants 
during postnatal weeks 3-6. 
Per time point, average relative 
abundances for each gestational 
age group are shown. Relative 
abundances were calculated 
using iBAQ intensities and read 
counts for protein and 16S based 
profiles respectively. Mec: 
meconium. 
Profiles per sample can be found 
in Fig S6.
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Table 3.3 | Top 10 KEGG 
Orthology identifiers per 
gestational age group during 
postnatal weeks 3-6. Per 
gestational age group, average 
relative abundances for each 
KEGG Orthology identifier 
were calculated based on iBAQ 
Abbreviations: GA: gestational 
age, KO: KEGG Orthology, ID: 
identifier, CHO: carbohydrate, 
EP: extremely preterm, VP: very 
preterm.
* iBAQ scores were used 
to calculate mean relative 
abundance
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A Bifidobacterium dominated community is associated with active metabolism towards human 
milk oligosaccharide degradation
VP infants showed to have a Bifidobacterium-dominated community, active in 
carbohydrate and energy metabolism. To metabolise complex CHO structures 
such as human milk oligosaccharides (HMOs), ABC transporters and glycolytic 
enzymes are required including galactosidases, fucosidases and sialidases. 
The glycolytic enzymes identified in our dataset were β-galactosidases 
derived from Bifidobacterium, Enterobacter, Streptococcus and Clostridium. 
Bifidobacterium-derived β-galactosidases were identified in all preterm 
infants, but were more abundant in VP than in EP infants (p=0.026) (Table S3.4). 
Enterobacter-, Streptococcus- and Clostridium-derived β-galactosidases could 
only be identified in very low abundance and just in a few samples. Similar 
accounted for ABC transporters for oligosaccharides; Bifidobacterium-derived 
ABC transporters were more abundant in VP than in EP infants (p=8.1E-06), 
while those Klebsiella- and Eubacterium-derived were rarely identified. ABC 
transporters for oligopeptides could only be identified in a few samples from 
both EP and VP infants.
Respiratory support and antibiotic treatment influences microbiota succession
The effect of clinical characteristics in association with microbiota composition 
and function were analysed by redundancy analysis. The GA-based separation 
of faecal microbiota composition and protein KO-ID profiles were mainly driven 
by the duration of respiratory support and antibiotic treatment-related factors 
(Fig 3.4). Respiratory support explained 24.1% and 4.9% of the variation in 
microbiota composition based on 16S and protein KO ID data respectively. 
Antibiotic treatment-related factors explained 25.6% and 44.6% of the variation 
respectively, and comprised the number and duration of treatment, and the 
administration of maternal antibiotics (Fig 3.4). Other factors, including mode of 
delivery, birth weight, feeding intolerance, proportion of human milk feeding and 
days until discharge did not have a significant influence. To provide more support 
for the association between microbiota composition and clinical factors, this 
analysis was repeated in all additional EP25-26 (n=14), EP27 (n=17) and VP30 
(n=6) infants from the complete cohort, albeit solely based on 16S rRNA gene 
sequencing (Illumina MiSeq, data not shown). Ventilation remained the main 
factor associated with microbiota composition (4.7%, p=0.002). In addition, 
maternal antibiotics and duration of the first and second course of antibiotic 
treatment respectively explained 2.0%, 2.6% and 1.8% of the observed variation 
in microbiota composition (p<0.05).
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DISCUSSION
The current study implements metaproteomics and 16S rRNA gene amplicon 
sequencing in a cohort of preterm infants to get insight into the establishment 
and activity of their intestinal microbiota. Metatranscriptomics and proteomics 
have only recently been applied to study GI- and microbiota function in preterm 
infants87,144,145. As such, a previous study showed that metaproteomics data is 
consistent with metagenomics and 16S rRNA gene analysis, and that bacterial 
activity transits towards more complex metabolic functions in time87. However, 
those findings were based on analysis of the faecal metaproteome of one 
preterm infant during the first three postnatal weeks. The current study adds 
up to this data by using a combination of metaproteomics and 16S rRNA gene 
sequencing to study microbiota development during the first six postnatal 
weeks in ten preterm infants of varying GA. 
Analysis of the faecal proteome indicated low bacterial load till the second 
postnatal week in all preterm infants. Low bacterial load might have 
contributed to the observed variation in microbiota composition during the 
first two postnatal weeks. From the third postnatal week onwards, microbiota 
composition and function could be distinguished between infants of varying 
GA. Bacterial colonisation was delayed in EP25-26 and EP27 infants compared 
to VP infants, emphasising that microbial colonisation pattern is related to GA. 
Facultative anaerobes remained dominant throughout the first six postnatal 
weeks in EP infants. Colonisation with obligate anaerobes was delayed, which 
is consistent with previous findings121-123. In VP infants, obligate anaerobe and 
beneficial early life coloniser Bifidobacterium became predominant from the 
third postnatal week. This is in concordance with a previous study showing 
that dominance of obligate anaerobes occurs around postconceptional age 
33-36 weeks in preterm infants65. The development towards a Bifidobacterium-
dominant microbiota as observed in VP infants, but not in EP infants, is more 
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Figure 3.4 | Redundancy 
analysis of the faecal 
bacterial community using 
(A) 16S rRNA gene-based 
microbiota profiles and 
(B) protein-based KEGG 
Orthology identifier profiles. 
Clinical factors that significantly 
explain the variation are shown. 
AB: antibiotic, AB1: duration of 
first course of antibiotics, AB2: 
duration of second course of 
antibiotics, Vent_CPAP_days: 
duration of ventilation and/or 
CPAP in days.
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representative of microbiota development in term, vaginally born, breastfed 
infants, which is considered most beneficial during early life development. 
The observed differences between proteome- and 16S-based taxonomy in 
EP infants could indicate that microbiota composition is not representative 
for metabolic activity of the microbiota. However, it should be noted that 
misclassification of bacterial genera could occur in case of high 16S rRNA 
gene similarity, which is the case for members of the Enterobacter and Klebsiella 
genera. Applying two complementary approaches, like metaproteomics and 
16S rRNA gene amplicon sequencing, is therefore of great added value for data 
interpretation. In general, 16S rRNA gene amplicon sequencing confirmed the 
findings obtained by metaproteomics, showing clear taxonomic differences 
between infants born at varying GA, with high abundance of Bifidobacterium 
in VP infants. 
In addition to taxonomic differences, our data shows clear differences in 
bacterial activity between GA groups. VP infants were associated with high 
abundance of proteins involved in CHO and energy metabolism, while proteins 
involved in membrane transport and translation were highly abundant in EP 
infants. Proteins related to HMO degradation were particularly abundant in VP 
infants, coinciding with the high abundance of Bifidobacterium. Bifidobacterium 
species are considered beneficial early life colonisers predominantly colonising 
the infant gut due to their ability to metabolise complex CHO structures, 
including HMOs. These findings indicate a well-established and metabolically 
active microbiota in VP infants, whereas in EP infants, the protein profile 
indicates a more active role on the generation and maintenance of biomass. 
Our findings indicate that GA is associated with microbiota establishment and 
its activity in preterm infants. However, one should be aware of the factors that 
are associated with preterm birth and keep in mind that these factors can be 
greatly related to GA, including the extent and duration of intensive care. In this 
study, the observed differences in microbiota development between EP and VP 
infants were mainly driven by respiratory support and antibiotic treatment, which 
extent is negatively correlated to GA. One of the respiratory support strategies 
is continuous positive airway pressure (CPAP) in which pressure is combined 
with air/oxygen administration, thereby allowing air to reach the GI-tract146. This 
might create an oxygen-rich environment in the GI-tract, which could impede 
the passage and survival of obligate anaerobes, hence lead to establishment 
of an intestinal microbiota dominated by aerobes and facultative anaerobes. 
Indeed, our findings show dominance of aerobic and facultative anaerobic 
bacteria in extremely preterm infants. These infants all received respiratory 
support throughout the six weeks study period. These findings are supported by 
a previous study, showing that duration of respiratory support in preterm infants 
was associated with predominance of faecal aerobes/facultative anaerobes 
and with the onset of Staphylococcal late-onset sepsis147. In addition to longer 
respiratory support, the duration and number of antibiotic treatment showed to 
be significant drivers of the observed GA-dependent microbiota development. 
Ceftazidime and amoxicillin are broad spectrum β-lactam antibiotics, targeting 069
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gram-negative and -positive bacteria. It has been shown that Bifidobacterium 
is sensitive to β-lactam antibiotics148,149 and that treatment with amoxicillin can 
greatly influence the composition of Bifidobacterium species in infant intestinal 
microbiota150. Vancomycin particularly targets gram-positive bacteria, and has 
been shown to affect Bifidobacterium148,149. Prolonged and multiple antibiotic 
treatment in EP infants could therefore delay or prohibit establishment of 
a Bifidobacterium-dominated microbiota. Previous studies indeed show 
that antibiotic treatment greatly affects microbiota development in preterm 
infants70,151,152. Although we were able to replicate our findings considering the 
role of respiratory support and antibiotic treatment on microbiota development 
in the complete cohort, the effect appeared to be less apparent. This variation 
could be due to differences in the distribution of gestational age in the groups, 
with 50% (5/10) of infants being born at 30 weeks gestation in the current study 
and only 16% (6/37) in the complete cohort. Since factors such as respiratory 
support and antibiotic treatment strategies are associated with gestational 
age, further studies are needed to unravel the true contribution of these factors 
to microbiota development. 
Overall, our findings indicate that gestational age is positively associated with 
abundance of Bifidobacterium and negatively associated with abundance of 
facultative anaerobic bacteria. Development of the intestinal microbiota most 
likely suffers from exposure to respiratory support and antibiotic treatment. 
High extent of exposure to these factors is common in EP infants, pressuring the 
bacterial community to become rich in facultative anaerobes and particularly 
active in translation and membrane transport. VP infants are to a lesser 
extent exposed to respiratory support and antibiotic treatment, allowing for 
development towards a more stable, metabolically active, Bifidobacterium-
dominated microbiota. A microbial signature characterised by low abundance 
of Bifidobacterium and high abundance of facultative anaerobes has been 
associated with several negative health outcomes in early life, including NEC 
and late-onset sepsis72,153. In addition, disturbances in microbiota development 
have been related to development of disorders in later life. In light of this, our 
data indicates that gestational age and its associated intensity of care could 
greatly influence early and later life health of preterm infants by interfering 
with microbiota development.
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Table S3.1 | Sampling scheme 
for metaproteomics and 16S 
rRNA sequencing. Red dots: 
samples for metaproteomics, 
Black dots: samples for 16S 
rRNA gene sequencing, A-J: 
individual infants.
 
Table S3.2 | Contents of the 
in-house generated protein 
database.
 
Table S3.3 | Correlation 
between 16S- and 
protein-based taxonomic 
classification. P-values below 
0.05 are considered significant 
(Spearman correlation with 
Monte Carlo permutation 
10.000x).
 
Table S3.4: Relative 
abundance of 
Bifidobacterium-derived 
beta-galactosidase and 
ABC transporters for 
oligosaccharides during 
postnatal weeks 3-6. Relative 
abundances were calculated 
using iBAQ intensities.
 
Figure S3.1 |Weighted unifrac 
distance between (A) and 
within (B) infants. A: Unifrac 
distance was determined with 
samples collected from all 
infants at time points meconium, 
week 1 and week 2 to show 
variation between infants at 
these time points. B: Unifrac 
distance was determined 
with samples collected from 
each infant during the first 
two postnatal weeks to show 
variation within infants. Mec: 
meconium, A-J: individual 
infants
 
Figure S3.2 | Microbiota 
composition profiles during 
the first two postnatal weeks. 
Taxonomy is based on 16S rRNA 
gene sequencing. Taxonomic 
profiles are shown for each 
available time point (1-14) per 
infants (A-J).
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Table S3.1 | Sampling scheme 
for metaproteomics and 16S 
rRNA sequencing. Red dots: 
samples for metaproteomics, 
Black dots: samples for 16S 
rRNA gene sequencing, A-J: 
individual infants.
  Ta
ble
	S3
.1	
|	S
am
pl
in
g	s
ch
em
e	f
or
	m
et
ap
ro
te
om
ics
	an
d	
16
S	r
RN
A	
se
qu
en
cin
g.
	Re
d	d
ot
s:	
sa
m
ple
s	f
or
	m
et
ap
ro
te
om
ics
,	B
lac
k	d
ot
s:	
sa
m
ple
s	f
or
	16
S	r
RN
A	
ge
ne
	se
qu
en
cin
g,	
	
A-
J:	
ind
ivi
du
al	
inf
an
ts.
	
	
 
 In
fa
nt
	/	
Tim
e	p
oi
nt
1
2
3
4
5
6
W
k	1
8
9
10
11
12
13
W
k	2
W
k	3
W
k	4
W
k	6
A
●●
●
●
●
●
●
●
●
●●
●
●●
●●
B
●
●
●
●
●
●
●
●●
●
●●
●
●●
C
●
●●
●●
●
●
●
●
●
●●
●●
●●
●●
D
●
●
●
●●
●
●
●
●
●
●●
●●
●●
●●
E
●●
●
●
●●
●
●
●
●●
●
●●
●●
●●
F
●●
●
●
●
●
●
●
●●
●●
●
●●
G
●
●
●
●
●●
●
●
●
●●
●●
●●
H
●●
●●
●
●●
●●
●●
●●
●
●●
●●
●●
●●
●●
●●
●●
I
●●
●
●
●
●●
●
●
●●
●
●●
●●
●●
J
●●
●
●
●●
●
●
●
●
●
●●
●●
●●
●●
Figure S3.3 | Principal 
response curve analysis 
summarising the differences 
in protein-based taxonomic 
profiles (A), 16S-based 
taxonomic profiles (B) 
and protein-based KEGG 
Orthology identifier profiles 
between EP25-26, EP27 and 
VP infants throughout 
postnatal weeks 3-6. Genera 
and proteins with a score lower 
than -0.85 or higher than 0.85 are 
shown on Resp1.
 
Figure S3.4 | Proportion of 
aerobes/fac. anaerobes and 
anaerobes according to 16S 
rRNA gene sequencing (A) 
and metaproteomics (B) data. 
Per time point, average relative 
abundance per gestational age 
group is shown. 
 
Figure S3.5 | Taxonomic 
profiles per functional 
category. Taxonomic profiles 
were made for the most 
abundant KEGG Brite level 
B functional categories. Per 
time point, average relative 
abundances for each GA group 
are shown. Relative abundances 
were calculated using iBAQ 
intensities.
 
Figure S3.6 | Protein-based 
(A) and 16S-based (B) 
taxonomic profiles and 
protein-based functional 
profiles (C) for all samples 
collected during postnatal 
weeks 3-6.
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Table S3.2 | 
Contents of the 
in-house generated 
protein database.
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075
Table S3.3 | Correlation 
between 16S- and 
protein-based taxonomic 
classification. P-values below 
0.05 are considered significant 
(Spearman correlation with 
Monte Carlo permutation 
10.000x).
Table S3.4: Relative 
abundance of 
Bifidobacterium-derived 
beta-galactosidase and 
ABC transporters for 
oligosaccharides during 
postnatal weeks 3-6. Relative 
abundances were calculated 
using iBAQ intensities.
* Independent sample t-test 
p<0.05
** Independent sample t-test 
P<0.001
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Figure S3.1 |Weighted unifrac 
distance between (A) and 
within (B) infants. A: Unifrac 
distance was determined with 
samples collected from all 
infants at time points meconium, 
week 1 and week 2 to show 
variation between infants at 
these time points. B: Unifrac 
distance was determined 
with samples collected from 
each infant during the first 
two postnatal weeks to show 
variation within infants. Mec: 
meconium, A-J: individual 
infants
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Figure S3.2 | Microbiota 
composition profiles during 
the first two postnatal weeks. 
Taxonomy is based on 16S rRNA 
gene sequencing. Taxonomic 
profiles are shown for each 
available time point (1-14) per 
infants (A-J).
Figure S3.3 | Principal 
response curve analysis 
summarising the differences 
in protein-based taxonomic 
profiles (A), 16S-based 
taxonomic profiles (B) 
and protein-based KEGG 
Orthology identifier profiles 
between EP25-26, EP27 and 
VP infants throughout 
postnatal weeks 3-6. Genera 
and proteins with a score lower 
than -0.85 or higher than 0.85 are 
shown on Resp1.
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Figure S3.4 | Proportion of 
aerobes/fac. anaerobes and 
anaerobes according to 16S 
rRNA gene sequencing (A) 
and metaproteomics (B) data. 
Per time point, average relative 
abundance per gestational age 
group is shown. 
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Figure S3.5 | Taxonomic 
profiles per functional 
category. Taxonomic profiles 
were made for the most 
abundant KEGG Brite level 
B functional categories. Per 
time point, average relative 
abundances for each GA group 
are shown. Relative abundances 
were calculated using iBAQ 
intensities.
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Figure S3.6 | Protein-based 
(A) and 16S-based (B) 
taxonomic profiles and 
protein-based functional 
profiles (C) for all samples 
collected during postnatal 
weeks 3-6.
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EFFECT OF VANCOMYCIN 
PROPHYLAXIS DURING 
REMOVAL OF A CENTRAL 
VENOUS CATHETER ON 
INTESTINAL MICROBIOTA 
COMPOSITION IN PRETERM 
INFANTS
ROMY D. ZWITTINK, ESTHER J. D’ HAENS, CLARA BELZER,  
MARIEKE A.C. HEMELS, RICHARD A. VAN LINGEN, INGRID B. RENES,  
JAN KNOL AND DINY VAN ZOEREN-GROBBEN
ABSTRACT
Early life is a critical period for development of the intestinal microbiota, a 
process alongside metabolic and immune development, and its succession is 
highly susceptible to host and environmental factors. Two doses of vancomycin 
around time of removal of a central venous catheter reduces the incidence 
of central venous line removal associated sepsis, but might negatively 
affect development of the gut microbiota in preterm infants during a critical 
developmental time window. We studied microbiota development during the first 
six postnatal weeks in fourteen preterm infants receiving two vancomycin doses 
as CRAS-prophylaxis and compared their microbiota composition at postnatal 
week six to five preterm infants without prophylactic vancomycin treatment. 
The gut microbiota of preterm infants was less diverse and contained lower 
relative abundance of Pseudomonas and members of the Comamonadaceae 
family after vancomycin treatment than before treatment. In addition, decreased 
abundance of Bifidobacterium and increased abundance of Staphylococcus was 
observed in some infants after treatment. Throughout the first six postnatal 
weeks, the preterm infant gut microbiota became more stable and more similar 
between infants. At postnatal week six, treated and control infants did not differ 
in microbiota composition, richness and diversity, except for the abundance of 
Veillonella. Our findings indicate that two dosages of vancomycin as CRAS-
prophylaxis might have short-term impact, but does not have profound lasting 
effects on the gut microbiota of preterm infants. Improved understanding of 
potential negative side effects of CRAS-prophylaxis, including its impact on 
microbiota development, is of clinical significance and could assist the cost-
benefit determination of prophylactic antibiotic use. 
INTRODUCTION
Central venous line removal associated sepsis (CRAS), defined as sepsis in the 
critical period 48 hours after removal of a central venous line, has an incidence 
of 11% in very low birthweight (VLBW, <1500 g) infants154,155. A randomised 
controlled trial showed the benefit of two prophylactic doses of antibiotics two 
hours before and 12 hours after removal of a central venous catheter (CVC) in 
reducing the incidence of CRAS154. It is important to consider advantages and 
disadvantages of CRAS-prophylaxis regarding disease burden, duration of 
hospital stay, antibiotic resistance and gut microbiota development. Disturbed 
development of the intestinal microbiota in premature infants and its potential 
lifelong consequences is a point of concern. Early life is a critical period for 
development of the intestinal microbiota, a process alongside metabolic 
and immune development, and its succession is highly susceptible to host 
and environmental factors120,129,156. Delivery mode, hospitalisation, timing of 
introduction of enteral feeding, formula feedings and antibiotics are examples 
of influencing factors. Premature infants are very likely to develop an altered 
intestinal microbiota157,158. Several observational studies showed an altered 
developmental pattern and composition of the gut microbiota in preterm infants 
and demonstrated the effect of short versus longer duration of antibiotics 
on microbiota development69,70,159. In the present pilot study, we evaluated 
microbiota development in preterm infants receiving two preventive doses of 
vancomycin. In addition, microbiota composition was compared with control 086
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infants, who did not receive antibiotic prophylaxis, at the postnatal age of six 
weeks. Primary outcome was defined as the effect of two preventive doses of 
vancomycin around time of removal of a CVC on microbiota composition shortly 
after dosing and at postnatal week six. Secondary outcome was defined as the 
difference in microbiota composition at postnatal week six between infants 
who did and did not receive vancomycin prophylaxis. 
MATERIALS AND METHODS
Subjects and sample collection
This pilot was part of an observational, non-interventional study performed 
from 2012 through 2013 in the level III NICU of Isala, Zwolle, The Netherlands. 
Included were all infants admitted to our unit with a gestational age less than 
32 weeks and admitted before 96 hours of life. Written informed consent was 
obtained from both parents, and the study was approved by the Medical Ethical 
Committee of the hospital. Faecal samples were longitudinally collected 
during the first six postnatal weeks. Fourteen VLBW preterm infants with a 
CVC, but without episodes of (suspected) late-onset sepsis, all breastmilk 
fed were included. The infants only received antibiotics for suspected early 
onset sepsis composed of amoxicillin and ceftazidime during the first days of 
life. Prophylaxis consisted of two dosages of vancomycin (10 mg/kg) one hour 
before and 12 hours after removal of a CVC. Faecal samples were collected 
before (<5 days) and after prophylaxis (<7 days) and at the age of six weeks. 
During the study year, the protocol of antibiotic prophylaxis around removal of 
the central venous line was introduced. This provided the opportunity to include 
five control infants without prophylaxis and matched for gestational age and 
antibiotics, all receiving breastmilk and without a period of (suspected) late-
onset sepsis. Additional clinical characteristics of all infants can be found in 
table 4.1. The timing of sampling, antibiotic use and prophylaxis of all infants 
are shown in figure 4.1. 
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Table 4.1 | Infant 
characteristics.  
Abbreviations: GA: gestational 
age, BW: birth weight, FEF: 
full enteral feeding, PAB: 
postpartum antibiotics, 
C-section: caesarean section
Figure 4.1 | Timelines per 
infant regarding antibiotic 
treatment, faecal samples 
and CRAS-prophylaxis. 
93 
 
Materials	and	methods	
Subjects	and	sample	collection	
This	pilot	was	part	of	an	observational,	non-interventional	study	performed	from	2012	through	2013	
in	the	level	III	NICU	of	Isala,	Zwolle,	The	Netherlands.	Included	were	all	infants	admitted	to	our	unit	
with	 a	 gestational	 age	 less	 than	32	weeks	 and	admitted	before	96	hours	of	 life.	Written	 informed	
consent	 was	 obtained	 from	 both	 parents,	 and	 the	 study	 was	 approved	 by	 the	 Medical	 Ethical	
Committee	of	the	hospital.	Faecal	samples	were	longitudinally	collected	during	the	first	six	postnatal	
weeks.	Fourteen	VLBW	preterm	 infants	with	a	CVC,	but	without	episodes	of	 (suspected)	 late-onset	
sepsis,	all	breastmilk	fed	were	included.	The	infants	only	received	antibiotics	for	suspected	early	onset	
sepsis	composed	of	amoxicillin	and	ceftazidime	during	the	first	days	of	life.	Prophylaxis	consisted	of	
two	dosages	of	vancomycin	(10	mg/kg)	one	hour	before	and	12	hours	after	removal	of	a	CVC.	Faecal	
samples	were	collected	before	(<5	days)	and	after	prophylaxis	(<7	days)	and	at	the	age	of	six	weeks.	
During	the	study	year,	the	protocol	of	antibiotic	prophylaxis	around	removal	of	the	central	venous	line	
was	introduced.	This	provided	the	opportunity	to	include	five	control	infants	without	prophylaxis	and	
matched	 for	 gestational	 age	 and	 antibiotics,	 all	 receiving	 breastmilk	 and	 without	 a	 period	 of	
(suspected)	late-onset	sepsis.	Additional	clinical	characteristics	of	all	infants	can	be	found	in	table	4.1.	
The	timing	of	sampling,	antibiotic	use	and	prophylaxis	of	all	infants	are	shown	in	figure	4.1.		
	
Table	4.1	|	Infant	characteristics.	
	
Infant	 GA	 BW	 Delivery	mode	 Days	until	FEF	 PAB	(days)	
1	 29	 1090	 C-section	 8	 5	
2	 28	 1210	 Vaginal	 7	 5	
3	 27	 1090	 Vaginal	 9	 6	
4	 29	 1050	 C-section	 8	 2	
5	 27	 1130	 C-section	 11	 2	
6	 27	 1050	 Vaginal	 10	 3	
7	 30	 1420	 C-section	 10	 2	
8	 26	 1250	 C-section	 10	 2	
9	 30	 1310	 Vaginal	 10	 2	
10	 28	 1380	 C-section	 9	 2	
11	 29	 1400	 Vaginal	 9	 3	
12	 29	 1445	 Vaginal	 8	 3	
13	 28	 1230	 C-section	 11	 3	
14	 30	 1390	 Vaginal	 7	 3	
Mean	(min-max)	 28.4	(26-30)	 1246	(1050-1445)	 	 9.1	(7-11)	 3.1	(2-6)	
C1	 27	 1210	 Vaginal	 8	 4	
C2	 27	 1070	 C-section	 9	 7	
C3	 31	 2230	 Vaginal	 6	 0	
C4	 27	 1050	 Vaginal	 10	 3	
C5	 27	 1090	 Vaginal	 10	 3	
Mean	(min-max)	 27.8	(27-31)	 1596	(1050-	2230)	 	 8.6	(6-10)	 3.4	(0-7)	
Abbreviations:	GA:	gestational	age,	BW:	birth	weight,	FEF:	full	enteral	feeding,	PAB:	postpartum	antibiotics,	C-
section:	caesarean	section	Birth             Week 6
01
02
03
04
05
06
07
08
09
10
11
12
13
14
C1
C2
C3
C4
C5
Postpartum amoxicillin-ceftazidime
CRAS-prophylaxis
Faecal sample collection 088
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16S rRNA gene amplicon sequencing
DNA extraction, library preparation and sequencing were performed by 
LifeSequencing S.L. (Valencia, Spain). DNA was extracted from 200 mg faeces 
using the QIAamp Fast DNA Stool Mini Kit (Qiagen), including enzymatic and 
chemical cell disruption by bead beating. DNA was purified and concentrated 
using the PowerMag DNA clean-up kit (MoBio) and 50 ng of DNA was amplified 
according to the Metagenomic Sequencing Library Illumina 15044223 B protocol 
(Illumina). For the first amplification step, primers were designed containing 
a universal linker sequence allowing amplicons for incorporation of indexes 
and sequencing primers by Nextera XT Index kit (Illumina) and 16S rRNA gene 
primers for region V3-V4 (Klindworth et al., 2013). Indexes were included during 
a second amplification step. Libraries were quantified using the Quant-iT™ 
PicoGreen™ dsDNA Assay Kit (Thermofisher) and pooled prior to sequencing 
on the MiSeq platform (Illumina, 300 bases paired-end). The size and quantity 
of the pool were respectively assessed on the Bioanalyzer 2100 (Agilent) and 
with the Library Quantification Kit for Illumina (Kapa Biosciences). 
Data analysis
Read filtering, OTU-picking and taxonomic assignment were performed using 
the NG-Tax pipeline with the following settings: read length of 70, ratio OTU 
abundance of 2, classify ratio of 0.8, minimum percentage threshold of 0.5, 
identity level of 100%, error correction of 98.5, using the Silva_128_SSU Ref 
database143,160. For within infant (dependent) or between infants (independent) 
comparisons, the nonparametric Wilcoxon Signed Rank test and Kruskal-Wallis 
test, both with Monte Carlo permutation (10000x), were applied respectively. 
Before testing for differences in taxonomy, the OTU table was filtered for 
OTUs present in less than 25% of the samples. For analysing intra-individual 
and inter-individual differences in microbiota composition, the distance metric 
Unifrac was used. To relate microbiota composition to clinical data, redundancy 
analysis (RDA) was performed using Canoco multivariate statistics software 
v5. Factors were considered to have a significant influence when the false 
discovery rate corrected p-value was below 0.05.
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Figure 4.2 | Microbiota 
composition profiles. The 15 
most abundant taxa are shown, 
which were determined by 
calculating the average relative 
abundance of all samples. 
Relative abundance of all other 
identified taxa were summed 
under category ‘other’. 
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RESULTS
Microbiota composition throughout the first six postnatal weeks
Gut microbiota composition was determined in fourteen infants before (BV) and 
shortly after (AV) two dosages of vancomycin, and at postnatal week six (PNW6) 
(Fig 4.2). Staphylococcus, Enterococcus, Bifidobacterium, Enterobacteriaceae, 
Streptococcus, Peptoclostridium, Clostridium and Lactobacillus were identified 
as abundant members, but their abundance, and the composition of the whole 
community, varied greatly between and within infants. Variation in microbiota 
composition within infants, as determined by comparing BV with AV samples, 
was of the same level as between infants before treatment and of higher level than 
between infants after treatment (Fig 4.3a). Microbiota composition became more 
stable over time, as indicated by a trend of higher unweighted unifrac distances 
between the BV and AV samples than between the AV and PNW6 samples (Fig 
4.3b). In addition, microbiota composition became more similar between infants 
over time, as indicated by gradually decreasing unifrac distances (Fig 4.3c). 
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Figure 4.3 | Unweighted and 
weighted unifrac distances. 
BV-AV: within infants before and 
after treatment, BV: between 
infants before treatment, AV: 
between infants after treatment, 
AV-PNW6: within infants after 
treatment to postnatal week 
6, PNW6: between treated 
infants at postnatal week 
6, Control: between control 
infants at postnatal week 
6, PNW6-Control: between 
treated and control infants. 
Boxplots show the median, 
25th and 75th percentiles, and 
minimal and maximal values 
except for outliers (circles). For 
within infant or between infants 
comparisons, respectively 
the nonparametric Wilcoxon 
Signed Rank test and Kruskal-
Wallis test with Monte Carlo 
permutation were applied.
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Microbiota composition before and after CRAS-prophylaxis
To determine the effect of vancomycin prophylaxis, microbiota composition was 
compared between samples collected before and after prophylaxis. Members 
of the genus Pseudomonas and the family Comamonadaceae were significantly 
decreased after vancomycin prophylaxis (p=0.015, Fig 4.4a, 4.4b). Although 
not significantly different, relative abundance of Bifidobacterium decreased 
to non-detectible levels in six infants (43%) after vancomycin prophylaxis (Fig 
4.4c). Strikingly, relative abundance of Staphylococcus, a target organism of 
vancomycin, increased in five infants (36%) after vancomycin prophylaxis (Fig 
4.4d). Diversity of the gut microbiota was higher before than after treatment 
(p=0.035), and a trend towards decreased community richness could be 
observed (p=0.062, Fig 4.5a).
Microbiota composition at postnatal weeks six in infants with or without CRAS-prophylaxis
To elucidate whether CRAS-prophylaxis has long lasting effects, microbiota 
composition was determined at postnatal week six in preterm infants who did 
(PNW6) or did not (control) receive vancomycin treatment (Fig 4.2). Variation 
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in microbiota composition was similar between vancomycin treated infants, 
between control infants and between vancomycin treated and control infants 
(Fig 4.3d). In addition, no difference in community richness and diversity was 
observed (Fig 4.5b). Regarding taxonomy, relative abundance of Veillonella was 
lower in vancomycin treated infants (p=0.024), but there were no significant 
differences in the abundance of other bacterial taxa.
DISCUSSION
Two doses of vancomycin around time of removal of a central venous catheter 
reduces the incidence of CVC-associated sepsis154,155. It may, however, 
affect development of the gut microbiota in preterm infants during a critical 
developmental time window. We studied microbiota development during the 
first six postnatal weeks in 14 preterm infants receiving two vancomycin doses 
as CRAS-prophylaxis and compared their microbiota composition at postnatal 
week six to five preterm infants without prophylactic vancomycin treatment.
The gut microbiota of preterm infants was less diverse and contained lower 
relative abundance of Pseudomonas and members of the Comamonadaceae 
family after vancomycin treatment than before treatment. In addition, decreased 
Figure 4.5 | Community 
richness (choa1) and diversity 
(phylogenetic diversity) 
before and after CRAS-
prophylaxis (A), and at 
postnatal week six in treated 
and control infants (B). 
Boxplots show the median, 
25th and 75th percentiles, and 
minimal and maximal values 
except for outliers (circles). For 
within infant or between infants 
comparisons, respectively the 
nonparametric Wilcoxon Signed 
Rank test and Kruskal-Wallis test 
with Monte Carlo permutation 
were applied.
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abundance of Bifidobacterium and increased abundance of Staphylococcus was 
observed in some infants after treatment. Since bifidobacteria are considered 
beneficial early life colonisers that are abundant during early life development 
of the gut microbiota, the observed decreased abundance of Bifidobacterium 
is a point of concern161. Bifidobacteria play an important role in milk digestion, 
limit the possibilities for pathogen colonisation and support development of 
the immune system31,32. We have previously associated postpartum antibiotic 
treatment with lower abundance of bifidobacteria during early development of 
the preterm infant gut microbiota 99,159. Decreased abundance of Bifidobacterium 
species might therefore be a result of postpartum amoxicillin/ceftazidime 
treatment rather than of two vancomycin dosages. The lack of a control group 
during the first two postnatal weeks prohibits to determine the sole effect of 
CRAS-prophylaxis on microbiota composition. The increasing abundance of 
Staphylococcus is a striking observation, since vancomycin is the preferred 
antibiotic to prevent and treat staphylococcal infections. This observation could 
indicate resistance to vancomycin which has been previously documented 
for S. capitis strains in hospitalised neonates162. However, it must be noted 
that relative abundances were evaluated in this study, which is not a good 
indication for the absolute abundance of Staphylococcus, which may actually 
be stable or decreasing.
Throughout the first six postnatal weeks, the preterm infant gut microbiota 
became more stable and more similar between infants. At postnatal week six, 
treated and control infants did not differ in microbiota composition, richness 
and diversity, except for the abundance of Veillonella. This indicates that two 
dosages of vancomycin as CRAS-prophylaxis does not have profound lasting 
effects on the gut microbiota of preterm infants. A two-week vancomycin course 
for treatment of Clostridium difficile infection has shown to have individual-
specific long-term impact on gut microbiota composition in adults163. In preterm 
neonates, the response to vancomycin treatment, in terms of shifts in microbiota 
composition, are individual-specific as well, but generally temporary164. It must 
be noted, however, that only 18 infants received vancomycin in that study, and 
that for 12 of these infants vancomycin was combined with cephalosporin164. 
Overall, our findings indicate that two dosages of vancomycin as CRAS-
prophylaxis does not have profound lasting effects on the gut microbiota of 
preterm infants, which, together with decreased disease burden and hospital 
stay, favours its application. Small subject size, great inter-individual variation, 
and exposure to other antibiotics during the first postnatal week, however, could 
have prohibited the detection of consistent alterations in microbiota composition 
as a result of two vancomycin dosages. A randomised controlled trial with more 
inclusions might aid elucidating the sole effect of vancomycin prophylaxis 
on microbiota development in preterm infants. Improved understanding of 
potential negative side effects of CRAS-prophylaxis, including its impact on 
microbiota development, is of clinical significance and could assist the cost-
benefit determination of prophylactic antibiotic use. 
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ABSTRACT
Antibiotic treatment is common practice in the neonatal ward for prevention 
and treatment of sepsis, which is one of the leading causes of mortality and 
morbidity in preterm infants. Although the effect of antibiotic treatment on 
microbiota development is well recognised, little attention has been paid 
to treatment duration. We studied the effect of short and long intravenous 
antibiotic administration on intestinal microbiota development in preterm 
infants. Faecal samples from fifteen preterm infants (35±1 weeks gestation 
and 2871±260 gram birthweight) exposed to no, short (≤3 days) or long (≥5 
days) treatment with amoxicillin/ceftazidime were collected during the first 
six postnatal weeks. Microbiota composition was determined through 16S 
rRNA gene amplicon sequencing and by qPCR. Short and long antibiotic 
treatment significantly lowered abundance of Bifidobacterium right after 
treatment (p=0.027) till postnatal week three (p=0.028). Long treatment 
caused Bifidobacterium abundance to remain decreased till postnatal week 
six (p=0.009). Antibiotic treatment was effective against members of the 
Enterobacteriaceae family, but allowed Enterococcus to thrive and remain 
dominant for up to two weeks after antibiotic treatment discontinuation. 
Community richness and diversity were not affected by antibiotic treatment, 
but were positively associated with postnatal age (p<0.023) and abundance 
of Bifidobacterium (p=0.003). Intravenous antibiotic administration during 
the first postnatal week greatly affects the infant’s gastrointestinal 
microbiota. However, quick antibiotic treatment cessation allows for its 
recovery. Disturbances in microbiota development caused by short and more 
extensively by long antibiotic treatment, could affect healthy development 
of the infant via interference with maturation of the immune system and 
gastrointestinal tract.
INTRODUCTION
Over the last years, the intestinal microbiota has been well recognised as major 
contributor to human health and disease165. Despite its described importance, 
intestinal microbiota development is not completely understood as it is a highly 
dynamic process affected by multiple host and environmental factors of which 
gestational age, mode of delivery, diet and antibiotics are perceived as major 
influencing factors120. Previous studies showed that antibiotic treatment 
in early life can lead to short- and long-term alterations of the intestinal 
microbiota, which has been related to early and later life health outcomes 
such as asthma and adiposity71,72,166. Antibiotic treatment is common practice 
in the neonatal ward for prevention and treatment of sepsis, which is one of 
the leading causes of mortality and morbidity in preterm infants. Antibiotics, 
such as amoxicillin, ceftazidime, erythromycin and vancomycin are frequently 
used as they target a broad spectrum of pathogens. Intrauterine infections 
are a common cause of preterm birth, thus many preterm infants are born 
with suspicion of infection and are therefore treated with antibiotics from 
birth onwards. In preterm infants, group B streptococci and Escherichia coli 
are associated with onset of neonatal sepsis167. Since sepsis in preterm 
infants still has a high mortality and morbidity it is not possible to wait for test 098
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results before starting antibiotic treatment. To reduce the antibiotic load in 
the neonatal ward it is common practice to evaluate the need for antibiotics 
after 48 hours and stop antibiotics if the infection is not proven. The applied 
antibiotic strategies in neonatology led to decreased mortality and morbidity 
rates. However, there is a risk of impeding gut microbiota development and 
increasing antibiotic resistance168. It has been shown that in infants intestinal 
microbiota composition and activity in early life is associated with gestational 
age and can be related to the degree of perinatal antibiotic administration67,99. 
In addition, it has been shown that preterm infants admitted to the neonatal 
intensive care unit (NICU) are particularly colonised by antibiotic resistant 
and virulent bacterial strains during early life, which was restored around two 
years of age68. Despite increased understanding of how antibiotic treatment 
affects preterm infant microbiota development, not much is known about 
the effect of duration of treatment. Previous studies showed that long 
antibiotic treatment (>5 days) in preterm infants results in lower diversity 
of the faecal microbiota than short treatment, but no clear differences in 
overall microbiota composition were observed69,70. This could be due to other 
factors that influence microbiota composition which were not accounted 
for during stratification of the infants, such as gestational age70 or mode of 
delivery69. As gestational age and mode of delivery by itself influence early 
life microbiota development, the present study accounted for these in order 
to further understand the effect of antibiotic treatment duration on preterm 
infant microbiota development.
MATERIALS AND METHODS
Subjects and sample collection
This study was part of an observational, non-intervention study involving (pre)
term infants admitted to the hospital level III NICU or the level II neonatal 
ward of Isala in Zwolle, The Netherlands. The ethics board from METC Isala 
Zwolle concluded that this study does not fall under the scope of the Medical 
Research Involving Human Subjects Act (WMO). Informed consent was 
obtained from both parents of all individual participants included in the study. 
For faecal microbiota profiling, fifteen late preterm infants (mean ± SD, 35.7 
± 0.9 weeks gestation, 2871 ± 261 grams birthweight) were longitudinally 
sampled during the first six postnatal weeks resulting in a total of 95 samples. 
Sampling days for each infant can be found in table 5.1. Infants received either 
no (control), short-term (ST, <3 days) or long-term (LT, >5 days) treatment 
with a combination of amoxicillin and ceftazidime during the first postnatal 
week. Infants started antibiotic treatment on clinical suspicion of a bacterial 
infection and upon negative or positive cultures antibiotic administration was 
respectively stopped (ST) after two to three days or continued (LT) up till a 
maximum of seven days. Of the LT infants, one was diagnosed with sepsis and 
three with pneumonia, and in all cases the causative pathogen was unknown. 
Meconium and faecal samples were collected at birth and at postnatal weeks 
one, two, three, four and six. Samples were stored temporally at -20°C until 
transfer to -80°C. Infant clinical characteristics can be found in table 5.1. All 
infants were born vaginally, only received enteral nutrition and did not have 
clinical signs of food intolerance. 099
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Table 5.1 | Infant 
characteristics.
Abbreviations: GA: gestational 
age, BW: birthweight, AB: 
antibiotics, FEF: full enteral 
feeding, PREE: preeclampsia, 
PROM: prolonged rupture of 
membranes, AM: antimycotics.
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DNA extraction
DNA was extracted from faeces by the repeated bead beating plus phenol/
chloroform method as described previously137. DNA was quantified using a 
NanoDrop ND-2000 spectrophotometer (Thermo Scientific, Wilmington, DE, 
USA) and by using a Qubit®2.0 fluorometer (Life Technologies, Carlsbad, CA, 
USA) according to manufacturer’s instructions. 
454 pyrosequencing
Amplification of the V3-V5 regions of the 16S rRNA gene was performed 
using the Bifidobacterium optimised 357F and 926Rb primers as described 
previously138. For each sample, the reverse primer included a unique barcode 
sequence to allow for multiplexing. PCR and 454 pyrosequencing (GS Junior, 
Roche) were performed by LifeSequencing S.L. (Valencia, Spain) as described 
previously138. Sequencing data is available in the European Nucleotide Archive 
(http://www.ebi.ac.uk/ena) under study accession PRJEB19937. 
Sequencing data analysis
Pyrosequencing data was analysed using the QIIME software package (v1.8)139 
applying Acacia140, USearch141, UCLUST142 and the SILVA 111 database143 
for denoising, chimera removal, OTU picking and taxonomic classification 
respectively. The obtained OTU table was filtered for OTUs with a number of 
sequences less than 0.005% of the total number of sequences169. To account for 
variation between samples total number of reads, rarefaction to 4085 reads per 
sample was applied. To identify bacterial taxa that were significantly different 
in abundance between control, ST and LT infants, the nonparametric Kruskal-
Wallis test with Monte Carlo permutation (10000x) was applied. The Kruskal-
Wallis test was done using absolute read counts for each taxonomic group 
and after the OTU table was filtered for OTUs present in less than 25% of the 
samples. To compare richness and diversity between samples, the Wilcoxon 
Signed Rank test, Mann-Whitney U test and Kruskal-Wallis test were applied for 
dependent, two groups of independent and more than two groups of independent 
samples respectively. To study (dis)similarities in microbiota composition and 
relate changes in microbiota composition to clinical data, principal component 
analysis (PCA) and redundancy analysis (RDA) were performed using the 
Canoco multivariate statistics software v5. For RDA analysis, factors were 
considered significant when the Bonferroni corrected p-value was below 0.05. 
Co-occurrence patterns were determined by Spearman correlation using the 
taxa that remained after the OTU table was filtered for OTUs present in less 
than 25% of the samples. Visualisation was done using the Gephi-0.9.1 platform 
(https://gephi.org/) and Adobe Illustrator CS6.
qPCR analysis
Real-time PCR amplification and detection were performed on a CFX384TM 
real-time PCR detection system (Bio-Rad). The reaction mixture was 
composed of 5 μl iQTM SYBR® Green Supermix, 0.2 μl forward and reverse 
primers (10 nmol), 1.6 μl nuclease-free water and 3 μl of DNA template (2 ng/
μl). Primers used targeted total 16S170, Bifidobacterium171, Enterococcus172 and 
Enterobacteriaceae173. The program for amplification of total 16S, Bifidobacterium 101
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and Enterococcus was initial denaturation at 94°C for 5 minutes, followed by 40 
cycles of denaturation at 94°C for 20 seconds, annealing at 60°C for 20 seconds 
and elongation at 72°C for 50 seconds, followed by a melt-curve from 60°C to 
95°C with 0.5°C steps. The program for amplification of Enterobacteriaceae was 
initial denaturation at 95°C for 5 minutes, followed by 40 cycles of denaturation 
at 95°C for 10 seconds, annealing at 55.8°C for 20 seconds and elongation at 72°C 
for 20 seconds, followed by a melt-curve from 60°C to 95°C with 0.5°C steps. 
Standard curves contained 101-109 16S rRNA copies/μl and were performed 
in triplicate. Data was analysed using CFX ManagerTM software (Bio-Rad). 
Relative abundances of the taxa were determined by dividing taxa specific 
16S rRNA gene copy number by total 16S rRNA gene copy number. qPCR and 
pyrosequencing data had a Spearman correlation of 0.758, 0.729 and 0.822 for 
Bifidobacterium, Enterococcus and Enterobacteriaceae respectively. To identify 
bacterial taxa that were significantly different in abundance between control, 
ST and LT infants, the nonparametric Kruskal-Wallis test with Monte Carlo 
permutation (10000x) was applied. 
RESULTS
Antibiotic treatment delays colonisation by Bifidobacterium
Microbiota composition throughout the first six postnatal weeks was determined 
in fifteen infants with varying antibiotic treatment duration. Microbiota 
composition of control infants was characterised by a high abundance of 
Bifidobacterium throughout the first six postnatal weeks, with an average relative 
abundance of 45% in meconium increasing towards 73% at postnatal week six 
(Fig 5.1a). In three out of five infants, Bifidobacterium already covered more 
than 50% abundance in the meconium sample (Fig S5.1). These findings were 
confirmed by qPCR analysis (Fig 5.1b, S5.2). Despite common characteristics, 
control infants microbiota composition also contained individual specific 
profiles. Outstanding were: dominance of Enterobacter at postnatal weeks one 
and two in one infant (infant C), dominance of Actinomyces at postnatal weeks 
three and four in another infant (infant B), members of Proteobacteria were only 
identified in three infants, and in three infants Enterococcus was a dominant 
member in the meconium sample (Fig S5.1). Microbiota composition of ST and 
LT infants was not characterised by a particular microbiota profile that lasted 
throughout the first six postnatal weeks, but showed high variability between and 
within infants (Fig 5.1a, S5.1). To understand the effect of antibiotic treatment 
duration on intestinal microbiota development, microbiota composition 
was compared between control, ST and LT infants. ST and LT infants had a 
significantly lower abundance of Bifidobacterium right after antibiotic treatment 
(p= 0.027, 0.027) and at postnatal weeks one (p=0.027, 0.021), two (p=0.016, 
0.009), and three (p=0.028, 0.028) compared to control infants. In LT infants, 
Bifidobacterium abundance also remained lower during postnatal weeks four 
(p=0.086) and six (p=0.009), whereas this could not be observed in ST infants. 
qPCR analysis confirmed the significantly lower quantity of Bifidobacterium 
right after a short (p=0.033) or long (p=0.035) antibiotic treatment compared to 
control infants. Enterococcus became a dominant member of the community 
in multiple ST and LT infants during the first postnatal week, which was not 102
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observed in any of the control infants (Fig 5.1, S5.1, S5.2), however, except 
for postnatal week two, differences were not statistically significant. Total 
bacterial count, as determined by qPCR, was not significantly reduced by 
antibiotic treatment (Fig S5.3). However, in some ST and LT infants, lower 
total bacterial count at early time points suggests delayed colonisation due 
to antibiotic treatment. The differences in microbiota development over time 
were further explored via principal response curve and redundancy analysis. 
Temporal microbiota development was different between control, ST and LT 
infants (p=0.002) (Fig 5.2a). Short treatment allowed for development towards a 
microbiota composition more similar to control infants, characterised by high 
abundance of Bifidobacterium (Fig 5.2a, 5.2c). Abundances of Bifidobacterium, 
Clostridium and Enterococcus were different between control and antibiotic 
treated infants (Fig 5.2b). The abundance of Bifidobacterium and Enterobacter at 
postnatal week six explained the difference in temporal microbiota development 
between ST and LT infants (Fig 5.2b). 
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Figure 5.1 | Microbiota 
composition profiles 
based on 16S rRNA-gene 
sequencing (A) and qPCR 
(B). Per time point, averages 
of five infants are shown. For 
16S rRNA gene sequencing 
data, genera with a relative 
abundance of more than 5% are 
shown.
103
Association between duration of intravenous antibiotic administration  
and early life microbiota development in late preterm infants
Antibiotic treatment duration was the main factor significantly explaining the 
observed variation in microbiota composition between samples (p=0.002, Fig 
5.2d). No, short and long antibiotic treatment explained 14.9%, 3.6% and 3.6% of 
the variation respectively. Other factors significantly explaining the variation 
were postnatal age (7.5%), gestational age (4.9%), preeclampsia (3.2%) and 
maternal antibiotics (2.9%) (Fig 5.2d). Gender, birth weight, proportion of human 
milk, days until full enteral feeding, days until discharge, indwelling catheters, 
pain medication, antimycotic use and prolonged rupture of membranes did not 
significantly affect microbiota composition.
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Figure 5.2 | Principal response 
curve (PRC) and redundancy 
analysis (RDA) of the faecal 
microbiota in control, ST and 
LT infants. A: PRC analysis. 
Genera with a score lower than 
-0.5 or higher than 0.5 are shown 
on PRC1 (Bifidobacterium: 
4.58, Enterococcus: -1.83, 
Clostridium: -1.70, Enterobacter: 
-0.73). B: Relative abundance of 
the bacterial genera associated 
with temporal development as 
observed in PRC. Per time point, 
average relative abundance is 
shown. C: RDA showing main 
bacterial genera explaining the 
variation. Percentages indicate 
the fit of the bacterial genera 
into the ordination space. 
Genera with a fit over 20% are 
shown. D. RDA showing the 
clinical factors associated with 
microbiota composition. Clinical 
factors that significantly 
(p<0.05) explain the variation are 
shown. AB: Antibiotics, PREE: 
Preeclampsia.
Microiota community structure is associated with its dominating taxa
Short and long antibiotic treatment did not affect community richness and 
diversity (Fig 5.3a, S5.4). Instead, community richness and diversity were related 
to postnatal age, and depended on which taxa was dominant in the community 
(Fig 5.3b, 5.3c). It was observed that one of the major differences in microbiota 
composition between control, ST and LT infants was expressed by dominance 
of either Bifidobacterium or another genus like Enterococcus, Enterobacter or 
Clostridium. Dominance of Bifidobacterium in the bacterial community was 
related to significantly increased richness and diversity (Fig 5.3c). To increase 
the understanding of bacterial community structure dynamics in control, ST 
and LT infants, co-occurrence patterns based on Spearman correlation were 
visualised (Fig 5.4). In control infants, abundance of Bifidobacterium was 
negatively correlated to Enterococcus, Veillonella, Clostridium, Escherichia-
Shigella and Enterobacter. In ST infants, Enterococcus was negatively correlated 
to Bifidobacterium, Propionibacterium, Clostridium and Enterobacter. In LT 
infants, Enterococcus was negatively correlated to Clostridium, Serratia, 
Escherichia-Shigella, Enterobacter and other Enterobacteriaceae.
Figure 5.3 | Bacterial 
community richness and 
diversity. A: Samples stratified 
on antibiotic treatment duration. 
No significant difference 
observed. B: Samples stratified 
on sampling time point. Samples 
at postnatal week one were 
significantly lower compared to 
all other time points (* p<0.05; 
Mann-Whitney U test with 
Monte Carlo Permutation). 
C: Samples stratified on 
dominating taxa. * p<0.01 
(Mann- Whitney U test with 
Monte Carlo Permutation)
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Figure 5.4 | Co-occurrence 
patterns of the bacterial 
community in control, ST 
and LT infants. Patterns are 
based on significant (p<0.05) 
Spearman correlations between 
genera.
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DISCUSSION
Intravenous antibiotic administration for the prevention and treatment of 
infection and sepsis occurs frequently in preterm infants during the neonatal 
period. Therefore, studying the side effects of antibiotic treatment, including 
the effect on microbiota development, is of great relevance. The idea that 
short antibiotic use negatively affects clinical success and induces antibiotic 
resistance is gradually being replaced by the aim to avoid antibiotic overuse174. 
In this study, we focused on the effect of intravenous antibiotic treatment 
duration on intestinal microbiota development in preterm infants during the first 
six postnatal weeks. Our main findings are: 1) Both short and long treatment with 
amoxicillin/ceftazidime during the first postnatal week drastically disturbed 
normal colonisation pattern, 2) Short, but not long, antibiotic treatment allowed 
for recovery of Bifidobacterium levels within the first six postnatal weeks and 3) 
Community richness and diversity were not affected by antibiotic treatment, but 
were associated with postnatal age and with dominance of specific bacterial 
taxa leading to differences in microbial networks. 
In the current study, 16S rRNA gene amplicon sequencing and qPCR analysis 
showed that infants faecal microbiota was dominated by Bifidobacterium 
throughout the first six postnatal weeks. Bifidobacterium species are 
considered beneficial early life colonisers, and are found in high abundance 
in term, vaginally delivered, breastfed infants48. Short and long treatment with 
a combination of amoxicillin and ceftazidime during the first postnatal week 
drastically disturbed normal colonisation pattern. Antibiotic treatment was 
effective against members of the Enterobacteriaceae family, but also negatively 
affected Bifidobacterium abundance and allowed Enterococcus to thrive. It 
must be noted that Bifidobacterium abundance was already lower in meconium 
samples of ST and LT infants compared to control infants, most likely a result 
of the relatively late (postnatal day 2-4) defecation of meconium samples by 
most preterm infants. Enterococcus remained dominant for up to two weeks 
after antibiotic treatment discontinuation. This might possess a health risk for 
the infants, as some Enterococcus species emerged from gut commensals to 
nosocomial pathogens via the acquisition of multi-drug resistance and other 
virulence determinants175,176. Short, but not long, antibiotic treatment allowed 
for recovery of Bifidobacterium levels within the first six postnatal weeks. 
Although the differences in average Bifidobacterium abundance between 
ST and LT infants was less apparent using qPCR instead of sequencing, it 
did show that Bifidobacterium levels recovered in 4/5 ST and only in 2/5 LT 
infants. In addition, both methods indicate that long antibiotic treatment 
results in increased abundance of members of the Enterobacteriaceae family 
at postnatal week six. Antibiotic treatment did not affect community richness 
and diversity. However, richness and diversity were affected by postnatal age 
and by dominance of specific bacterial taxa. Dominance of Bifidobacterium was 
negatively associated with abundance of other bacterial genera. It’s dominance, 
however, allowed for higher community richness and diversity compared to 
dominance by other bacterial genera such as Enterococcus. We speculate that 
Bifidobacterium species control, but not outcompete, other bacterial species 
and that the microbial networks associated with Bifidobacterium species can 107
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therefore play an important role in early life tolerance induction and immune 
system maturation. Microbiota profiles associated with antibiotic treatment 
could negatively influence immune system maturation via disturbance of the 
normal colonisation pattern. Indeed, previous studies showed that early life 
antibiotic exposure increased susceptibility to immune-related diseases such 
as asthma and allergy, and associated this with perturbations in microbial 
composition129,177. In addition to antibiotic treatment, our findings show 
that postnatal age, gestational age, preeclampsia and maternal antibiotics 
influenced microbiota composition. The latter two highlight the importance of 
maternal health status on infant microbiota development. Previous studies 
showed that microbes can be vertically transmitted, and that maternal health 
status, such as bodyweight and antibiotic use, affect infant microbiota 
development178-180. Maternal antibiotics could affect infant microbiota 
composition via prenatal exposure of the foetus to antibiotics, via alteration 
of the mothers microbiota and therefore the inoculum at birth, and via transfer 
of antibiotics through breastfeeding. In the study described herein, the use of 
perinatal antibiotics was unevenly distributed among the study groups. This, 
in addition to the relatively small sample size, hindered to unravel the true 
impact of maternal antibiotics on infant microbiota development. Preeclampsia 
is a condition characterised by high blood pressure and proteinuria, and is 
associated with maternal and neonatal morbidity and mortality, preterm birth 
and intrauterine growth restriction181. The aetiology of preeclampsia is unknown, 
but this disorder could be linked to genetic factors, obesity, abnormal formation 
of placental blood vessels and autoimmune disorders181. Our findings suggest 
that preeclampsia or its accompanying conditions are associated with infant 
microbiota composition. However, the relation between preeclampsia and 
infant microbiota development needs to be further elucidated as this study 
was not designed for studying this matter. 
Overall, our findings show that intravenous antibiotic administration during 
the first postnatal week greatly affects infant gastrointestinal microbiota 
community structure. However, quick cessation of antibiotic treatment allows 
for recovery of the microbiota. Disturbances in microbiota development caused 
by short and more extensively by long antibiotic treatment, could affect healthy 
development of the infant via interference with maturation of the immune system 
and gastrointestinal tract. Clinicians should be aware of the disturbances 
that antibiotic treatment can cause and be strict in discontinuing antibiotic 
treatment as soon as possible to allow for a fast recovery of microbiota 
community structure.
Supplementary data
Figure S5.1 | Microbiota 
composition profiles based 
on 16S rRNA gene sequencing 
in control (A), ST (B) and 
LT (C) infants. Genera with a 
relative abundance of more than 
5% are shown.
 
Figure S5.2 | Microbiota 
composition profiles based 
on real-time qPCR data in 
control (A), ST (B) and LT (C) 
infants. 
 
Figure S5.3 | Total bacterial 
count as determined by real-
time qPCR. No significant 
difference observed between 
gestational age groups at each 
time point as determined by the 
Kruskal-Wallis test with Monte 
Carlo Permutation.
 
Figure S5.4 | Bacterial 
richness and diversity in 
control, ST and LT infants 
during the first six postnatal 
weeks. No significant 
difference observed between 
gestational age groups at each 
time point as determined by the 
Kruskal-Wallis test with Monte 
Carlo Permutation.
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Figure S5.1 | Microbiota 
composition profiles based 
on 16S rRNA gene sequencing 
in control (A), ST (B) and 
LT (C) infants. Genera with a 
relative abundance of more than 
5% are shown.
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Figure S5.2 | Microbiota 
composition profiles based 
on real-time qPCR data in 
control (A), ST (B) and LT (C) 
infants. 
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Figure S5.3 | Total bacterial 
count as determined by real-
time qPCR. No significant 
difference observed between 
gestational age groups at each 
time point as determined by the 
Kruskal-Wallis test with Monte 
Carlo Permutation.
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Figure S5.4 | Bacterial 
richness and diversity in 
control, ST and LT infants 
during the first six postnatal 
weeks. No significant 
difference observed between 
gestational age groups at each 
time point as determined by the 
Kruskal-Wallis test with Monte 
Carlo Permutation.
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INTRAVENOUS AMOXICILLIN/
CEFTAZIDIME TREATMENT 
EXERTS THRIVING OF 
ENTEROCOCCUS SPECIES IN 
PRETERM AND TERM INFANTS
ROMY D. ZWITTINK, DINY VAN ZOEREN-GROBBEN, INGRID B. RENES,  
RICHARD A. VAN LINGEN, OBBE F. NORBRUIS, ROCIO MARTIN,  
LIESBETH J. GROOT JEBBINK, JAN KNOL AND CLARA BELZER
ABSTRACT
Most preterm infants receive broad spectrum antibiotics before infection 
is diagnosed. This strategy of prophylactic treatment has led to decreased 
mortality and morbidity among preterm neonates but may also lead to treatment 
of infants that not necessarily require antibiotics and increases the risk of 
antibiotic resistance and disturbed gut microbiota development. We studied 
the effect of intravenous amoxicillin/ceftazidime administration on intestinal 
microbiota development during the immediate postnatal life of preterm and 
term infants. Faecal samples from 63 infants were collected at postnatal weeks 
one, two, three, four and six (total of 263 samples). Infants received either 
no (control, n=28), short-term (<3 days, ST, n=22) or long-term (>5 days, LT, 
n=13) treatment with a combination of amoxicillin and ceftazidime during the 
first postnatal week. Microbiota composition was determined by amplicon 
sequencing of the 16S rRNA gene. Compared to control infants, ST and LT 
infants’ microbiota contained a significantly higher abundance of Enterococcus 
during the first two postnatal weeks (p<0.05) at the expense of Bifidobacterium 
and Streptococcus. In addition, microbiota composition was less stable over 
time within ST and LT infants compared to control infants. Short and long 
antibiotic treatment both allowed for restoration of the intestinal microbiota 
within the first six postnatal weeks. However, Enterococcus and Bifidobacterium 
abundance were affected in fewer ST than LT infants. Overall, our findings show 
that intravenous administration of amoxicillin/ceftazidime affects intestinal 
microbiota composition, particularly by increasing the relative abundance of 
Enterococcus species during the first two postnatal weeks. Although being 
of short-term, the rise of antibiotic resistant enterococci at the expense of 
bifidobacteria and streptococci, including the potential effect of disturbed 
microbiota development on health outcomes in terms of metabolic and 
immune programming, should be considered as an aspect of the cost-benefit 
determination for antibiotic prescription.
INTRODUCTION
Neonatal infections are a major cause of mortality and morbidity, especially in 
preterm infants182,183. Since symptoms of infection are mostly nonspecific and 
infection can rapidly progress, most preterm infants are treated with broad-
spectrum antibiotics before diagnosis. This, however, results in overtreatment 
and the risk of selection for resistant bacteria184. To reduce the use of antibiotics 
in a neonatal unit, it is recommended to evaluate the need for further antibiotic 
treatment after 36-48 hours and to stop antibiotics if infection is not proven. In 
addition to increasing the risk of antibiotic resistance, antibiotics might interfere 
with the development of the intestinal microbiota. During birth and thereafter, 
microbes rapidly colonise the human gastrointestinal (GI) tract, a process 
that is not yet completely understood as it is highly dynamic and influenced by 
multiple host and environmental factors120. An abnormal pattern of bacterial 
colonisation has been observed in preterm infants compared to term infants, 
which might be associated with greater exposure to factors like caesarean 
section, hospitalisation, formula feeding and antibiotic treatment185,186. 
Development of the gut microbiota coincides with, and influences, development 116
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of the gastrointestinal tracts and immune system. Disturbances in early life 
microbiota development could therefore affect early and later life health 
outcomes72,187. Previous studies showed that the intestinal microbiota of 
preterm infants is affected by antibiotic treatment and characterised by 
high levels of facultative anaerobic bacteria and delayed colonisation with 
obligate anaerobes like Bifidobacterium99,151,168. Despite increasing knowledge 
about the effect of antibiotics on the intestinal microbiota, little research has 
focussed on treatment duration. In light of this, we previously performed a pilot 
study of 15 preterm infants exposed to no, short (<72 hours) or long (>5 days) 
antibiotic treatment during the first postnatal week159. We showed that short 
and long treatment affects the infant’s gastrointestinal microbiota, however, 
short antibiotic treatment allows for its recovery within the first six postnatal 
weeks. In continuation of this pilot study, we aimed to verify these results in a 
bigger cohort. Therefore, we determined microbiota composition throughout 
the first six postnatal weeks in 63 infants in the present study. Herein, the 
primary outcome was defined as the effect of antibiotic treatment duration on 
microbiota composition. As secondary outcome, the effect of other parameters 
on microbiota composition were studied, including gestational age, delivery 
mode, maternal antibiotics, tolerance of enteral feeding, feeding type and 
respiratory support. 
MATERIALS AND METHODS
Subjects and sample collection
This study was part of an observational, single centre, non-intervention study 
involving (pre)term infants admitted to the hospital level III NICU or the level 
II neonatal ward of Isala in Zwolle, The Netherlands. For the study described 
herein, all infants born between 32 and 42 weeks gestation, admitted to the level 
II neonatal ward and without major congenital malformation or malformations 
of the gastrointestinal tract, were eligible for inclusion. Informed consent was 
obtained from both parents of all individual participants included in the study. 
Antibiotic treatment was started on the suspicion of early-onset neonatal 
sepsis according to the hospital protocol and the judgement of the attending 
physician. After 48 hours, the need of antibiotic treatment was evaluated on 
the basis of clinical signs, blood culture and serial CRP. Faecal samples were 
collected from 63 infants at postnatal weeks one, two, three, four and six and 
stored at -20°C until transfer to -80°C. Infants received either no (control, n=28), 
short-term (<3 days, ST, n=22) or long-term (>5 days, LT, n=13) treatment with 
a combination of amoxicillin and ceftazidime during the first postnatal week. 
Their clinical characteristics can be found in table 6.1. 
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Table 6.1 | Infant 
characteristics.  
Abbreviations: AB: antibiotics, 
CPAP: continuous positive 
airway pressure, TPN: total 
parenteral nutrition, FEF: full 
enteral feeding, HM: human 
milk, PNW: postnatal week, 
PROM: prolonged rupture of 
membranes
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Table	6.1	|	Infant	characteristics.		
	
	 	 Control	 ST	 LT	
Infants	 n	 28	 22	 13	
	 Gestational	age	(weeks)	 34.8	±	1.4	 34.2	±	2.2	 37.2	±	3.1	
	 Birthweight	(gram)	 2309	±	456	 2406	±	588	 3111	±	863	
	 Vaginal	birth	 13	(46.4%)	 15	(68.2%)	 6	(46.2%)	
	 Male	 13	(46.4%)	 13	(59.1%)	 8	(61.5%)	
	 Preterm	 24	(85.7%)	 19	(86.4%)	 7	(53.8%)	
	 Twin	 11	(39.3%)	 5	(22.7%)	 2	(15.4%)	
	 AB	treatment	(days)	 0	 2.2	±	0.5	 7.5	±	2.2	
	 CPAP	 5	(17.9%)	 10	(45.5%)	 0	(0%)	
	 Food	intolerant	 0	(0%)	 0	(0%)	 1	(7.7%)	
	 TPN	 2	(7.1%)	 0	(0%)	 1	(7.7%)	
	 Days	until	FEF	 7.0	±	1.0	 7.2	±	1.3	 7.6	±	0.9	
	 HM	>50%	throughout	6	PNW	 19	(67.9%)	 15	(68.2%)	 7	(53.8%)	
	 %	HM	throughout	6	PNW	 68	±	27	 71	±	34	 63	±	32	
	 Cause	of	infection:	
Proven	sepsis	
Clinical	sepsis	
Pneumonia	
Meningitis	
	 	 	
3	(23.1%)	
6	(46.2%)	
3	(23.1%)	
1	(7.7%)	
	 Causative	pathogen:	
Group	B	Streptococcus	
Escherichia	coli	
Unknown	
	 	 	
4	(30.8%)	
1	(7.7%)	
8	(61.5%)	
Mothers	 Pre-eclampsia	 5	(17.9%)	 3	(13.6%)	 2	(15.4%)	
	 PROM	 5	(17.9%)	 5	(22.7%)	 6	(46.2%)	
	 AB	around	birth	 19	(67.9%)	 15	(68.2%)	 9	(69.2%)	
	 AB	>48h	after	birth	 2	(7.1%)	 3	(13.6%)	 4	(30.8%)	
Abbreviations:	AB:	antibiotics,	CPAP:	continuous	positive	airway	pressure,	TPN:	total	parenteral	nutrition,	FEF:	
full	enteral	feeding,	HM:	human	milk,	PNW:	postnatal	week,	PROM:	prolonged	rupture	of	membranes	 	
16S rRNA gene amplicon sequencing
DNA extraction, library preparation and sequencing were performed by 
LifeSequencing S.L. (Valencia, Spain). DNA was extracted from 200 mg faeces 
using the QIAamp Fast DNA Stool Mini Kit (Qiagen), including enzymatic and 
chemical cell disruption by bead beating. DNA was purified and concentrated 
using the PowerMag DNA clean-up kit (MoBio) and 50 ng of DNA was amplified 
according to the Metagenomic Sequencing Library Illumina 15044223 B protocol 
(Illumina). For the first amplification step, primers were designed containing 
a universal linker sequence allowing amplicons for incorporation of indexes 
and sequencing primers by Nextera XT Index kit (Illumina) and 16S rRNA gene 
primers for region V3-V4188. Indexes were included during a second amplification 
step. Libraries were quantified using the Quant-iT™ PicoGreen™ dsDNA 
Assay Kit (Thermofisher) and pooled prior to sequencing on the MiSeq 
platform (Illumina, 300 bases paired-end). The size and quantity of the pool 
were respectively assessed on the Bioanalyzer 2100 (Agilent) and with the 
Library Quantification Kit for Illumina (Kapa Biosciences). 
Data analysis
Read filtering, operational taxonomic unit (OTU)-picking and taxonomic 
assignment were performed using the NG-Tax pipeline with the following 
settings: read length of 70, ratio OTU abundance of 2, classify ratio of 0.8, 
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minimum percentage threshold of 0.5, identity level of 100%, error correction of 
98.5, using the Silva_128_SSU Ref database143,160. For within infant (dependent) 
or between infants (independent) comparisons, the nonparametric Wilcoxon 
Signed Rank test and Kruskal-Wallis test, both with Monte Carlo permutation 
(10000x), were applied respectively. To correlate the abundance of taxa with 
each other, Spearman’s rank correlation coefficient was determined. Before 
testing for differences in taxonomy, the OTU table was filtered for OTUs 
present in less than 25% of the samples. To relate microbiota composition 
to clinical data, redundancy analysis (RDA) was performed using Canoco 
multivariate statistics software v5. Clinical factors included in the analysis 
were gestational age, birthweight, delivery mode, singlet/twin/triplet, gender, 
postnatal age, maternal antibiotics around birth and at least 48 hours after birth, 
preeclampsia, prolonged rupture of membranes, ventilation, CPAP, days of total 
parenteral nutrition, days until full enteral feeding, food intolerance, proportion 
of parenteral/enteral nutrition per week, percentage human milk and formula 
feeding per week and average percentage of human milk feeding throughout 
the first six postnatal weeks and the duration of antibiotic treatment. Factors 
were considered to have a significant influence on microbiota composition 
when the false discovery rate corrected p-value was below 0.05.
RESULTS
Succession of the gut microbiota in infants receiving no, short or long antibiotic treatment
Faecal microbiota composition was determined during the first six postnatal 
weeks in moderate- to late preterm and term infants (32-42 weeks gestation) 
receiving either no (control), short-term (ST) or long-term (LT) antibiotic 
treatment during the first postnatal week. In control infants, the intestinal 
microbiota was characterised by high abundance of Bifidobacterium, 
Streptococcus, Enterococcus, Staphylococcus, Escherichia-Shigella and 
members of the Enterobacteriaceae family (Fig 6.1). During the first six postnatal 
weeks, average relative abundance of Bifidobacterium increased (18.9% to 
41.1%; p=0.007), while Staphylococcus decreased (15.5% to 7.0%; p=0.0002). 
In addition, community richness and diversity gradually increased over time, 
being significantly higher at later time points compared to early time points (Fig 
6.2a). Vaginal delivery and postnatal age explained most variation in microbiota 
composition between samples (7.7% and 5.5% respectively, Table 6.2). Delivery 
through primary and secondary caesarean section were associated with 
increased abundance of Enterobacteriaceae and Enterococcus respectively, 
while vaginal delivery was associated with increased Bifidobacterium, 
Bacteroides and Escherichia-Shigella (Fig 6.3a). In addition, days until full enteral 
feeding, amount of human milk feeding throughout the first six postnatal weeks, 
gender, continuous positive airway pressure, maternal antibiotics around birth 
and gestational age influenced microbiota composition (Table 6.2). 
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Figure 6.1 | Microbiota 
composition profiles in 
control, ST and LT infants 
during the first six postnatal 
weeks. Average relative 
abundances per time point are 
shown.
Figure 6.2 | Community 
richness and diversity during 
the first six postnatal weeks 
in control (A), ST (B) and 
LT (C) infants. Boxplots 
show the median, 25th and 
75th percentiles, and minimal 
and maximal values with the 
exception of outliers (circles) 
and extremes (asterisks). 
Differences in richness and 
diversity between time points 
were determined using the 
Wilcoxon Signed Rank test with 
Monte Carlo permutation. 
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Figure 6.3 | Redundancy 
analysis using microbiota 
composition profiles from 
(A) control infants and (B) all 
infants. Species with a 15-100% 
fit into the ordination space 
and explanatory variables that 
significantly explain variation 
are shown. Abbreviations: 
C-section: caesarean section, 
AB: antibiotics, FEF: full enteral 
feeding, PNW: postnatal weeks.
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Table 6.2 | Factors explaining 
the variation in microbiota 
composition between 
samples as determined by 
redundancy analysis. Factors 
significantly explaining the 
variation are shown.
 
Abbreviations: FDR: false 
discovery rate, C-section: 
caesarean section, FEF: full 
enteral feeding, HM: human 
milk, CPAP: continuous 
positive airway pressure, AB: 
antibiotics, GA: gestational 
age, PROM: prolonged rupture 
of membranes, TPN: total 
parenteral nutrition.
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The intestinal microbiota of infants receiving short-term antibiotic treatment 
was characterised by a high abundance of Bifidobacterium, Enterococcus, 
Staphylococcus, Streptococcus, Escherichia-Shigella, Clostridium and members 
of the Enterobacteriaceae family (Fig 6.1). During the first six postnatal weeks, 
average relative abundance of Bifidobacterium (6.4% to 35.9%, p=0.001), 
Streptococcus (4.2% to 13.0%, p=0.001) and Escherichia-Shigella (0.4% to 5.1%, 
p=0.013) increased. In addition, there was a trend of decreasing Enterococcus 
(44.2% to 6.7%, p=0.077) and Staphylococcus (28.6% to 2.8%, p=0.053) throughout 
this time. Community richness and diversity showed a temporal increase, being 
significantly higher at later time points compared to early time points (Fig 6.2b). 
Postnatal age (7.4%), prolonged rupture of membranes (5.4%) and gender (4.9%) 
explained the variation in microbiota composition between samples (Table 6.2). 
The intestinal microbiota of infants receiving long-term antibiotic treatment 
was characterised by a high abundance of Bifidobacterium, Enterococcus, 
Clostridium, Staphylococcus, Escherichia-Shigella, Bacteroides and members 
of the Enterobacteriaceae family (Fig 6.1). Over time, a trend of increasing 
Bifidobacterium (10.22% to 31.4%, p=0.077) and decreasing Enterococcus (57.3% 
to 12.0%, p=0.079) could be observed. Overall, community richness and diversity 
increased over time (Fig 6.2c). At the first postnatal week, however, richness and 
diversity varied greatly between infants. Postnatal age (7.8%), delivery mode 
(6.9%) and days of total parenteral nutrition (6.5%) explained the variation in 
microbiota composition between samples (Table 6.2). 
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Figure 6.4 | Unweighted (A) 
and weighted (B) unifrac 
distances within control, 
ST and LT infants. Boxplots 
show the median, 25th and 
75th percentiles, and minimal 
and maximal values with the 
exception of outliers (circles). 
Differences were determined 
using the Kruskal Wallis test 
with Monte Carlo permutation.
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Antibiotic treatment exerts thriving of Enterococcus species
To understand the effect of antibiotic treatment duration on intestinal microbiota 
development, microbiota composition was compared between control, ST and 
LT infants. Compared to control infants, ST and LT infants’ microbiota contained 
a significantly higher abundance of Enterococcus during the first two postnatal 
weeks (p<0.05). The abundance of Enterococcus negatively correlated with 
Bifidobacterium (ρ=-0.260, p=1.3*10-5) and Streptococcus (ρ=-0.279, p=3*10-6). 
In addition, microbiota composition was less stable over time within ST and LT 
infants compared to control infants as indicated by significantly higher unifrac 
distances (Fig 6.4). Microbiota composition did not significantly differ between 
ST and LT infants. However, Enterococcus became a dominant member of the 
community during the first two postnatal weeks in a higher percentage of LT than 
ST infants (Fig 6.5). In addition, Bifidobacterium was an abundant member of 
the community in a higher percentage of ST than LT infants at postnatal weeks 
four and six (Fig 6.5). Community richness and diversity were not consistently 
affected by antibiotic treatment. Instead, community richness and diversity 
related to which taxa dominated the community. In mixed communities, or 
communities dominated by Bifidobacterium, richness and diversity were higher 
than when the community was dominated by Enterococcus, Streptococcus or 
Staphylococcus, with the lowest richness and diversity being observed for 
Enterococcus (Fig 6.6).
Figure 6.5 | Fraction of infants 
in which Bifidobacterium (A) 
or Enterococcus (B) was an 
abundant member of the 
bacterial community. An 
abundant member was defined 
as representing an abundance 
of ≥10%.
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Figure 6.6 | Richness and 
diversity in samples with 
different dominating 
bacterial taxa. Taxa were 
considered dominant in a 
sample when it was the most 
abundant taxon and at least 10% 
more abundant than the second 
most abundant taxon. When 
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most abundant taxa was less 
than 10%, is was considered 
a mixed community. Boxplots 
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Figure 6.7 | Microbiota 
composition profiles during 
the first six postnatal weeks 
in preterm and term infants 
receiving no, short or long 
antibiotic treatment. Average 
relative abundances per time 
point are shown.
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Higher gestational and postnatal age, no antibiotic treatment and less days until full enteral feeding 
are associated with increased abundance of Bifidobacterium
The effect of clinical characteristics in association with microbiota composition 
were determined by redundancy analysis. Duration of antibiotic treatment 
explained 2.5% of the variation in microbiota composition between all samples 
(Table 6.2). In addition, postnatal age (5.5%), gender (2.9%), days until full enteral 
feeding (2.2%), delivery mode (2.0%) and gestational age (1.5%) were associated 
with differences in microbiota composition (Table 6.2). Boys were associated 
with increased abundance of Escherichia-Shigella, while girls were associated 
with increased abundance of other members of the Enterobacteriaceae family 
(Fig 6.3b). This difference was statistically significant at postnatal weeks two, 
three and four (p<0.05). Increased postnatal age, no antibiotic treatment, less 
days until full enteral feeding and higher gestational age were associated 
with increased abundance of Bifidobacterium (Fig 6.3b). Regarding gestational 
age, this study included infants born between 32-42 weeks gestation, thus 
comprised preterm and term infants. Comparing the intestinal microbiota 
between term and preterm infants showed that they respond similarly to 
antibiotic treatment (Fig 6.7). On average, abundance of Bifidobacterium was 
higher in term compared to preterm infants, however, this difference was not 
statistically significant. 
DISCUSSION
Intravenous antibiotic administration for the prevention and treatment of 
infection and sepsis occurs frequently in the neonatal unit. Therefore, it is of 
great relevance to study the side effects of antibiotic treatment, including its 
effect on microbiota development. As a sequel to our pilot study159, we studied 
the effect of intravenous antibiotic treatment duration on intestinal microbiota 
development in 63 (pre)term infants during the first six postnatal weeks. 
The genera Bifidobacterium, Streptococcus, Enterococcus, Staphylococcus, 
Escherichia-Shigella and members of the Enterobacteriaceae family made 
up the biggest proportion of the (pre)term infant faecal microbiota. Overall, 
relative abundances of Enterococcus and Staphylococcus were decreasing 
over the first six postnatal weeks, while abundances of Streptococcus and 
Bifidobacterium were increasing. Short and long antibiotic treatment with 
amoxicillin and ceftazidime affected microbiota composition by allowing 
Enterococcus to thrive during the first two postnatal weeks. Enterococcus 
thrived at the expense of Bifidobacterium and Streptococcus. These findings 
are in concordance with our previous study159. The increased abundance of 
Enterococcus at time of treatment could indicate antibiotic resistance as it 
is a target organism of amoxicillin. As some Enterococcus species emerged 
from gut commensals to nosocomial pathogens, this might possess a health 
risk for the infants176. Enterococcus species have been identified as causative 
organism in late-onset sepsis189,190. In contrast to the pilot study, no significant 
difference in microbiota composition could be observed between infants 
receiving short or long antibiotic treatment. However, it must be noted that 
Enterococcus became an abundant member of the community during the 126
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first two postnatal weeks in a higher percentage of long than short treated 
infants. As well, Bifidobacterium did not become an abundant member of the 
community at postnatal weeks four and six in a higher percentage of long than 
short treated infants. This indicates that long antibiotic treatment has a more 
profound effect on microbiota development than short treatment, similar 
to what we have previously observed159. High inter-individual variation, in 
combination with the relatively small number of long treated infants, most 
certainly decreased statistical power. In addition, inclusion of all infants, 
instead of studying a carefully selected subset, did not allow to prevent 
possible bias by parameters like gestational age, delivery mode, gender, 
maternal antibiotics and feeding. For example, 46.2% of the long-treated 
infants were born at term, while only 13.6% of the short-treated infants were 
born at term. 
Community richness and diversity were not consistently affected by antibiotic 
treatment. Instead, richness and diversity were increasing over time, and were 
related to which bacterial taxa was dominant. Richness and diversity were 
lower when the community was dominated by Enterococcus, Streptococcus 
or Staphylococcus, and higher when dominated by other taxa, including 
Bifidobacterium. As the abundance of Bifidobacterium was increasing over 
time, these two factors seem related and hinders to elucidate their sole effect 
on community richness and diversity.
In addition to antibiotic treatment duration, microbiota composition was 
associated with postnatal age, gender, days until full enteral feeding, delivery 
mode and gestational age. Increased gestational- and postnatal age and less 
days until full enteral feeding were associated with higher abundance of early 
life coloniser Bifidobacterium. A Bifidobacterium-dominated microbiota is more 
representative of microbiota development in term, vaginally born, breast-fed 
infants, which is considered most beneficial during early life development161. 
The beneficial effect of Bifidobacterium species is speculated to be due to its 
protection against pathogens and its immune modulating properties32. Since 
dominance by Bifidobacterium, compared to other bacterial taxa, allowed for 
higher community richness and diversity, we speculate that Bifidobacterium 
species control, but not outcompete, other bacterial species. Bifidobacteria 
could therefore play an important role in the development of a healthy and 
diverse ecosystem that promotes tolerance induction and immune system 
maturation. In addition, bifidobacteria are optimal milk degraders and are 
known for their role in the degradation of simple and complex sugars like 
human milk oligosaccharides31. Early differences in microbiota composition 
may affect the infants’ food digestion capacity and subsequent energy harvest 
21,79. This is particularly relevant for infants born preterm with protein and energy 
deficits98. Regarding gender, boys’ microbiota contained higher abundance of 
Escherichia-Shigella, while the microbiota of girls contained more members 
of the Enterobacteriaceae family that could not be classified to genus level. 
Several studies have shown that gut microbiota composition differs between 
adult males and females191,192, but the gender-effect during early life is relatively 
unexplored156. 127
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Overall, our findings show that intravenous administration of amoxicillin 
and ceftazidime affects intestinal microbiota composition, particularly by 
increasing the relative abundance of Enterococcus species during the first two 
postnatal weeks. Short and long antibiotic treatment both allow for restoration 
of the intestinal microbiota within the first six postnatal weeks as characterised 
by increasing relative abundance of Bifidobacterium species. Long treatment, 
however, potentially has a more enduring effect on microbiota development 
than short treatment, but this needs to be further elucidated. Although being 
of short-term, the rise of antibiotic resistant enterococci at the expense of 
bifidobacteria and streptococci, including the potential effect of disturbed 
microbiota development on health outcomes, should be considered as an aspect 
of the cost-benefit determination for antibiotic prescription.
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CHAPTER 7
GENERAL DISCUSSION AND 
FUTURE PERSPECTIVES
Preterm infants are prone to health complications during their early life including 
respiratory distress syndrome, jaundice, infection, sepsis and NEC. Health 
complications are mainly associated with organ immaturity and are therefore 
related to the infant’s gestational age. Preterm infants are born with an immature 
gut and are therefore likely to experience feeding constraints, raising a major 
challenge in meeting their nutritional needs. In addition to its function in nutrient 
digestion and absorption, the gastrointestinal tract is in close interaction with 
the endocrine, neural and immune system. Gastrointestinal immaturity could 
therefore impact processes distant from the gut. The gastrointestinal tract is 
densely populated by microorganisms, the gut microbiota, playing a pivotal role 
in human physiology. Establishment of a healthy gut microbiota could benefit the 
preterm infant via its participation in metabolic processes, pathogen resistance 
and immune modulation. Development of the gut microbiota starts during birth 
and evolves further during life being affected by multiple host and environmental 
factors. Early life provides a window of opportunity since the gut microbiota 
is still developing and relatively responsive to interventions. Before the gut 
microbiota can be targeted as means of therapy in preterm infants, it is important 
to understand how their gastrointestinal tract is functioning, which microbes 
colonise, what the microbes are doing and how microbiota establishment is 
affected. The work in this thesis aimed to provide a better understanding of 
gastrointestinal function and microbiota development during the early life of 
preterm infants and to provide insight in which host and environmental factors 
play a key role in this development.
FUNCTIONING OF THE PRETERM GASTROINTESTINAL TRACT
When born preterm, the gastrointestinal tract may have immature motility 
functions and decreased digestive enzyme activity, with its degree of immaturity 
being associated with gestational age. Structural and functional maturation 
of the gastrointestinal tract are required for proper digestion and absorption 
of nutrients from milk feedings. Feeding constraints, reflected by abdominal 
distension, vomiting and gastric retention, are common, and preterm infants 
rarely meet in utero growth rates despite the existence of various nutrition 
support strategies8,91. Since sampling of various sites of the gastrointestinal 
tract is invasive and limited by ethical considerations, studying gastrointestinal 
development is challenging and often relies on animal models193. The application 
of metaproteomics analysis on faecal samples to study gut microbiota functioning 
in preterm infants (chapter 3) provided the opportunity to study host functioning 
since, in addition to bacterial proteins, many human- and bovine-derived 
proteins were identified. The inclusion of gastric aspirates from the same infants 
allowed to obtain insights in the gastric and faecal proteome as indication for 
gastrointestinal functioning and maturation, as described in chapter 2. The 
gastric proteome was mainly affected by percentage human milk feeding, 
while gestational age mainly affected the faecal proteome. The inability to 
functionally categorise a substantial proportion of identified proteins restricted 
comprehensive data interpretation. Nevertheless, our findings verified current 
knowledge considering the passage of proteins through the gastrointestinal 
tract and revealed gestational age-related developmental patterns for multiple 132
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marker proteins. Although we were able to obtain first clues from the information 
contained in this complex dataset, we believe that more extensive analysis will 
provide further insights in gastrointestinal function and maturation in preterm 
infants. As Dallas et al stated, ‘digestion is more complicated than the simple sum 
of the cleavage patterns of well-known proteases’95. Digestive capacity relies on 
the digestive environment (the combination of motility, secretory and regulatory 
functions), feeding strategy, and microbial colonisation. Bacteria residing the 
human gastrointestinal tract play an essential role in metabolism of dietary 
components, with their metabolic capacity being distinct, but complementary, to 
the activity of human enzymes96. In addition, variation in microbiota composition 
could differentially affect energy harvest and storage by the host21,79. Regarding 
preterm infants, who commonly experience protein deficits and growth 
retardation, further exploration of the gut microbiota’s metabolic traits is 
particularly relevant97,98. Microbiota development coincides with gastrointestinal 
development, which was reflected by our observation that the quantity of gut 
maturation markers correlates with abundance of specific bacterial taxa 
(chapter 2). Overall, increased understanding of gastrointestinal function and 
maturation in relation to feeding regimen and microbiota development supports 
identification of diagnostic markers and aids improvement of nutritional and 
therapeutic strategies for preterm infants. In light of this, several nutritional 
strategies targeting the gut microbiota are being studied, of which human milk, 
probiotics and lactotransferrin seem most promising regarding infections and 
NEC77,82. Probiotics did so far not consistently improve growth outcomes in 
neonates194,195, but they potentially reduce the number of days until full enteral 
feeding196, which is of clinical relevance.
THE PRETERM INFANT GUT MICROBIOTA
The concept of a sterile in utero environment is being questioned since 
the observation of bacterial signatures in the placenta, amniotic fluid and 
meconium. Since meconium particularly consists of material ingested in 
utero it can serve as representative sample for studying the presence of 
an intra-uterine microbiota. Microbiota of meconium samples, as included 
in chapter 3-5, showed high compositional variability and a relatively high 
richness and diversity. It should be noted, however, that low biomass samples 
like meconium are prone to the introduction of PCR errors and could therefore 
result in overestimation of community richness and diversity, particularly 
when the number of PCR cycles is increased to obtain results197. Inclusion of 
proper negative controls during sampling and sample processing is therefore 
of foremost importance. In our attempt to study the meconium microbiota of 
preterm twins and triplets, around 85% of 59 samples seemed sterile as indicated 
by the inability to amplify the 16S rRNA gene by means of PCR and qPCR (data 
not shown). In 15% of the meconium samples, however, 104-106 copies of the 16S 
rRNA gene per 10ng DNA could be detected, and presence of bifidobacteria 
and members of the Enterobacteriaceae could be confirmed. Considering the 
analysis of meconium samples, is important to take the sampling day, high 
contamination risk, detection limit and bacterial viability into account. Based 
on these considerations, critical evaluation of current literature showed that 133
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evidence for an in utero microbiome is weak47. Further studies are necessary to 
unambiguously confirm the existence of a viable intra-uterine microbiota and 
whether this affects postnatal development of the infant and its microbiota. 
Regardless of whether an infant is born sterile, majority of the microbiota 
residing the human body are acquired during and after birth. During the birthing 
process, the neonate is exposed to its mothers vaginal, faecal or skin microbiota, 
depending on delivery mode, thereby acquiring its first environmental-derived 
inoculum of microorganisms. After birth, the infant is exposed to a wide range 
of microorganisms that are residing in its direct environment, including parental 
skin and human milk feedings, which drives microbiota development further.
Bacterial load
In healthy neonates born at term, bacterial density reaches 1010 cells per gram 
faeces at the first postnatal week156,198. A study among very preterm infants 
showed that bacterial density reaches 109 cells per gram faeces at their tenth 
postnatal day97. In late preterm infants, quantification of total bacteria by qPCR 
showed the presence of 108 16S rRNA gene copies per 2ng faecal DNA from the 
first postnatal week onwards (chapter 6). Surprisingly, quantitative data of total 
bacteria in the gastrointestinal tract during early life is limited. Quantification 
has either focussed on specific bacterial taxa or total bacterial counts were solely 
used to transform absolute counts to relative abundances for specific taxa62,137. 
In addition, variation in methodology and in presentation of results hinders 
comparison between studies. The distribution of bacterial- and human-derived 
proteins, obtained by metaproteomics as described in chapter 3, indicates a 
low bacterial load in extremely and very preterm infants during the first two 
postnatal weeks, and a delayed colonisation up till the sixth postnatal week in 
extremely preterm infants. Equivalent results have previously been reported 
for one very preterm and four extremely preterm infants86,87. Low bacterial load 
could be an explanation for high variation in microbiota composition. It has 
recently been shown that bacterial load is a driver of microbiota composition199. 
In addition, it was stated that relative approaches, like sequencing of 16S rRNA 
gene amplicons, ignore the possibility that altered quantity of the microbiota 
by itself could be a marker of a disease-associated ecosystem and that relative 
profiling hampers linking microbiota composition to quantitative physiological 
parameters199. It must be noted, however, that quantitative and relative methods 
both have their limitations and that one should apply both complementary 
approaches to obtain full insight in microbiota composition and its temporal 
dynamics200. This understanding is currently resulting in the development of 
methodologies that integrate absolute and relative quantification201-203.
Microbiota composition
Although the intestinal microbiota is dynamic during the first weeks of life, it is 
generally believed that the first colonisers are facultative anaerobic bacteria, 
particularly Staphylococcus, Streptococcus, Enterococcus and Enterobacter. 
These bacteria create an anaerobic environment to allow for colonisation by 
obligate anaerobes like Bifidobacterium, Bacteroides and Clostridium from the 
first postnatal week onwards. Previous studies have shown that preterm infants, 
compared to term infants, harbour a less diverse gut microbiota characterised 134
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by high levels of facultative anaerobic bacteria and delayed colonisation with 
obligate anaerobic bacteria like Bifidobacterium63,64,121. The studies described 
in this thesis showed that Staphylococcus, Enterococcus, Streptococcus, 
Enterobacter, Escherichia-Shigella, Enterobacteriaceae, Clostridium and 
Bifidobacterium are abundant members of the bacterial community during 
the first six postnatal weeks in preterm infants (chapters 3-6). Community 
richness and diversity increased with increasing postnatal age in moderate to 
late preterm infants (chapter 5 and 6). In addition to postnatal age, richness 
and diversity were associated with the community’s dominating taxa (chapter 
5 and 6). When the community was dominated by one bacterial taxa, richness 
and diversity were generally lower, however, Bifidobacterium allowed for higher 
richness and diversity than Enterococcus, Streptococcus and Staphylococcus. 
Bifidobacteria may therefore play a significant role in the development of a 
healthy and diverse ecosystem. The correlation between postnatal age and 
abundance of these bacterial genera, however, hinders distinguishing their sole 
effect on community richness and diversity. Overall, abundance of facultative 
anaerobic bacteria and Bifidobacterium respectively decreases and increases 
with postnatal age, however, this process seems affected by gestational age and 
its associated factors. The observation that Bifidobacterium species colonise the 
preterm infant gut between 33-36 weeks postconceptional age, independent of 
postnatal age, indicates a substantial influence of gestational age on microbiota 
development65,164. When comparing microbiota establishment between extremely 
and very preterm infants, as described in chapter 3, we indeed observed that 
Bifidobacterium became an abundant member at the third postnatal week (33rd 
postconceptional week) in very preterm infants, while remaining low in extremely 
preterm infants up till the sixth postnatal week (31st-33rd postconceptional week). 
In another set of extremely and very preterm infants, as described in chapter 4, 
Bifidobacterium was an abundant member of the bacterial community at postnatal 
week six in 89% of the very preterm infants (35th-37th postconceptional week), 
while only in 50% of the extremely preterm infants (32nd-34th postconceptional 
week). Unfortunately, our dataset was limited to sampling up till the sixth 
postnatal week, disabling further elaboration about the existence of a postnatal/
postconceptional age threshold for Bifidobacterium colonisation. In addition, 
colonisation of the gut by Bifidobacterium species does not solely depend on 
age. In moderate to late preterm infants, as described in chapters 5 and 6, 
Bifidobacterium was abundant at postnatal week six in 92-100%, 78-80% and 20-67% 
of infants receiving respectively no, short or long antibiotic treatment. The effect 
of various environmental factors on microbiota development is described later 
in this discussion. An overview of the relative abundance of Bifidobacterium 
at postnatal week six as observed throughout chapters 3-6 is shown in figure 
7.1. The incentive to explore the existence of an age threshold for colonisation 
by Bifidobacterium species, and to understand other factors impacting its 
colonisation derives from their beneficial effect on intestinal, metabolic and 
immune health. The gut microbiota of term, vaginally born, breastfed infants 
generally contains high abundance of Bifidobacterium species, in particular B. 
breve and B. longum. Elucidating Bifidobacterium colonisation patterns and a 
potential age threshold in preterm infants is important to advance therapeutic 
strategies targeting the microbiota.135
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Microbiota activity
The number of studies aiming to unravel microbiota development in preterm 
infants is rising and, as such, knowledge about gut microbiota composition 
is increasing. However, despite the existence of various methodologies to 
study microbiota function based on DNA, RNA, proteins and metabolites, data 
regarding the functional signatures of the preterm infant intestinal microbiota 
remains limited. The application of metagenome sequencing allows for a 
functional prediction of the bacterial community based on gene content and 
has shown that the preterm infant gut microbiota is likely to become dominated 
by antibiotic resistant and pathogenic bacteria as pressured by broad-spectrum 
antibiotics64,83-85. Such findings are of clinical importance since antibiotic 
treatment is common in preterm infants due to their high susceptibility to 
infection and sepsis. In addition to antimicrobial resistance genes, stool 
metagenome data has been applied to determine host-microbe interactions 
as presented by metabolic- and immune-modulating capacities204. However, 
such functional traits of the preterm infant gut microbiota were not elaborated 
on in current literature. While the metagenome provides a static view of the 
community’s functional capabilities, the metatranscriptome gives more dynamic 
insights by highlighting gene expression. However, metatranscriptomics has 
so far not been applied on preterm infant gastrointestinal samples. Some 
literature is available about the preterm infant faecal metaproteome, which may 
provide a better indication of the actual phenotype of the gut microbiota86-88. 
It must be noted, that these three studies were conducted within the same 
research group. Temporal development of the preterm infant gut microbiota 
composition was associated with increasing activity towards the degradation 
of complex carbohydrates87. However, this study only included one preterm 
infant who was longitudinally sampled up till the third postnatal week. The 
temporal development towards increasing carbohydrate degradation could be 
individual-specific as was shown in a study in which four preterm infants were 
included86. Here, the exploitation of carbohydrates, amino acids and lipids by the 
Figure 7.1 | Relative 
abundance of 
Bifidobacterium at postnatal 
week six among all infants 
included in the studies 
described in chapters 3, 
4, 5 and 6. EP: extremely 
preterm, VP: very preterm, AB: 
antibiotics, MLP: moderate- to 
late preterm.
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gut microbiota showed large inter- and intra-individual variation, but could be 
related to the presence of specific bacterial taxa. Metaproteomics data of ten 
longitudinally sampled preterm infants, as described in chapter 3, revealed that 
a Bifidobacterium-dominated community is associated with increased proteins 
involved in carbohydrate and energy metabolism, including those involved in 
the degradation of complex carbohydrates like human milk oligosaccharides. 
Proteins involved in membrane transport and translation were abundant in 
communities dominated by Enterococcus or Enterobacter, confirming taxa-
specific functional contributions to the bacterial community. Genomes of 
bifidobacteria contain gene cassettes devoted to the utilisation of various 
carbohydrates205 and our metaproteomics data indicates that bifidobacteria 
are well capable to establish and to be metabolically active in the gut of very 
preterm infants. Early establishment and metabolic activity of bifidobacteria, 
and of the whole bacterial community, may be relevant considering the digestion 
capacity and potential energy harvest from milk feedings by preterm infants as 
mentioned earlier. It is worthy to further elucidate the metabolic capacities of 
the microbiota, and of its specific members, in relation to digestive functioning 
and growth outcomes in preterm infants97,98. Metabolomics studies showed 
that bifidobacteria are particularly abundant in healthy preterm infants, and 
are positively associated with raffinose, sucrose and acetic acid206. Specific 
metabolites involved in the ‘C21-steroid hormone biosynthesis’, ‘linoleate 
metabolism’ and ‘leukotriene metabolism and prostaglandin formation from 
arachidonate’ pathways are increased prior NEC diagnosis130. Like with 
metaproteomics, a metabolomics approach identified taxa-specific functional 
contributions. High abundance of Enterococcus, Pseudomonas and Escherichia-
Shigella, as observed in antibiotic treated preterm infants, were associated 
with increased L-tyrosine and citric acid207. Complexity of the preterm infant 
faecal metabolome generally increases with age and can be associated with 
weaning89. Functional profiles are stable at 1-3 years of age and, at that time, 
cannot be associated with early life events including delivery mode, gestational 
age, antibiotic use and NEC/LOS89. It must be noted that all, except one, of 
these metabolome studies were conducted within the same research group, 
indicating that metaproteomics and metabolomics approaches are not yet 
widely applied to study gut microbiota functioning in preterm infants. To obtain 
more detailed insights in host-microbe interactions, functional analysis of 
the microbiota needs further implementation in current microbiota research.
FACTORS MAKING A DIFFERENCE
The findings presented in this thesis show that the faecal proteome and 
microbiota are associated with gestational age. The duration and extend of 
care for the preterm infant are strongly related to gestational age. Therefore, 
one should be aware that observed differences in the faecal proteome and 
microbiota between infants of varying gestational age might actually be 
attributable to gestational age-associated environmental factors rather than to 
gestational age itself. Early life microbiota development is influenced by factors 
like delivery mode, antibiotics and feeding type120. In preterm infants, various 
aspects of the NICU environment influence microbiota composition208. Multiple 137
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variables were taken along during data analysis for the studies described 
in this thesis, among others gestational age, birthweight, gender, delivery 
mode, perinatal and postnatal antibiotics, feeding regimen, postnatal age and 
days until discharge. The gestational age-dependent microbiota signature in 
extremely and very preterm infants, as described in chapter 3, was associated 
with variation in exposure to antibiotics and with duration of respiratory support. 
Extremely preterm infants are to a greater extend exposed to antibiotics and 
respiratory support as compared to very preterm infants. The association 
between these factors, however, hinders to understand their sole effect on 
microbiota development. It is well recognised that antibiotics impact early life 
microbiota development209. In contrast, documentation regarding the effect 
of respiratory support on gut microbiota development is currently limited and 
deserves more attention137,147. While the EIBER study was not designed to 
further elucidate the effect of respiratory support strategies on microbiota 
development, it did aim to study the effect of antibiotics. 
Postnatal antibiotics
Treatment with amoxicillin/ceftazidime during the first postnatal week altered 
the microbiota of late preterm infants to become dominated by enterococci 
at the expense of bifidobacteria (chapter 5 and 6). Despite inconsistencies, 
more than five days of treatment seems to have had a longer lasting effect on 
microbiota composition than less than three days of treatment. Elongation 
of antibiotic treatment with a few days potentially delays (re)colonisation by 
Bifidobacterium species with weeks. Two dosages of vancomycin during removal 
of a central venous catheter did not significantly alter microbiota composition 
and diversity (chapter 4). However, great inter- and intra-individual variation in 
microbiota composition in very preterm infants during the first postnatal weeks, 
and exposure to other antibiotics during the first postnatal week, could have 
prohibited the detection of consistent alterations in microbiota composition 
as a result of two vancomycin dosages. Considering the effect of antibiotics 
on intestinal microbiota development, antibiotic type, dose and duration 
should be taken into account. The by antibiotics affected microbiota, generally 
characterised by low abundance of Bifidobacterium and high abundance of 
facultative anaerobes including Enterococcus and Enterobacter, has previously 
been associated with onset of NEC and late-onset sepsis72,153. In addition, the 
early use of antibiotics and its associated disturbances of the gut microbiota 
have been associated to negative health outcomes in later life73,74. It must be 
noted, however, that applied antibiotic strategies decreased neonatal mortality 
and morbidity rates and that antibiotics are indispensable in preterm infant 
care. It is therefore of importance to further elucidate the cost-benefit balance 
of empiric antibiotic use in neonatology. As long as the use of broad-spectrum 
antibiotics is a necessity in caring for the preterm infant, development of their 
intestinal microbiota will most certainly remain impeded. 
Perinatal antibiotics
In addition to postnatal antibiotic treatment, maternal antibiotics during the 
perinatal period were associated with microbiota composition of preterm 
infants (chapter 3, 5 and 6). Perinatal antibiotics are generally provided in 138
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case of prolonged rupture of membranes, group B Streptococcus colonisation, 
caesarean section or chorioamnionitis210. Maternal antibiotics may affect 
infants’ microbiota composition via prenatal exposure of the foetus to 
antibiotics, via alteration of the mothers’ microbiota and therefore the inoculum 
at birth, and via transfer of antibiotics through breastfeeding. Previous studies 
showed that maternal antibiotic use during the perinatal period altered gut 
microbiota establishment of the preterm infant and potentially affected the 
functional capabilities of the developing bacterial community67,211. Another 
study, however, showed no profound difference in bacterial colonisation pattern 
of three days old infants born to mothers with or without intrapartum amoxicillin 
treatment, except for colonisation by Clostridium212. It is noteworthy, however, 
that Bifidobacterium species colonised 48% of infants born from non-exposed 
mothers, while this was observed in only 24% of infants born from antibiotic-
exposed mothers212. This is in concordance with findings regarding postnatal 
antibiotic exposure, which generally delays colonisation by anaerobic bacteria. 
Like postnatal antibiotics, the use of perinatal antibiotics has been related to 
negative health outcomes of the infant in later life, but these antibiotics are also 
essential for preventing and curing maternal- and neonatal infections213-216.
Feeding
Human milk is considered the best possible nutrition for all infants and the World 
Health Organisation therefore recommends exclusive breastfeeding during the 
first six postnatal months for the infant to benefit from the nutritive, immune 
modulating and antimicrobial components contained in human milk52,217. Human 
milk feeding is desirable regarding infant growth and for development of the 
digestive, immune and cognitive system. The ratio of human milk to infant 
formula in enteral feeding was the main driver of the composition of the gastric 
proteome, and also affected composition of the faecal proteome (chapter 2). 
More human milk feeding resulted in higher levels of digestive- and immune-
related proteins that might be beneficial to preterm infants who are affected by 
immature gastrointestinal and immune functioning. Human milk and cow milk 
vary in composition, and their protein counterparts might possess different 
bioactivity. Human milk-derived, but not cow milk-derived, lactotransferrin 
as well as IgA, were abundant in preterm infant faeces. In addition to its 
influence on gastrointestinal and immune system maturation, human milk 
feeding is considered beneficial for development of the gut microbiota120. 
Human milk might in itself be a source of bacteria, but also contains complex 
oligosaccharides selectively stimulating bacteria that are specialised in the 
degradation of these compounds, like bifidobacteria. The percentage of human 
milk feeding, as well as other feeding parameters like food intolerance, ratio of 
enteral:parenteral feeding, days of total parenteral feeding and days until full 
enteral feeding were not identified as significant contributors to microbiota 
development in preterm infants (chapter 3-5). The effect of feeding regimen 
on microbiota development may have been eliminated or overshadowed by 
the detrimental effects caused by antibiotic administration in these infants. 
In moderate to late preterm infants who did not receive antibiotic treatment, 
days until full enteral feeding and percentage human milk feeding throughout 
the first six postnatal weeks were among the factors that significantly affected 139
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microbiota composition (chapter 6). Delayed enteral feeding and less human 
milk feeding most certainly impedes colonisation by Bifidobacterium species. 
Delayed enteral feeding is generally not favourable and may delay maturation of 
the gastrointestinal tract and has been associated with increased permeability 
and bacterial translocation8. Furthermore, the combination of delayed enteral 
feeding and an immature immune system in preterm infants has been associated 
with negative health outcomes like NEC and sepsis. In addition to the effect of 
feeding regimen on microbiota development, one should consider the role of 
the gut microbiota in nutrient digestion and energy harvest21,79. Preterm infants 
require more energy and proteins for optimal development than term infants, 
and preterm infants rarely meet in utero growth rates despite application of 
various nutrition support strategies91. The gut microbiota should be considered 
as therapeutic target for optimising nutrient digestion and uptake and for 
improvement of growth outcomes in preterm infants98.
Delivery mode
The birthing process provides the first major bacterial inoculum for an infant that, 
depending on delivery mode, contains bacteria representing the vaginal, faecal 
or skin microbiota. This initial inoculum is the initiator to a succession of events 
leading to the development of the infant’s own microbiota. Delivery through 
caesarean section has been associated with the epidemic of autoimmune 
and allergic diseases, in which a disturbed gut microbiota may have been 
attributable218. In moderate to late preterm infants without antibiotic treatment, 
delivery mode was the main driver of microbiota composition during the first 
six postnatal weeks (chapter 6). The gut microbiota of vaginally delivered 
infants was compositionally distinct from infants delivered through primary or 
secondary caesarean section. Vaginal delivery was associated with increased 
abundance of Bacteroides, Bifidobacterium and Escherichia-Shigella, but 
microbiota composition still varied greatly between infants. In preterm infants 
receiving antibiotics, an effect of delivery mode was generally not observed 
(chapter 3, 5 and 6). Antibiotics greatly affect microbiota composition and 
possible influences of delivery mode may therefore not be detectable. The 
realisation that caesarean section negatively affects early life microbiota 
development and consequently may affect early and later life health outcomes, 
led to studying the application of vaginal microbiota transfer to caesarean 
section delivered neonates219. Vaginal microbiota transfer has shown effective 
and safe, its long-term effects, however, need to be elucidated. Nevertheless, 
vaginal microbiota transfer seems successful and its application should also 
be considered for preterm infants, particularly in those who do not receive 
antibiotics. 
Other factors
In addition to antibiotics, feeding regimen and delivery mode, various other 
factors were considered for their potential effect on gastrointestinal function 
and microbiota development in preterm infants. Postnatal age influenced 
composition of the gastric and faecal proteome (chapter 2) and was consistently 
identified as factor influencing gut microbiota composition (chapter 3-6). With 
age, the gastrointestinal tract and immune system are maturing, which most 140
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certainly affects bacterial community structure in the gut. In addition, an older 
infant has simply been exposed to the environment and various influencing 
factors longer and offered the microbiota more time to ‘settle down’. Gender 
was identified as minor, but significant, contributor to microbiota composition 
(chapter 3 and 6). Currently, data considering a gender-effect during early life 
microbiota development is limited and our findings regarding its contribution 
were inconsistent and biased by other variables. A previous study among 108 
infants showed that, during the first three postnatal months, the gut microbiota 
of girls contains more lactobacilli than the microbiota of boys156. Differences 
in microbiota composition related to gender have been identified in adults 
and is suggested to be driven by gender-specific functioning of the immune 
system220. In this context, it is relevant to note that preterm born girls generally 
‘perform better’ relative to preterm born boys regarding health complications 
and mortality221,222. A better general health status most likely affects microbiota 
development. However, a gender-effect during early life gut microbiota 
development needs to be further elucidated. In chapter 5, preeclampsia was 
identified as factor contributing to microbiota composition, but our study design 
did not allow to further elucidate their relation. Preeclampsia is a maternal 
health complication characterised by high blood pressure, and is associated 
with preterm delivery181. One study describes a relation between preeclampsia 
and the gut microbiota, however, I consider their conclusions questionable223. The 
aetiology of preeclampsia is unknown, but this disorder is linked to inflammation, 
which might have an infectious origin. Periodontitis is strongly associated 
with preeclampsia, and in addition to increased inflammatory status, bacterial 
translocation from the oral cavity to placental tissue has been suggested as 
underlying mechanism224-226. However, attempts to relate the presence of 
bacteria in the placental tissue of preeclamptic women have so far failed to 
identify consistent differences in their situation compared to woman without 
preeclampsia227-229. As for gender, the effect of preeclampsia on infant microbiota 
development needs to be further elucidated.
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
The research described in this thesis contributes to current knowledge 
regarding gastrointestinal function and microbiota development during the 
early life of preterm infants and the factors associated with this development. 
This contribution is not only relevant from microbial ecology perspective, but 
aids clinical practice and development of therapeutic strategies. The findings 
presented in this thesis confirmed previous knowledge, showing disturbed 
colonisation patterns in preterm infants, which is particularly associated 
with perinatal antibiotic treatment. However, it also revealed less expected 
associations, like the potential influence of respiratory support and maternal 
preeclampsia. Furthermore, we obtained new insights in gut microbiota 
functioning via the application of a metaproteomics approach. This approach 
also allowed for a sneak peek at human- and bovine-derived proteins contained 
in the gastric and faecal proteome of preterm infants, thereby providing insights 
in their gastrointestinal functioning from a different perspective. I hereby end 
the discussion of this thesis with a couple of concluding statements and the 
future perspectives related to this statement:141
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Human microbiota research is a composition-oriented field. To fully comprehend 
the host-microbiota relationship and its consequences to health and disease, 
functional analysis of the microbiota should be further implemented in current 
and future research. Depending on the research question; metatranscriptomics, 
metaproteomics, metabolomics, or a combination of these, can be applied 
to obtain functional insights. I acknowledge that implementation of such 
methodologies is costly and require expertise. This, however, stimulates 
extensive research collaborations and provides the opportunity to further 
advance the field. 
Gut microbiota development in preterm infants remains impeded as long as 
antibiotics are a necessity during their care. To allow healthy development of 
the gut microbiota in preterm infants, antibiotics should be minimised and 
preferably not be provided at all. The latter, however, is currently impossible due 
to their role in infection prevention and treatment. Since antibiotic resistance 
became a major concern for health care and public health, the quest for 
alternatives is rapidly expanding. Alternatives under investigation include 
bacteriophages, bacteriocins and competitive exclusion by providing pre-, 
pro- or synbiotics, of which the latter brings me to the next statement.
Microbiota-targeting therapeutic strategies must be considered when caring 
for the preterm infant. Although not studied as part of this thesis, disturbed 
colonisation pattern during early life, as observed in preterm infants, has 
been related to a variety of negative health outcomes in early and later life. 
It is therefore of importance to prevent disturbances, or to early recover the 
microbiota whenever possible. Administration of probiotics or lactotransferrin, 
have shown effective for the prevention of infections and NEC. Although 
probiotics have so far failed to consistently improve neonatal growth outcomes, 
they potentially reduce days until full enteral feeding, which is relevant to 
elucidate further. Regarding probiotics, it is important to reach consensus 
about the used bacterial strains, their load and timing of administration. In this 
context, it is important to mention that human milk in itself is a source of bacteria, 
and that infant formula for term neonates is often supplemented with probiotic 
bacteria to better resemble human milk feeding. Since the safety and efficacy 
of probiotics for preterm infants are still inconsistent, routine administration 
of probiotics and addition of probiotics to preterm infant formula is not yet 
practiced routinely. In addition to microbiota-modulation via the oral route, 
results regarding vaginal microbiota transplantation to caesarean section 
born neonates are promising. When deemed safe and effective, also in preterm 
infants, vaginal microbiota transplantation is relatively simple and inexpensive 
to apply in daily clinical practice. Since disturbed microbiota is most certainly 
involved in negative outcomes like infections, NEC and allergies, which are 
common complications of preterm birth, microbiota targeting therapies have 
great potential for preterm infant care.
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SAMENVATTING
Het maag-darmstelsel, en de bacteriën die het bevat, zijn essentieel 
voor de vertering en opname van voedingsstoffen, de weerstand tegen 
pathogenen en optimaal functioneren van het immuun systeem. In de vroege 
levensfase vindt de ontwikkeling van de darmbacteriën tegelijk plaats met 
de ontwikkeling van het metabole-, cognitieve- en immuunsysteem, en deze 
processen beïnvloeden elkaar. Goede ontwikkeling van de darmbacteriën, 
ofwel de darmmicrobiota, wordt daarom noodzakelijk geacht voor een 
gezond levensverloop. Tijdens de eerste paar jaar van een mensenleven is 
de samenstelling van de darmmicrobiota relatief onstabiel en extra vatbaar 
voor verstoringen. Zwangerschapsduur, wijze van bevallen, voeding en 
antibiotica gebruik zijn factoren welke de darmmicrobiota samenstelling 
van een baby sterk kunnen beïnvloeden. Te vroeg geboren baby’s hebben 
een onderontwikkeld maag-darmstelsel, worden vaak geboren via een 
keizersnede, volgen een speciaal voedingsschema en worden regelmatig 
blootgesteld aan antibiotica. Zodoende, is een verstoorde ontwikkeling 
van de darmmicrobiota zeer aannemelijk bij prematuren. Ondanks dat de 
ontwikkeling van de darmmicrobiota verstoord kan worden tijdens de vroege 
levensfase, biedt de onstabiele en zich ontwikkelende darmmicrobiota ook de 
mogelijkheid als doelwit te dienen voor de ondersteuning van een gezonde 
groei en ontwikkeling. Vanuit dit oogpunt is het van belang de kennis te 
vergroten omtrent het functioneren van het maag-darmstelsel, de kolonisatie 
van de darm met bacteriën, wat deze doen, en welke factoren deze processen 
beïnvloeden. Voor dit proefschrift, werden de ontwikkeling van het maag-darm 
kanaal en de darmmicrobiota tijdens de vroege levensfase van premature 
baby’s, en de factoren die hierop van invloed zijn, bestudeerd. 
Voor de studies omschreven in dit proefschrift is gebruik gemaakt van 
monsters welke zijn verzameld tijdens observationeel onderzoek bij baby’s 
welke zijn geboren tussen 24-42 weken zwangerschap en opgenomen op 
de neonatale intenstive care. Klinische informatie, fecale monsters en 
maagaspiraties werden gedurende de eerste zes weken na de geboorte 
verzameld voor het bestuderen van de microbiota. Naast het bepalen van 
de microbiota samenstelling door middel van qPCR en sequencen van 16S 
rRNA gen amplicons, is ook de activiteit en functie van de microbiota in kaart 
gebracht middels LC-MS/MS (metaproteomics). Dit geeft nieuwe inzichten 
betreffende het functioneren van het maag-darmstelsel en de darmbacteriën. 
Door middel van metaproteomics hebben wij patronen in de ontwikkeling van 
het maag-darm proteoom kunnen identificeren welke specifiek zijn voor de 
zwangerschapsduur waarop het kindje is geboren. Zowel zwangerschapsduur 
als de leeftijd van de baby waren geassocieerd met eiwitten welke de rijping 
van het maag-darmstelsel en de microbiota aanduiden. De compositie van het 
fecale proteoom van ernstig premature baby’s duidde meer bifidobacteriën en 
een betere spijsverteringscapaciteit aan, vergeleken met extreem prematuren. 
Wij hebben aangetoond dat wanneer de darmmicrobiota veel bifidobacteriën 
bevat, er meer enzymen aanwezig zijn welke een belangrijke rol spelen in 
koolhydraat- en energiemetabolisme, onder andere enzymen betrokken bij 155
de afbraak van complexe koolhydraten zoals humane melk oligosacchariden. 
Het gegeven dat prematuren vaak een eiwit tekort en groei achterstand 
hebben, maakt de metabole capaciteit van de darmmicrobiota extra relevant. 
De mate van vroeggeboorte hangt nauw samen met de mate van zorg. In 
deze studie waren de blootstelling aan antibiotica en duur van beademing 
significant geassocieerd met bovengenoemde zwangerschapsduur-specifieke 
patronen van de darmmicrobiota ontwikkeling. De samenhang tussen 
zwangerschapsduur en mate van zorg, maakt het bijna onmogelijk om enkel 
het effect van zwangerschapsduur op de microbiota te bepalen. 
Premature baby’s zijn extra vatbaar voor infecties, sepsis en necrotiserende 
enterocolitis . Antibiotica, ter voorkoming en behandeling hiervan, zijn de 
meest gebruikte medicatie op de neonatale intensive care. Gezien de rol van 
de darmbacteriën in gezondheid en ziekte, is het van belang de consequenties 
van antibiotica gebruik op microbiota ontwikkeling in kaart te brengen. Wij 
hebben aangetoond dat twee vancomycine toedieningen, rond de tijd van het 
verwijderen van een centraal veneuze katheter, vermoedelijk geen blijvend 
effect had op de samenstelling van de darmmicrobiota van prematuren. In 
tegendeel, postpartum amoxicilline/ceftazidim verstoorde de microbiota 
samenstelling aanzienlijk gedurende de eerste twee postnatale weken, ten 
voordele van Enterococcus soorten en ten nadele van Bifidobacterium soorten. 
Daarnaast lijkt het herstel van de microbiota met weken te zijn vertraagd in 
geval van een kuur van meer van vijf dagen, ten opzichte van een kuur van 
minder dan drie dagen. 
Naast zwangerschapsduur en antibiotica gebruik, zijn er tijdens de studies 
beschreven in dit proefschrift meerdere factoren meegenomen in de bepaling, 
zodat hun effect op de microbiota ontwikkeling bepaald kon worden. Naast 
factoren welke al bekend zijn de microbiota te beïnvloeden, zoals wijze van 
geboorte en type voeding, hebben wij een mogelijk effect van geslacht, 
beademing en zwangerschapsvergiftiging aangetoond. Deze bevindingen 
kunnen aanleiding geven tot nader onderzoek betreffende het effect van deze 
factoren op de darmmicrobiota ontwikkeling.
Al met al draagt het onderzoek beschreven in dit proefschrift bij aan de huidige 
kennis omtrent de ontwikkeling van het maag-darm kanaal en de darmmicrobiota 
tijdens de vroege levensfase van premature baby’s, en de factoren die hierop 
van invloed zijn. Onze bevindingen ondersteunen de klinische praktijk en de 
ontwikkeling van nieuwe therapieën. In het kader hiervan raden wij het volgende 
aan voor toekomstig onderzoek 1) implementatie van functionele analyse 
van de microbiota, 2) bestuderen van alternatieven voor antibiotica voor de 
behandeling en preventie van infecties, en 3) onderzoeken van de mogelijkheden 
van microbiota gerichte therapieën tijdens de zorg voor prematuren.
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